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The comprehensive delineation of cancer-causing genes is an essential step in 
understanding the molecular basis of cancer.  While much research has interrogated the 
role of protein-coding genes in cancer, recent discoveries demonstrate that the human 
genome may additionally contain thousands of non-protein-coding genes, termed non-
coding RNAs (ncRNAs).  However, the identity and function of these genes is largely 
unknown. 
Here, I describe the systematic discovery and functional characterization of long 
non-coding RNAs (lncRNAs) in prostate cancer.  We used transcriptome sequencing 
(RNA-Seq) of human prostate cancer samples to identify over 1,800 unannotated, 
intergenic lncRNAs, of which 121 Prostate Cancer Associated Transcripts (PCATs) 
demonstrated aberrant expression patterns between benign prostate samples, localized 
cancers, and metastatic cancers. 
 xii
To study novel lncRNAs in prostate cancer, we focused on two: PCAT-1 and 
SChLAP-1 (Second Chromosome Locus Associated with Prostate-1, also referred to as 
PCAT-114), which are overexpressed in subsets of prostate cancer.  We found that 
upregulation of PCAT-1 mediates increased cellular proliferation in vitro and in vivo 
through the regulation of genes involved in DNA maintenance, including BRCA2, a 
tumor suppressor gene essential for DNA break repair by homologous recombination 
(HR).  Mechanistically, PCAT-1 expression repressed BRCA2 in a microRNA-like 
manner via the BRCA2 3’ untranslated region.  BRCA2 repression resulted in defective 
HR in PCAT-1-expressing prostate cells, leading to increased cell sensitivity to PARP1 
inhibitors, which engender synthetic lethality in the context of impaired HR. 
By contrast, our investigation of SChLAP-1 revealed a nuclear lncRNA that is 
involved in prostate cell invasiveness and metastasis in vitro and in vivo.  
Mechanistically, SChLAP-1 antagonizes the SWI/SNF chromatin remodeling complex, a 
tumor suppressor complex inactivated in cancer, by directly binding SWI/SNF proteins 
and impairing their ability to regulate gene expression.  Clinically, SChLAP-1 expression 
defined a subset of prostate cancers associated with aggressive phenotypes and poor 
outcome. 
Taken together, this thesis work represents the first comprehensive assessment of 
lncRNAs in a major cancer type and describes novel oncogenic lncRNAs in prostate 
cancer that may further serve as predictive (PCAT-1) or prognostic (SChLAP-1) 
biomarkers.  Broadly, this work suggests that uncharacterized lncRNAs may play critical 









Introduction: Long non-coding RNAs in biology and disease 
 
 
THE CENTRAL DOGMA OF MOLECULAR BIOLOGY 
 In the 50 years following the discovery of DNA in the 1950s, molecular 
biology—though ever more complex with each passing year—was grounded by a 
unifying principle: the central dogma.  Part science, part philosophy, the central dogma 
was formulated by Francis Crick in 1958, only 5 years after he and James Watson 
reported the basic structure of DNA (1, 2).  In this short time, Crick had catapulted his 
thinking beyond nucleic acids and toward proteins.  What kind of relationship existed 
between the two?  He posited his thesis thus: 
 
The Central Dogma. This states that once ‘information’ has passed into 
protein it cannot get out again. In more detail, the transfer of information 
from nucleic acid to protein may be possible, but transfer from protein to 
protein, or from protein to nucleic acid is impossible. Information means 
here the precise determination of sequence, either of bases in the nucleic 
acid or of amino-acid residues in the protein. (1) 
 
Soon, Crick and others expanded this initial model.  In addition to DNA and protein, 
RNA, the enzymatic synthesis of which earned Severo Ochoa the 1959 Nobel Prize in 
Medicine, was quickly added (2, 3).  Originally, transfer of genetic information was 
possible from DNA to RNA, RNA to protein, RNA to DNA, and DNA to protein, 
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although Crick believed that transfer of genetic information from RNA to DNA or DNA 
directly to protein was unlikely (1, 2, 4).  Thus was born the central dogma of biology.  
Another generation of researchers would codify these concepts in a simple dictum: DNA 
is transcribed into RNA, and RNA is translated proteins (Figure 1.1). 
 
A genome full of genes? 
According to the central dogma, the regions of DNA that ultimately give rise to 
RNA and proteins are the complement of genes in an organism.  A “gene” is therefore 
defined somewhat empirically: if a certain part of DNA is essential for the generation of 
RNA and protein, it is then part of a gene.  Thus, the question of which regions of the 
human genome constitute its genes has long been a central topic in biology.  While early 
cloning-based methods revealed more than 7000 human genes in the 1970s and 1980s 
(5), large-scale analyses of expressed sequence tags (ESTs) in the 1990s suggested that 
the estimated number of human genes lay in the 35,000–100,000 range (6).  The 
completion of the Human Genome Project narrowed the focus considerably by 
highlighting the surprisingly small number of protein-coding genes, which is now 
conventionally cited as less than 25,000. 
While the number of protein-coding genes (20,000–25,000) has maintained broad 
consensus, recent studies of the human transcriptome have revealed an astounding 
number of non-coding RNAs (ncRNAs).  These transcribed elements, which lack the 
capacity to code for a protein, are bafflingly abundant in all organisms studied to date, 
from yeast to humans (7-9), and they represent a break with the central dogma of biology 
because they do not engage in protein synthesis.  Yet, over the past decade, numerous 
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studies have demonstrated that ncRNAs have distinct biological functions and operate 
through defined mechanisms.  Still, their sheer abundance—some reports estimate that up 
to 70% of the human genome is transcribed into RNA (7, 10, 11)—has sparked debates 
as to whether ncRNA transcription reflects true biology or byproducts of a leaky 
transcriptional system.  Encompassed within these studies are the broad questions of what 
constitutes a human gene, what distinguishes a gene from a region that is simply 
transcribed, and how we interpret the biological meaning of transcription. 
These developments have been matched by equally insightful discoveries 
analyzing the role of ncRNAs in human diseases, especially cancer, lending support to 
the importance of their cellular functions (12, 13).  Initial evidence suggests that 
ncRNAs, particularly long ncRNAs (lncRNAs), have essential roles in tumorigenesis 
(12), and that lncRNA-mediated biology occupies a central place in cancer progression 
(14).  With the number of well-characterized cancer-associated lncRNAs growing, the 
study of lncRNAs in cancer is now generating new hypotheses about the biology of 
cancer cells.  Here, I review the current understanding of ncRNAs in cancer, with 
particular focus on lncRNAs as novel drivers of tumorigenesis. 
 
NON-CODING RNAs: A NEW KIND OF GENE 
ncRNAs are RNA transcripts that do not encode for a protein.  In the past decade, 
a great diversity of ncRNAs have been observed.  Depending on the type of ncRNA, 
transcription can occur by any of the three RNA polymerases (RNA Pol I, RNA Pol II, or 
RNA Pol III).  General conventions divide ncRNAs into two main categories: small 
ncRNAs less than 200 bp and long ncRNAs greater than 200 bps (15).  Within these two 
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categories, there are also many individual classes of ncRNAs (Table 1.1), although the 
degree of biological and experimental support for each class ranges substantially and 
should be evaluated individually. 
 
Small ncRNAs 
The diversity of small ncRNAs has perhaps grown the most, where several dozen 
classes of small ncRNAs have been proposed (15, 16).  These include well-characterized 
housekeeping ncRNAs (transfer RNA (tRNA) and some ribosomal RNA (rRNA)) 
essential for fundamental aspects of cell biology, splicing RNAs (small nuclear RNAs 
(snRNAs)), and a variety of recently-observed RNAs associated with protein-coding gene 
transcription, such as tiny transcription-initiation RNAs, promoter-associated short 
RNAs, termini-associated short RNAs, 3’UTR-derived RNAs, and antisense termini-
associated short RNAs (15). 
To date, the most extensively studied small RNAs in cancer are microRNAs 
(miRNAs).  Elegant studies over the past 15 years have defined an intricate mechanistic 
basis for miRNA-mediated silencing of target gene expression through the RNA-induced 
silencing complex (RISC), which employs Argonaute family proteins (such as AGO2) to 
cleave target mRNA transcripts or to inhibit the translation of that mRNA (Figure 1.2A) 
(17).  Aberrant expression patterns of miRNAs in cancer has been well documented in 
most tumor types (Figure 1.2B), and detailed work from many labs have shown that 
numerous miRNAs, including miR-10b, let-7, miR-101, and the miR-15a-16-1 cluster, 




Recent observations of novel long ncRNA species has led to a complex set of 
terms and terminologies used to describe a given long ncRNA.  These include antisense 
RNAs, which are transcribed on the opposite strand from a protein-coding gene and 
frequently overlap that gene (18), transcribed ultraconserved regions (T-UCRs), which 
originate in regions of the genome showing remarkable conservation across species, and 
ncRNAs derived from intronic transcription.  
Although many RNA species are >200 bp in length, such as repeat or 
pseudogene-derived transcripts (19), the abbreviated term lncRNA (also referred to as 
lincRNA, for long intergenic ncRNA) does not uniformly apply to all of these.  While the 
nomenclature is still evolving, lncRNA typically refers to a polyadenylated long ncRNA 
that is transcribed by RNA polymerase II and associated with epigenetic signatures 
common to protein-coding genes, such as trimethylation of histone 3 lysine 4 (H3K4me3) 
at the transcriptional start site (TSS) and trimethylation of histone 3 lysine 36 
(H3K36me3) throughout the gene body (20).  This description similarly suits many T-
UCRs and some antisense RNAs, and the overlap between these categories may be 
substantial.  lncRNAs also commonly exhibit splicing of multiple exons into a mature 
transcript, as do many antisense RNAs but not RNAs transcribed from gene enhancers 
(eRNAs) or T-UCRs (21-23).  Transcription of lncRNAs occurs from an independent 
gene promoter and is not coupled to the transcription of a nearby or associated parental 
gene, as with some classes of ncRNAs (promoter/termini-associated RNAs, intronic 
ncRNAs) (15).  In this thesis, I will use the term lncRNA in this manner.  When the data 
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is supportive, I include specific T-UCRs and antisense RNAs under the lncRNA umbrella 
term, and I distinguish other long ncRNAs, such as eRNAs, where appropriate. 
 
Identification of long ncRNAs 
Many initial lncRNAs, such as XIST and H19, were discovered in the 1980s and 
1990s by searching cDNA libraries for clones of interest (24, 25).  In these studies, the 
intention was generally to identify new genes important in a particular biological 
process—X chromosome inactivation in the example of XIST—by studying their 
expression patterns.  At the time, most genes uncovered were protein-coding, and this 
tended to be the assumption, with a handful exceptions, such as XIST, which were 
subsequently determined to be noncoding as a secondary observation (24). 
In the past decade, however, large-scale analyses have focused on identifying 
ncRNA species in a comprehensive fashion.  This paradigm shift was mediated by 
dramatic advances in high-throughput technologies, including DNA tiling arrays and next 
generation RNA sequencing (RNA-Seq) (10, 11, 14, 26, 27).  These platforms provide 
systems with which RNA transcription can be observed in an unbiased manner, and have 
thereby highlighted the pervasive transcription of ncRNAs in cell biology.  Moreover, 
whereas conventional cDNA microarrays detected only the transcripts represented by 
probes on the array, the introduction and popularization of RNA-Seq as a standard tool in 
transcriptome studies has removed many barriers to detecting all forms of RNA 
transcripts (14, 28).  RNA-Seq studies now suggest that several thousand uncharacterized 
lncRNAs are present in any given cell type (14, 20).  Observations that many lncRNAs 
demonstrate tissue-specific expression therefore enables speculations that the human 
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genome may harbor nearly as many lncRNAs as protein-coding genes (perhaps ~15,000 
lncRNAs), though only a fraction are expressed in a given cell type. 
 
LONG NON-CODING RNAs IN CANCER 
Emerging evidence suggests that lncRNAs constitute an important component of 
tumor biology (Table 1.2).  Dysregulated expression of lncRNAs in cancer marks the 
spectrum of disease progression (14) and may serve as an independent predictor for 
patient outcomes (29).  Mechanistically, most well-characterized lncRNAs to date show a 
functional role in gene expression regulation, typically transcriptional rather than post-
transcriptional regulation.  This can occur by targeting either genomically local (cis-
regulation) or genomically distant (trans-regulation) genes.  Recently, a new type of long 




cis-regulation by lncRNAs contributes to local control of gene expression by 
recruiting histone modification complexes to specific areas of the genome (Figure 1.3).  
This effect can either be highly specific to a particular gene, such as the regulation of 
IGF2 by lncRNAs (31); or, it can encompass a wide chromosomal region, such as X-
chromosome inactivation in women through XIST.  Historically, cis-regulation through 
lncRNAs was studied earlier than trans-regulation, as several cis-regulatory lncRNAs, 
including H19, AIR, KCNQ1OT1, and XIST were earlier discoveries (24, 25, 32).  Several 
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cis-regulatory lncRNAs, including H19, AIR and KCNQ1OT1, are also functionally 
related through their involvement in epigenetic imprinting regions. 
 
Imprinting lncRNAs 
lncRNA involvement in imprinted regions of the genome is critical for 
maintaining parent-of-origin-specific gene expression.  In particular, an imprinted region 
of human chromosome 11 (orthologous to mouse chromosome 7) has been extensively 
studied for the role of lncRNAs.  In humans, most well-known are the H19 and 
KCNQ1OT1 lncRNAs (25, 32), which are expressed on the maternal and paternal alleles, 
respectively, and maintain silencing of the IGF2 and KCNQ1 genes on those alleles 
(Figure 1.3A) (33). 
Of the imprinting-associated ncRNAs, H19 has been most extensively studied in 
cancer.  Aberrant expression of H19 is observed in numerous solid tumors, including 
hepatocellular and bladder cancer (31, 34).  The functional data on H19 point in several 
directions, and it has been linked to both oncogenic and tumor suppressive qualities (35).  
For example, there is evidence for its direct activation by cMYC (36) as well as its 
downregulation by p53 and during prolonged cell proliferation (37).  In model systems, 
siRNA-mediated knockdown of H19 expression impaired cell growth and clonogenicity 
in lung cancer cell lines in vitro (36) and decreased xenograft tumor growth of Hep3B 
hepatocellular carcinoma cells in vivo (31).  Together, these data support a general role 
for H19 in cancer, although its precise biological contributions are still unclear. 
Other imprinting-associated lncRNAs are only tangentially associated with 
cancer.  While loss of imprinting is observed in many tumors, the role for lncRNAs in 
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this process is not well defined.  For example, Beckwith-Wiedemann syndrome (BWS), a 
disorder of abnormal development with an increased risk for cancer, displays aberrant 
imprinting patterns of KCNQ1OT1 (33, 38); but a direct association or causal role for 
KCNQ1OT1 in cancer is not described (38).  Conversely, aberrant H19 methylation in 
BWS appears to predispose to cancer development more strongly (38).   
 
XIST 
XIST, perhaps the most well studied lncRNA, is transcribed from the inactivated 
X chromosome, in order to facilitate that chromosome’s inactivation, and manifests as 
multiple isoforms (39, 40).  On the active X allele, XIST is repressed by its antisense 
partner ncRNA, TSIX (40).  XIST contains a double-hairpin RNA motif in the RepA 
domain, located in the first exon, which is crucial for its ability to bind Polycomb 
Repressive Complex 2 (PRC2) and propagate epigenetic silencing of an individual X 
chromosome (Figure 1.3B) (41). 
Despite the body of research on XIST, a precise role for XIST in cancer has 
remained elusive (42).  Some evidence initially suggested a role for XIST in hereditary 
BRCA1-deficient breast cancers (43, 44), where data indicated that BRCA1 was not 
required for XIST function in these cells (45).  Others have reasoned that XIST may be 
implicated in the X chromosome abnormalities observed in some breast cancers.  There 
have also been surprising accounts of aberrant XIST regulation in other cancers, including 
lymphoma and male testicular germ-cell tumors, where XIST hypomethylation is, 
unexpectedly, a biomarker (46).  Yet, it remains unclear whether these observations 
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reflect a passenger or driver status for XIST, as a well-defined function for XIST in cancer 
has yet to attain a broad consensus. 
 
ANRIL 
Located on Chr9p21 in the INK4A/ARF tumor suppressor locus, ANRIL was 
initially described by examining the deletion of this region in hereditary neural system 
tumors, which predispose for hereditary cutaneous malignant melanoma (47).  ANRIL 
was subsequently defined as a polyadenylated lncRNA antisense to the CDKN2A and 
CDKN2B genes.  In vitro data have suggested that ANRIL functions to repress the 
INK4A/INK4B isoforms (48), but not ARF.  This repression is mediated through direct 
binding to CBX7 (48), a member of Polycomb Repressive Complex 1 (PRC1), and 
SUZ12 (49), a member of PRC2, which apply repressive histone modifications to the 
locus.  However, these studies were performed in different cell types and it is not known 
whether ANRIL binds both complexes simultaneously.   
ANRIL also displays a highly complicated splicing pattern, with numerous 
variants, including circular RNA isoforms (50).  Currently it is unclear whether these 
isoforms have tissue-specific expression patterns or unique functions, which may suggest 
a biological basis for this variation.  Through genome wide association studies (GWAS), 
ANRIL has also been identified by single nucleotide polymorphisms (SNPs) correlated 
with a higher risk of atherosclerosis and coronary artery disease (51), and ANRIL 
expression has been noted in many tissues.  The function and isoform-level expression of 
ANRIL in these tissue types is not yet elucidated, but may shed light onto its role in 
diverse disease processes. 
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HOTTIP and HOTAIRM1 
An intriguing theme emerging in developmental biology is the regulation of HOX 
gene expression by lncRNAs.  Highly conserved among metazoan species, HOX genes 
are responsible for determining tissue patterning and early development, and in humans 
HOX genes reside in four genomic clusters.  Within these clusters, HOX genes display 
intriguing anterior-posterior and proximal-distal expression patterns that mirror their 
genomic position 5’ to 3’ in the gene cluster. 
Two recently-discovered lncRNAs, termed HOTTIP and HOTAIRM1, may help 
to explain this co-linear patterning of HOX gene expression.  HOTTIP and HOTAIRM1 
are located at opposite ends of the HoxA cluster, and each helps to enhance gene 
expression of the neighboring HoxA genes (52, 53).  HOTAIRM1, located at the 3’ end, 
coordinates HOXA1 expression and has tissue-specific expression patterns identical to 
HOXA1 (52).  HOTTIP, by contrast, is at the 5’ end of the cluster and similarly enhances 
expression of the 5’ HoxA genes, most prominently HOXA13 (53).  Mechanistic studies 
of HOTTIP suggest that it binds WDR5 and recruits the MLL H3K4 histone 
methyltransferase complex to the HoxA cluster to support active chromatin confirmation 
(53).  These observations distinguish HOTTIP and HOTAIRM1, as most lncRNAs to date 
facilitate gene repression. 
While HOTAIRM1 and HOTTIP have not been extensively studied in cancer, 
expression of these may have important roles in the differentiation status of cancer cells.  
For example, differentiation of myeloid cancer cell lines, such as K562 and NB4, by 
treatment with retinoic acid led to an increase in HOTAIRM1 expression, implicating it in 
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myeloid differentiation (52).  Moreover, HoxA genes are broadly known to be important 
for many cancers, particularly HOXA9, which is essential for oncogenesis in leukemias 
harboring MLL rearrangements.  Thus, HOTAIRM1 and HOTTIP also suggest a potential 
role for lncRNAs in MLL-rearranged leukemias. 
 
trans-Regulatory lncRNAs 
Like most cis-acting lncRNAs, trans-acting lncRNAs typically facilitate 
epigenetic regulation of gene expression.  However, because trans-acting lncRNAs may 
operate at geographically distant locations of the genome, it is generally thought that the 
mature lncRNA transcript is the primary actor in these cases, as opposed to cis-regulating 
lncRNAs, like H19, AIR and KCNQ1OT1, which may function through the act of 
transcription itself (35, 54, 55). 
 
HOTAIR 
trans-Regulatory lncRNAs were brought to widespread attention by the 
characterization of HOTAIR.  First described in fibroblasts, HOTAIR is located in the 
HoxC cluster; but unlike HOTTIP and HOTAIRM1, HOTAIR was found to regulate 
HoxD cluster genes in a trans-regulatory mechanism (Figure 1.3C) (56).  These 
observations raise the question of whether all Hox clusters are regulated by lncRNAs, 
either by a cis-regulatory or a trans-regulatory mechanism.   
In cancer, HOTAIR is upregulated in breast and hepatocellular carcinomas (15), 
and in breast cancer overexpression of HOTAIR is an independent predictor of overall 
survival and progression-free survival (29).  Work by Howard Chang and colleagues has 
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further defined a compelling mechanistic basis for HOTAIR in cancer.  HOTAIR has two 
main functional domains, a PRC2-binding domain located at the 5’ end of the RNA, and 
a LSD1/CoREST1-binding domain located at the 3’ end of the RNA (56, 57).  In this 
way, HOTAIR is thought to operate as a tether that links two repressive protein 
complexes in order to coordinate their functions.  In breast cancer, HOTAIR 
overexpression facilitates aberrant PRC2 function by increasing PRC2 recruitment to the 
genomic positions of target genes.  By doing so, HOTAIR mediates the epigenetic 
repression of PRC2 target genes, and profiling of repressive (H3K27me3) and active 
(H3K4me3) chromatin marks shows widespread changes in chromatin structure 
following HOTAIR knockdown (29). 
Furthermore, HOTAIR dysregulation results in a phenotype in both in vitro and in 
vivo models. Ectopic overexpression of HOTAIR in breast cancer cell lines increases their 
invasiveness both in vitro and in vivo.  Supporting this, in benign immortalized breast 
cells overexpressing a core component of PRC2 (EZH2), knockdown of HOTAIR 
mitigated EZH2-induced invasion in vitro (29).  Taken together, these data provide the 
most thorough picture of a lncRNA in cancer. 
 
GAS5 
GAS5, first identified in murine NIH-3T3 cells, is a mature, spliced lncRNA 
manifesting as multiple isoforms up to 12 exons in size (58).  Using HeLa cells 
engineered to express GAS5, Kino et al. recently described an intriguing mechanism by 
which GAS5 modulates cell survival and metabolism by antagonizing the glucocorticoid 
receptor (GR).  The 3’ end of GAS5 both interacts with the GR DNA-binding domain 
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(DBD) and is sufficient to repress GR-induced genes, such as cIAP2, when cells are 
stimulated with dexamethasone.  By binding to the GR, GAS5 serves as a decoy that 
prevents GR binding to target DNA sequences (Figure 1.3D) (58). 
In cancer, GAS5 induces apoptosis and suppresses cell proliferation when 
overexpressed in breast cancer cell lines, and in human breast tumors GAS5 expression is 
downregulated (59).  Although it is unclear whether this phenotype is due to an 
interaction with GR, it is intriguing that GAS5 may also be able to suppress signaling by 
other hormone receptors, such as androgen receptor (AR), though this effect was not seen 
with estrogen receptor (ER) (58). 
 
Other long ncRNAs 
eRNAs 
eRNAs are transcribed by RNA polymerase II at active gene enhancers (21).  But 
unlike lncRNAs, they are not polyadenylated and are marked by a H3K4me1 histone 
signature denoting enhancer regions (21), rather than the H3K4me3/H3K36me3 signature 
classically associated with lncRNAs.  While research on eRNAs is still in the earliest 
phases, an emerging role for them in hormone signaling is already being explored.  
Nuclear hormone receptors, such as AR and ER, are critical regulators of numerous cell 
growth pathways and are important in large subsets of prostate (AR), breast (ER), and 
thyroid (PPARγ) cancers.  To date, eRNAs have been most directly implicated in prostate 
cancer, where they assist in AR-driven signaling and are maintained by FOXA1, a 





Ultraconserved regions in the genome were initially described as stretches of 
sequence >200 bp long with 100% conservation between humans and mice but harboring 
no known gene (60).  As high levels of sequence conservation are hallmarks of exonic 
sequences in protein-coding genes, ultraconserved regions strongly suggest the presence 
of either a gene or a regulatory region, such as an enhancer.  Subsequently, numerous 
ultraconserved sequences were found to be transcriptionally active, defining a class of T-
UCRs as ncRNAs (22).  Many transcripts from T-UCRs are polyadenylated and 
associated with H3K4me3 at their transcriptional start sites (TSSs), indicating that many 
are likely lncRNAs according to our definition (61). 
Aberrant expression of T-UCRs has been noted in several cancer types, including 
neuroblastoma (61), leukemia (22), and hepatocellular carcinoma (23).  Most notably, 
one T-UCR gene, termed TUC338, has been shown to promote both cell proliferation and 
anchorage-independent growth in hepatocellular carcinoma cell lines (23), and TUC338 
transcript is localized to the nucleus, suggesting a role in regulation of expression (23).  
Calin et al. further demonstrated that T-UCRs are targets for miRNAs (22).  While T-
UCRs remain poorly characterized as a whole, additional exploration of the role and 
mechanism of these ncRNAs will likely elucidate novel aspects of tumor biology. 
 
FUNCTIONS AND MECHANISMS OF LONG NON-CODING RNAs 
Like protein-coding genes, there is considerable variability in the function of long 
ncRNAs.  Yet, clear themes in the data suggest that many long ncRNAs contribute to 
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associated biological processes.  These processes typically relate to transcriptional 
regulation or mRNA processing, which is reminiscent of miRNAs and may indicate a 
similar sequence-based mechanism akin to miRNA binding to seed sequences on target 
mRNAs.  However, unlike miRNAs, long ncRNAs show a wide spectrum of biological 
contexts that demonstrate greater complexity to their functions. 
 
Epigenetic transcriptional regulation 
The most dominant function explored in lncRNA studies relates to epigenetic 
regulation of target genes.  This typically results in transcriptional repression, and many 
lncRNAs were first characterized by their repressive functions, including ANRIL, 
HOTAIR, H19, KCNQ1OT1, and XIST (15, 48, 56).  These lncRNAs achieve their 
repressive function by coupling with histone modifying or chromatin remodeling protein 
complexes.   
The most common protein partners of lncRNAs are the PRC1 and PRC2 
polycomb repressive complexes.  These complexes transfer repressive post-translational 
modifications to specific amino acid positions on histone tail proteins, thereby facilitating 
chromatin compaction and heterochromatin formation in order to enact repression of 
gene transcription.  PRC1 may be comprised of numerous proteins, including BMI1, 
RING1, RING2 and Chromobox (CBX) proteins, which act as a multi-protein complex to 
ubiquitinate histone H2A at lysine 119 (62).  PRC2 is classically composed of EED, 
SUZ12, and EZH2, the latter of which is a histone methyltransferase enzymatic subunit 
that trimethylates histone 3 lysine 27 (62).  Both EZH2 and BMI1 are upregulated in 
numerous common solid tumors, leading to tumor progression and aggressiveness (62). 
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Indeed, ANRIL, HOTAIR, H19, KCNQ1OT1, and XIST have all been linked to the 
PRC2 complex, and in all except H19, direct binding has been observed between PRC2 
proteins and the ncRNA itself (41, 49, 56, 63, 64).  Binding of lncRNAs to PRC2 
proteins, however, is common and observed for ncRNAs which do not appear to function 
through a PRC2-mediated mechanism.  It is estimated that nearly 20% of all lncRNAs 
may bind PRC2 (65), though the biological meaning of these observations remains 
unclear.  It is possible that PRC2 promiscuously binds lncRNAs in a non-specific 
manner.  However, if lncRNAs are functioning in a predominantly cis-regulatory 
mechanism—such as ANRIL, KCNQ1OT1, and XIST—then numerous lncRNAs may 
bind PRC2 to facilitate local gene expression control throughout the genome.  Relatedly, 
studies of PRC2-ncRNA binding properties have been able to determine a putative 
PRC2-binding motif that includes a GC-rich double hairpin, indicating a structural basis 
for PRC2-ncRNA binding in many cases (41). 
Similarly, PRC1 proteins, particularly CBX proteins, have been implicated in 
ncRNA-based biology.  For example, ANRIL binds CBX7 in addition to PRC2 proteins, 
and this interaction with CBX7 recruits PRC1 to the INK4A/ARF locus to mediate 
transcriptional silencing (48).  More broadly, work with mouse polycomb proteins 
demonstrated that treatment with RNAse abolished CBX7 binding to heterochromatin on 
a global level, supporting the notion that ncRNAs are critical for PRC1 genomic 
recruitment (66). 
  While PRC1 and PRC2 are perhaps the most notable partners of lncRNAs, 
numerous other epigenetic complexes are implicated in ncRNA-mediated gene 
regulation.  For example, the 3’ domain of HOTAIR contains a binding site for the 
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LSD1/CoREST, a histone deacetylase complex that facilitates gene repression by 
chromatin remodeling (Figure 1.4A) (57).  AIR is similarly reported to interact with G9a, 
an H3K9 histone methyltransferase (67).  KCNQ1OT1 has been shown to interact with 
PRC2 (64), G9a (64), and DNMT1, which methylates CpG dinucleotides in the genome.  
More rarely, lncRNAs have been observed in activating epigenetic complexes.  In a 
recent example, HOTTIP interacts with WDR5 to mediate recruitment of the MLL 
histone methyltransferase to the distal HoxA locus.  MLL transfers methyl groups to 
H3K4me3, thereby generating open chromatin structures that promote gene transcription 
(53).   
In some cases, the mere act of lncRNA transcription is critical for the recruitment 
of protein complexes.  Studies for both H19, KCNQ1OT1 and AIR suggest that 
transcriptional elongation of these genes is an important component of their function (35, 
54, 55).  By contrast, other lncRNAs, including HOTTIP as well as many trans-
regulatory ones, do not show this relationship (53).  For these lncRNAs, biological 
function may be centrally linked to their role as flexible scaffolds.  In this model, 
lncRNAs serve as tethers that rope together multiple protein complexes through a loose 
arrangement.  Supporting this model are the multiple lncRNAs found to bind multiple 
protein complexes, such as ANRIL (binding PRC1 and PRC2) and HOTAIR (binding 
PRC2 and LSD1/CoREST) (Figure 1.4A). 
 
Enhancer-associated long ncRNAs 
In addition to facilitating epigenetic changes that impact gene transcription, 
emerging evidence suggests that some ncRNAs contribute to gene regulation by 
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influencing the activity of gene enhancers.  For example, HOTTIP is implicated in 
chromosomal looping of active enhancers to the distal HoxA locus (53), though 
knockdown and overexpression of HOTTIP is not sufficient to alter chromosomal 
confirmations (53).  There is also a report of local enhancer-like ncRNAs that typically 
lack the H3K4me1 enhancer histone signature, but possess H3K4me3, and function to 
potentiate neighbor gene transcription in a manner independent of sequence orientation 
(68). 
A major recent development has been the discovery of eRNAs, which are critical 
for the proper coordination of enhancer genomic loci with gene expression regulation.  
While the mechanism of their action is still unclear, in prostate cancer cells, induction of 
AR signaling increased eRNA synthesis at AR-regulated gene enhancers, suggesting that 
eRNAs facilitate active transcription upon induction of a signaling pathway (30).  Using 
chromatin conformation assays, Wang et al. showed that eRNAs are also important for 
the establishment of enhancer-promoter genomic proximity by chromosomal looping.  
Moreover, eRNAs work in conjunction with cell lineage-specific transcription factors, 
such as FOXA1 in prostate cells, thereby creating a highly specialized enhancer network 
to regulate transcription of genes in individual cell types (Figure 1.4B) (30).  Future 
work in this area will likely provide insight into signaling mechanisms important in 
cancer. 
 
Modulating tumor suppressor activity 
The role of many lncRNAs as transcriptional repressors lends itself to inquiry as a 
mechanism for suppression of tumor suppressor genes.  Here, one particular hotspot is 
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the chromosome 9p21 locus, harboring the tumor suppressor genes CDKN2A and 
CDKN2B, which give rise to multiple unique isoforms, such as p14, p15, and p16, and 
function as inhibitors of oncogenic cyclin dependent kinases.  Expression of this region is 
impacted by several repressive ncRNAs, such as ANRIL (Figure 1.4C, upper), and the 
p15-antisense RNA, the latter of which also mediates heterochromatin formation through 
repressive histone modifications and was observed in leukemias (48, 69). 
Moreover, several lncRNAs are implicated in the regulation of p53 tumor 
suppressor signaling.  MEG3, a maternally-expressed imprinted lncRNA on Chr14q32, 
has been shown to activate p53 and facilitate p53 signaling, including enhancing p53 
binding to target gene promoters (70).  MEG3 has also been linked to p53 signaling in 
meningioma (71), and MEG3 overexpression suppresses cell proliferation in meningioma 
and hepatocellular carcinoma cell lines (71, 72).  In human tumors, MEG3 
downregulation is widely noted, with frequent hypermethylation of its promoter observed 
in pituitary tumors (15) and leukemias (73).  Taken together, these data implicate MEG3 
as a putative tumor suppressor. 
A recently described murine lncRNA located near the p21 gene, termed linc-p21, 
has also emerged as a promising p53-pathway gene.  In murine lung, sarcoma, and 
lymphoma tumors, linc-p21 expression is induced upon activation of p53 signaling and 
represses p53 target genes through a physical interaction with hnRNP-K, a protein that 
binds the promoters of genes involved in p53 signaling (Figure 1.4C, lower) (74).  linc-
p21 is further required for proper apoptotic induction (74).  These data highlight linc-p21 
as a candidate tumor suppressor gene.  However, due to sequence differences between 
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species, it is currently unclear whether the human homologue of linc-p21 plays a 
similarly important role in human tumor development. 
 
Regulation of mRNA processing and translation 
While many lncRNAs operate by regulating gene transcription, post-
transcriptional processing of mRNAs is also critical to gene expression.  A primary actor 
in these processes is the nuclear paraspeckle, a sub-cellular compartment found in the 
interchromatin space within a nucleus and characterized by PSP1 protein granules (75).  
While nuclear paraspeckle functions are not fully elucidated, this structure is known to be 
involved in a variety of post-transcriptional activities, including splicing and RNA editing 
(75).  Paraspeckles are postulated to serve as storage sites for mRNA prior to its export to 
the cytoplasm for translation, and one study discovered a paraspeckle-retained, 
polyadenylated nuclear ncRNA, termed CTN-RNA, that is a counterpart to the protein-
coding murine CAT2 (mCAT2) gene (76).  CTN-RNA is longer than mCAT2, and under 
stress conditions, cleavage of CTN-RNA to the mCAT2 coding transcript resulted in 
increased mCAT2 protein (76). 
In cancer, two ncRNAs involved in mRNA splicing and nuclear paraspeckle 
function, MALAT1 and NEAT1, are overexpressed.  MALAT1 and NEAT1 are genomic 
neighbors on Chr11q13, and both are thought to contribute to gene expression by 
regulating mRNA splicing, editing, and export (Figure 1.4D) (77, 78).  MALAT1 may 
further serve as a precursor to a small, 61-base-pair ncRNAs that is generated by RNase P 
cleavage of the primary MALAT1 transcript and exported into the cytoplasm (79).  
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Although a unique role for MALAT1 in cancer is not yet known, its overexpression in 
lung cancer predicts for aggressive, metastatic disease (80). 
 
Regulatory RNA-RNA interactions 
Recent work on mechanisms of RNA regulation has highlighted a novel role for 
RNA-RNA interactions between ncRNAs and mRNA sequences.  These interactions are 
conceptually akin to miRNA regulation of mRNAs, as sequence homology between the 
ncRNA and the mRNA is important to the regulatory process. 
This sequence homology may be derived from ancestral repeat elements that 
contribute sequence to either the untranslated sequences of a protein-coding gene, or, less 
frequently, the coding region itself.  For example, STAU1-mediated mRNA decay 
involves the binding STAU1, a RNA degradation protein, to protein-coding mRNAs that 
interact with lncRNAs containing ancestral Alu repeats.  In this model, sequence 
repeats—typically Alus—in lncRNAs and mRNAs partially hybridize, forming double-
stranded RNA complexes that then recruit STAU1 to implement RNA degradation 
(Figure 1.4E) (81).  A related concept is found with XIST, which contains a conserved 
repeat, termed RepA, in its first exon.  RepA is essential for XIST function and the RepA 
sequence is necessary to recruit PRC2 proteins for X-chromosome inactivation (41). 
Another model for mRNA regulation was recently posited by Pandolfi and 
colleagues, who suggested that transcribed pseudogenes serve as decoy for miRNAs that 
target the protein-coding mRNA transcripts of their cognate genes (82).  Sequestration of 
miRNAs by the pseudogene then regulates the gene expression level of the protein-
coding mRNA indirectly (Figure 1.4F).  Beyond just pseudogenes, this model more 
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broadly suggests that all long ncRNAs, as well as other protein-coding mRNAs, may 
function as molecular “sponges” that bind and sequester miRNAs in order to control gene 
expression indirectly.  In their study, Pandolfi and colleagues demonstrate that 
pseudogenes of two cancer genes, PTEN and KRAS, may be biologically active, and that 
PTENP1, a pseudogene of PTEN that competes for miRNA binding sites with PTEN, 
itself functions as a tumor suppressor in in vitro assays and may be genomically lost in 
cancer (82).  This intriguing hypothesis may shed new light onto the functions or 
ncRNAs, pseudogenes, and even the UTRs of a protein-coding gene. 
 
METHODS TO DISCOVER LONG NON-CODING RNAs 
ncRNAs have historically been more difficult to detect than protein-coding genes.  
This is largely because ncRNAs tend to be more tissue-specific in their expression (83), 
exhibit lower overall levels of expression (26, 27, 84), and cannot be predicted by 
computational algorithms scanning for open reading frames (ORFs) in the human 
genome.  This last point is particularly germane, as the Human Genome Project 
employed hidden Markov Model-based methods to predict protein coding genes from 
DNA sequence, arriving at estimates between 20,000 – 25,000 (85, 86). 
However, the advance of high-throughput RNA profiling methods has enabled 
more precise and accurate cataloguing of ncRNAs.  While the Human Genome Project 
emphasized only protein-coding genes in their computational analysis of DNA, groups 
investigating RNA had long observed a great number of unannotated transcripts (5, 6).  
Many of these transcripts were discovered using cloning and sequencing of Expressed 
Sequence Tags (ESTs), and the detection of a spliced EST suggested the presence of two 
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exons being post-transcriptionally processed (87).  Prior to the completion of the Human 
Genome Project, analyses of ESTs routinely generated estimates of 30,000 – 120,000 
human genes (6, 88). 
The first studies to systematically catalogue ncRNAs used DNA tiling arrays, 
which utilized probes designed to densely cover a specific genomic region.  While these 
analyses were not genome-wide, they did cover several chromosomes in full (10, 11).  
The major drawback of this methodology is that there is no reliable way to exclude all of 
the degraded portions of gene introns, which can be detected as independent fragments of 
RNA but do not represent unique ncRNAs themselves.  Thus, these methods predicted a 
genome that was nearly universally transcribed into RNA (7, 10, 11). 
A major advance came when Guttman et al. combined the methodology of DNA 
tiling arrays with the logic of epigenetics (20).  Here, the authors reasoned that ncRNAs 
could resemble protein-coding genes in their fundamental structure and epigenetic 
characteristics.  Thus, ncRNAs could be polyadenylated and spliced, and, like protein-
coding genes, they could have a gene promoter marked by H3K4me3 and a gene body 
marked by H3K36me3.  By using ChIP-seq data of these epigenetic marks as well as 
RNA polymerase II, the authors observed several thousand regions of unannotated 
transcription by DNA tiling arrays in the same locations as these epigenetic marks (20).  
These were defined as lncRNAs based on their length and characteristics. 
The introduction of RNA-seq subsequently enabled the direct detection of all 
RNA species in a cell.  RNA-seq-based methods have been adapted to selectively 
measure small RNAs (89), long RNAs (26, 27, 84), RNA stability (90), the act of RNA 
transcription (30, 91, 92), and RNA species bound to protein complexes such as PRC2 
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(93).  RNA-seq is now the gold standard method to discover lncRNAs, but a major 
challenge with these data is their interpretation.  Sequence reads commonly harbor multi-
mapping potential, especially for lncRNAs whose DNA sequence is overall less 
conserved and harbors a greater degree of repetitive elements.  Thus, stringent filtration 
and rigorous analysis is required to eliminate spurious transcripts. 
 
PROSTATE CANCER 
This year, over one million prostate biopsies will be performed (94), over 200,000 
new diagnoses of prostate cancer are expected (95), and over 30,000 deaths will result 
from prostate cancer—the second leading cause of death from cancer (after lung cancer) 
in American men (95).  While autopsy-based analysis reveals prostate cancer as one of 
the most common male diseases—afflicting an estimated 65% of 70 year old men (96)—
there is only a 1 in 6 lifetime risk of developing clinically-detected disease (95), with 
African Americans having a increased risk and Asians having a lower risk of disease 
compared to Caucasians (97).  Furthermore, the incidence of lethal prostate cancer is 
approximately 1 in 35 (98, 99).  Given this gap in prevalence and clinical incidence, 
deciphering the molecular events that both cause and distinguish high-risk prostate cancer 
lesions from low risk ones continues to be an area of significant research.  
In the normal adult male, the prostate gland is a walnut-sized exocrine gland that 
contributes clear, slightly alkaline fluid secretions to a male’s semen as the sperm course 
down the reproductive tract.  Grossly, it is divided into five lobes: the anterior, median, 
and posterior lobes, as well as two lateral lobes.  Pathologically, however, the prostate is 
sectioned into four zones: the peripheral, central, transition, and anterior fibro-muscular 
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zones.  Whereas benign prostatic hyperplasia (BPH), an enlargement of the prostate 
commonly seen in aging men, is generally a product of hyperplasia of the transition zone, 
prostate cancer typically arises in the peripheral zone (100, 101). 
 
The molecular basis of prostate cancer 
While the development and progression of prostate cancer is linked to many 
factors, including dietary and lifestyle changes, advancements in genomics in the past 20 
years have placed a major emphasis on the causative role of somatic aberrations in 
tumorigenesis.  Aided by RNA and DNA sequencing technologies, the ability to study 
the underlying genomic alterations that distinguish cancers from normal tissue has led to 
a widespread paradigm shift in the way in which both cancer tumorigenesis and cancer 
therapeutics are conceptualized.  In 2000, Hanahan and Weinberg delineated the 
currently accepted mechanistic steps involved in cancer development: (1) self-sufficiency 
in growth signals; (2) insensitivity to anti-growth signals; (3) evading apoptosis; (4) 
sustained angiogenesis; (5) limitless replicative potential; (6) tissue invasion and 
metastasis (102).  For prostate cancer, these criteria have been investigated as multiple 
somatic events that occur as normal or benign tissues transform into malignant disease. 
 
Genetic aberrations in prostate cancer 
 Prostate cancer is characterized by a low mutational rate compared to other 
cancers, such as lung, melanoma and colon (103).  As a result, the landscape of prostate 
cancer lacks the preponderance of recurrent mutations observed in other cancers.  For 
example, mutations in canonical oncogenes such as KRAS, IDH1/2, BRAF, EGFR, and 
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PIK3CA are absent or relatively uncommon in prostate cancer (103).  A recent study 
using exome sequencing to comprehensively profile all known coding exons found low 
levels of recurrent mutations in BRAF, RET, and multiple androgen receptor cofactor 
genes, including FOXA1, MLL2, MLL, and ASHXL (104).  The ubiquitin ligase SPOP, a 
novel cancer gene discovered through whole-genome sequencing of prostate cancer 
(105), is also mutated in ~5% of all prostate cancers (~10% of ETS-negative cancers), 
though it is unclear how this gene is functioning in the disease.  Several tumor suppressor 
genes, most prominently p53, are also mutated in prostate cancer (104). 
 Although prostate cancer is not dominated by mutations, gene rearrangements and 
copy-number changes characterize much of the genomic landscape of this disease (104, 
105).  Several well-characterized tumor suppressor genes are commonly deleted, 
including PTEN and RB1 (Figure 1.5) (106, 107).  Deletion of PTEN, in particular, has 
been widely studied as a prognostic indicator of poor outcomes in approximately 1/3rd of 
patients (108-111).  Loss of PTEN activates the PI3K pathway (112), which results in 
resistance to androgen-based therapies in transgenic mouse models of prostate cancer 
(113), suggesting that patient cancers with a PTEN deletion may also be predisposed to 
resistance to androgen deprivation therapy.  Interestingly, a recent report suggests that 
deletion of MAGI2, a PTEN-interacting gene, may also occur a smaller subset of patients 
lacking PTEN deletion (105). 
The NK3 homeobox 1, NKX3.1, encodes a prostate-specific transcription factor 
that is positively regulated by androgen signaling (114-116).  A putative tumor 
suppressor gene, NKX3.1 is located on chromosome 8p21.2, a region that exhibits loss of 
heterozygosity in 50% to 85% of prostate cancers (115, 117-120) (Figure 1.5).  
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Decreased levels of NKX3.1 protein are also observed in ~75% of PINs, though only 
~12% of PIN lesions harbor genomic loss of NKX3.1, indicating that loss of the protein 
generally precedes loss of the gene itself (117).  While the exact functional role of 
NKX3.1 loss in prostate cancer in unclear, NKX3.1 appears both to regulate cell cycle and 
cell death pathways through stabilization of TP53 and to inhibit AKT1 activation (121).  
Further research has linked NKX3.1 with protection against damage from reactive oxygen 
species (122). 
 Amplifications of several oncogenes also helps to drive prostate cancer 
pathogenesis.  The cMYC oncogene is frequently amplified as part of an arm-level copy 
number gain of Chr8q, leading to its transcriptional upregulation in cancer (Figure 1.5) 
(123).  In mouse models, cMYC contributes to cellular proliferation angiogenesis, and 
apoptosis (124), and amplification of chromosome 8 occurs commonly in PIN, 
carcinomas, and metastases, identifying it as an early lesion in prostate cancer (125).  In 
addition, PIK3CA, though rarely mutated, resides in a common Chr3q amplicon (104).   
 
Androgen receptor alterations in prostate cancer 
Among the most well-studied genomic alterations in prostate cancer are those 
relating to the androgen receptor (AR) itself.  Androgen signaling is a major component 
of prostate cancer development, and androgen ablation therapy has been a mainstay in 
cancer therapy since Huggins first described the method in the early 1940s (126, 127).  
Though androgen ablation therapy can be an effective means for tumor regression, it 
frequently fails to cure the disease, leading to an aggressively metastatic, often fatal, 
castrate-resistant prostate cancer (CRPC) instead.  Whereas AR mutations are very rare in 
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androgen-naïve cancers, CRPC is characterized by a number of genetic alterations, with 
30 - 60% of CRPC tumors harboring an amplified AR gene (104, 128-131) and perhaps 
20 - 30% of metastatic CRPC tumors possessing mutations of AR (Figure 1.5) (130-135). 
 Many of these alterations result in hypersensitivity to androgen signaling.  
Increased AR expression (128), amplified co-activators, increased AR stability, and 
enhanced nuclear localization all contribute to abnormal AR sensitivity (131, 136, 137).  
Variants in the 5-alpha reductase gene, which converts testosterone into the more potent 
dihydrotestosterone (DHT), can also result in enhanced enzymatic activity and increased 
DHT levels (138-140).  Supporting this, there is some evidence that, after androgen 
ablation therapy, DHT levels in the prostate tissue decrease by only 60% though serum 
testosterone drops by 95%, indicating that androgen levels may remain relatively high 
(141).  
Another major mechanism in the alteration of androgen signaling is through 
increased AR promiscuity.  Many mutations of the AR, most occurring within the ligand 
binding domain, have been correlated with the ability for the AR to bind nonclassical 
ligands (130, 131, 136).  Androgen receptors harboring the T877A and L701H mutations, 
in particular, are able to bind and respond to corticosteroids, which ordinarily function as 
AR antagonists (130, 133, 136, 142).  Overexpression of AR co-regulators, such as TIF2, 
ARA70, SRC1, and oncostatin M, an IL-6-related cytokine, have also been shown to 





Gene fusions in prostate cancer 
In 2005, our group described the presence of recurrent fusions between the ETS 
family transcription factors, ERG and ETV1, and the androgen-regulated transmembrane 
serine protease, TMPRSS2 (145) (Figure 1.5).   Subsequently, multiple other 5’ fusion 
partners have been described for ERG and ETV1, as well as other members of the ETS 
family (Table 1.3)  (145, 146).  All told, ETS fusions are found in roughly 50% of 
prostate cancers, of which 90% are TMPRSS2-ERG fusions (145, 147-149).  Because 
ERG and TMPRSS2 are separated by only ~ 3 kb on the long arm of chromosome 21, two 
mechanisms are implicated in their creation: an intrachromosomal deletion within 
chromosome 21, and an inversion of that same region (145, 150).  For gene fusion 
generation, it is thought that AR plays a causative role in bringing TMPRSS2 and ERG 
into spatial proximity, which allows for faulty DNA repair following genotoxic stress 
(151, 152).  While these mechanisms may create TMPRSS2-ETS gene fusions, 
TMPRSS2 typically contributes only untranslated sequences to the final transcript, 
thereby functioning only to upregulate ETS transcription factor expression (145, 153). 
Following this discovery, the TMPRSS2-ERG fusions have emerged as a major 
factor in prostate tumorigenesis, contributing to cellular invasiveness in vitro (146-149).  
Moreover, TMPRSS2-ERG fusions are detectable in pre-malignant prostate lesions such 
as high-grade prostatic intraepithelial neoplasia (HGPIN) if these lesions are proximal to, 
or continguous with, regions of cancer (154-156), suggesting that these fusions may be 
important in early tumorigenesis. 
In addition, the detection of TMPRSS2-ERG RNA in patient urine became widely 
investigated.  Since the presence of these transcripts is diagnostic for prostate cancer, a 
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positive TMPRSS2-ERG urine assay may indicate cancer even if prostate needle biopsy 
results failed to detect cancer.  Because of this remarkable attribute, clinical TMPRSS2-
ERG urine assays significantly improve upon serum PSA for the delineation of prostate 
cancer in PSA-prescreened cohorts.  Our lab recently published a large study of more 
than 1300 men demonstrating that combined measurement of PCA3, a prostate cancer 
biomarker, and TMPRSS2-ERG in urine outperforms serum PSA for prostate cancer 
diagnosis (AUC = 0.71 – 0.77 for TMPRSS2-ERG + PCA3; AUC = 0.61 for PSA) and 
adds to available clinical in the Prostate Cancer Prevention Trial (PCPT) risk estimates 
for predicting cancer (157). 
There has been some debate as to whether the presence of a TMPRSS2-ERG 
fusion is itself a prognostic biomarker when detected in tissues.  Several groups have 
reported an association between TMPRSS2-ERG and aggressive prostate cancer (157-
159).  However, others have not observed this association (160, 161).  One complication 
to these studies has been heterogeneity in the patient populations studied and the clinical 
outcomes evaluated.  Interestingly, quantitative levels of urine TMPRSS2-ERG, however, 
appear to be associated with clinically significant prostate cancer based on Epstein 
criteria, which stratifies disease aggressiveness using PSA density and characteristics of 
the patient’s biopsy (Gleason score, the percent tumor observed, and number of cores 
with tumor) (157). 
Additional efforts to discover gene fusions using RNA-seq have been employed 
to interrogate prostate cancers lacking an ETS gene fusion.  Here, our group defined 
functionally-recurrent gene fusions of the BRAF and RAF oncogenes in a subset of ETS-
negative prostate cancers (162).  These fusions promoted cell transformation and growth, 
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and, of note, these fusions were found to retain sensitivity to BRAF inhibitors in vitro, 
suggesting that they may be appropriate as a predictive biomarker in patients.  Similar 
efforts also described an activating KRAS gene fusion in the Du145 prostate cancer cell 
line, and rare genomic disruption of the KRAS locus in prostate cancer may contribute to 
a subset of cancers (163). 
 
lncRNAs in prostate cancer 
 To date, the most prominent lncRNA investigated in prostate cancer has been 
PCA3.  PCA3 is a prostate-specific gene elevated in >90% of prostate cancer tissues, but 
not in normal or BPH tissues (164, 165).  However, the biological function of PCA3 
remains unknown, and thus the high sensitivity and specificity of PCA3 in tissues have 
led to its evaluation as a non-invasive biomarker for prostate cancer, where numerous 
assays have been developed to detect it in patient urine samples, which contain cells shed 
from the prostate during urination (Figure 1.6).  Over the past decade, several iterations 
of PCA3 urine tests have also emerged (166) and, currently, a clinical-grade assay based 
on transcription-mediated amplification is available (166). 
Urine PCA3 measurements add to the diagnostic information obtained from the 
PSA test, with higher AUC values of 0.66 to 0.72, compared to 0.54 to 0.63 for serum 
PSA alone (167).  Unlike PSA, PCA3 levels are independent of prostate size (168).  
Sensitivities for urine PCA3 levels range from 47 to 69%, with most between 58 and 
69%, although it is difficult to directly compare the studies because of different analysis 
platforms, different criteria for enrolling patients (for example, serum PSA 
concentrations), and relatively small patient cohorts of several hundred men rather than 
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thousands (167).  In addition, combining a serum PSA value with a urine PCA3 analysis 
improves both measures, with the combination AUC of 0.71 to 0.75 (169).  In 2012, 
PCA3 was FDA-approved as a diagnostic for prostate cancer in the setting of a prior 
negative biopsy (http://www.accessdata.fda.gov/cdrh_docs/pdf10/p100033a.pdf). 
 Another lncRNA, PCGEM1, has been reported to be elevated in prostate cancer 
(170).  PCGEM1 expression increased cell proliferation and transformation in vitro 
(171).  Interestingly, PCGEM1 expression was associated with patients of African-
American ethnicity, a patient population with worse disease outcomes, though it was not 
associated with disease grade or stage (171).  Overexpression of PCGEM1 decreased cell 
apoptosis following genotoxic stress (172), suggesting that this gene may be involved in 
apoptotic processes, though the mechanism remains unknown.  
 
CONCLUSION 
lncRNAs represent a promising avenue for uncovering previously unknown 
mechanisms of cancer biology.  However, to date only a handful of lncRNAs have been 
well-characterized in human disease, partly because systematic discovery of all lncRNA 
species has been technically challenging to accomplish.  The introduction of RNA-seq 
promises to facilitate the genome-wide characterization of thousands of unannotated 
lncRNAs, revealing a new complement of genes to investigate.  In cancer, several 
lncRNAs have been described, such as HOTAIR and ANRIL, and most of these appear to 
coordinate epigenetic regulation of gene expression by physically partnering with major 
histone-modifying complexes.  In prostate cancer, however, little is known about the role 
of lncRNAs.  The most prominent lncRNA in prostate cancer, PCA3, remains 
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functionally uncharacterized, and only anecdotal studies have suggested a role for 































Figure 1.1: A schematic of the central dogma of molecular biology, wherein DNA is 





Figure 1.2. MicroRNA-mediated pathways in cancer.  (A) MicroRNA (miRNA) 
transcription usually occurs by RNA Polymerase II, generating a primary pri-miRNA 
transcript. The pri-miRNA is processed by DROSHA and cleaved by DICER to generate a 
mature miRNA, which then associates with Argonaute family proteins in the RNA-
induced silencing complex (RISC) to achieve gene expression control.  (B) In cancer, 
aberrant miRNA expression levels can lead either to the repression of tumor suppressor 
(typically when miRNA levels are upregulated) or de-repression of oncogenes (typically 
when miRNA levels are downregulated).  The colored triangles indicate different miRNA 
binding sites in the 3’ untranslated region (UTR) of a protein-coding mRNA.  
Abbreviation: CDS, coding sequence.   (C) Two examples of aberrant miRNA signaling 
in cancer are let-7, which is downregulated in cancer and regulates oncogenes such as 






Figure 1.3: Gene expression regulation by lncRNAs.  (A) and (B): cis-regulation of 
gene expression results in local control of genes neighboring, or on the same 
chromosome as, lncRNA transcription.  (A) H19 and KCNQ1OT1 are imprinted 
lncRNAs on chromosome 11 associated with allele-specific expression of IGF2 and 
KCNQ1.  (B) XIST transcription facilitates inactivation of an individual X chromosome in 
women by recruiting the Polycomb Repressive Complex 2 (PRC2).  (C) and (D) trans-
regulation of gene expression results in control of genomically-distant genes.  (C) 
HOTAIR is transcribed from the HoxC cluster on chromosome 12 but represses the HoxD 
locus via PRC2-mediated epigenetic modifications.  (D) The GAS5 lncRNA binds 
Glucocorticoid Receptor (GR) and sequesters it, preventing upregulation of GR-target 





Figure 1.4: Mechanisms of lncRNA function.  (A) lncRNAs, such as HOTAIR, may 
serve as a scaffolding base for the coordination of epigenetic or histone-modifying 
complexes, including Polycomb repressive complexes and LSD1/CoREST.  (B) 
Enhancer RNAs (eRNAs) transcribed from gene enhancers may facilitate hormone 
signaling by cooperating with lineage-specific complexes such as FOXA1 and Androgen 
Receptor.  (C) lncRNAs may directly impact tumor suppressor signaling either by 
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transcriptional regulation of tumor suppressor genes through epigenetic silencing (e.g. 
ANRIL, upper) or by mediating activation of tumor suppressor target genes (e.g. linc-
p21, lower).  (D) MALAT1 and NEAT2 lncRNAs may be integral components of the 
nuclear paraspeckle and contribute to post-transcriptional processing of mRNAs.  (E) 
Gene expression regulation may occur through direct lncRNA-mRNA interactions which 
arise from hybridization of homologous sequences and can serve as a signaling for 
STAU1-mediated degradation of the mRNA.  (F) RNA molecules, including mRNAs, 
pseudogenes, and ncRNAs, can serve as molecular sponges for miRNAs.  This generates 
an environment of competitive binding of miRNAs to achieve gene expression control 
based upon the degree of miRNA binding to each transcript.  The colored triangles 










Figure 1.5: Major molecular events in prostate cancer progression.  
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Figure 1.6: Schematic of urine sample analysis. Men selected for prostate cancer 
screening produce a urine sample for analysis.  Urine samples are centrifuged to obtain 
cells shed into the urine, including cancer cells.  Nucleic acids, such as RNA and DNA, 
are isolated from these cells, and molecular tests, such as PCA3 and TMPRSS2-ERG, are 
run on this genetic material to generate a molecular profile that distinguishes men with 


















Transfer RNAs High No No
Ribosomal RNAs High No No
Small nucleolar RNAs High No No






Tiny transcription initiation RNAs High Not known Not known
Repeat associated small interfering RNAs High Not known Not known
Promoter‐associated short RNAs High Not known Not known
Termini‐associated short RNAs High Not known Not known
Antisense termini associated short RNAs High Not known Not known
Transcription start site antisense RNAs Moderate Not known Not known
Retrotransposon‐derived RNAs High Not known Not known
3'UTR‐derived RNAs Moderate Not known Not known








Enhancer RNAs High Yes Not known
Repeat‐associated ncRNAs High Not known Not known
Long intronic ncRNAs Moderate Not known Not known
Antisense RNAs High Yes Gene expression
Promoter‐associated long RNAs Moderate Not known Not known









Table 1.2: Examples of lncRNAs in cancer 
p
lncRNA Function Cancer Type Cancer Phenotype Molecular Interactors
HULC Biomarker Hepatocellular Not known Unknown





































































TMPRSS2 ERG ~40-50% 
NDRG1 ERG <1% 
TMPRSS2 ETV1 5-10% 
HERV_K ETV1 <1% 
C15orf21 ETV1 <1% 
HNRPA2B1 ETV1 <1% 
SLC45A3 ETV1 <1% 
ACSL3 ETV1 <1% 
FLJ35294 ETV1 <1% 
TMPRSS2 ETV4 1-2% 
KLK2 ETV4 <1% 
CANT1 ETV4 <1% 
DDX5 ETV4 <1% 
TMPRSS2 ETV5 1-2% 
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Transcriptome sequencing across a cohort of prostate cancers identifies 




High-throughput sequencing of polyA+ RNA (RNA-Seq) in human cancer shows 
remarkable potential to identify both novel markers of disease and uncharacterized 
aspects of tumor biology, particularly non-coding RNA (ncRNA) species.  We employed 
RNA-Seq on a cohort of 102 prostate tissues and cells lines and performed ab initio 
transcriptome assembly to discover unannotated ncRNAs.  In total, we identified >6,000 
unannotated transcripts, of which 1,857 were intergenic in nature.  These transcripts were 
associated with histone marks supporting independent transcriptional start sites and active 
transcription, including H3K4me3, H3K36me3, and RNA Polymerase II.  To identify 
novel transcripts that may be implicated in cancer biology, we nominated 121 such 
Prostate Cancer Associated Transcripts (PCATs) with cancer-specific expression 
patterns, several of which also scored as prominent outliers expressed in only a subset of 
samples.  Strikingly, many PCATs exhibited prostate-specific expression, suggesting that 
lineage-restricted expression of lncRNAs may contribute to disease biology.  These 
findings establish the utility of RNA-Seq to identify disease-associated ncRNAs that may 




Recently, next generation transcriptome sequencing (RNA-Seq) has provided a 
method to delineate the entire set of transcriptional aberrations in a disease, including 
novel transcripts and non-coding RNAs (ncRNAs) not measured by conventional 
analyses (1-5).  To facilitate interpretation of sequence read data, existing computational 
methods typically process individual samples using either short read gapped alignment 
followed by ab initio reconstruction (2, 3), or de novo assembly of read sequences 
followed by sequence alignment (4, 5).  These methods provide a powerful framework to 
uncover uncharacterized RNA species, including antisense transcripts, short RNAs <250 
bps, or long ncRNAs (lncRNAs) >250 bps. 
While still largely unexplored, ncRNAs, particularly lncRNAs, have emerged as a 
new aspect of biology, with evidence suggesting that they are frequently cell-type 
specific, contribute important functions to numerous systems (6, 7), and may interact 
with known cancer genes such as EZH2 (8).  Indeed, several well-described examples, 
such as HOTAIR (8, 9) and ANRIL (10, 11), indicate that ncRNAs may be essential actors 
in cancer biology, typically facilitating epigenetic gene repression via chromatin 
modifying complexes (12, 13).  Moreover, ncRNA expression may confer clinical 
information about patient outcomes and have utility as diagnostic tests (9, 14).  The 
characterization of RNA species, their functions, and their clinical applicability is 
therefore a major area of biological and clinical importance. 
Here, we describe a comprehensive analysis of lncRNAs in 102 prostate cancer 
tissue samples and cell lines by RNA-Seq.  We employ ab initio computational 
approaches to delineate the annotated and unannotated transcripts in this disease, and we 
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find 121 ncRNAs, termed Prostate Cancer Associated Transcripts (PCATs), whose 
expression patterns distinguish benign, localized cancer, and metastatic cancer samples.   
 
RESULTS 
RNA-Seq analysis of the prostate cancer transcriptome 
Over two decades of research has generated a genetic model of prostate cancer 
based on numerous neoplastic events, such as loss of the PTEN (15) tumor suppressor 
gene and gain of oncogenic ETS transcription factor gene fusions (16-18) in large subsets 
of prostate cancer patients.  We hypothesized that prostate cancer similarly harbored 
disease-associated ncRNAs in molecular subtypes. 
To pursue this hypothesis, we employed transcriptome sequencing on a cohort of 
102 prostate tissues and cell lines (20 benign adjacent prostates (benign), 47 localized 
tumors (PCA), and 14 metastatic tumors (MET) and 21 prostate cell lines). From a total 
of 1.723 billion sequence fragments from 201 lanes of sequencing (108 paired-end, 93 
single read on the Illumina Genome Analyzer and Genome Analyzer II), we performed 
short read gapped alignment (19) and recovered 1.41 billion mapped reads, with a median 
of 14.7 million mapped reads per sample.  We used the Cufflinks ab initio assembly 
approach (3) to produce, for each sample, the most probable set of putative transcripts 
that served as the RNA templates for the sequence fragments in that sample (Figures 2.1 
and 2.2). 
As expected from a large tumor tissue cohort, individual transcript assemblies 
may exhibit sources of “noise”, such as artifacts of the sequence alignment process, 
unspliced intronic pre-mRNA, and genomic DNA contamination.  To exclude these from 
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our analyses, we trained a decision tree to classify transcripts as “expressed” versus 
“background” on the basis of transcript length, number of exons, recurrence in multiple 
samples, and other structural characteristics (Figure 2.1b, left).  The classifier 
demonstrated a sensitivity of 70.8% and specificity of 88.3% when trained using 
transcripts that overlapped genes in the AceView database (20), including 11.7% of 
unannotated transcripts that were classified as “expressed” (Figure 2.1b, right).  We then 
clustered the “expressed” transcripts into a consensus transcriptome and applied 
additional heuristic filters to further refine the assembly. The final ab initio transcriptome 
assembly yielded 35,415 distinct transcriptional loci (Table 2.1). 
 
Discovery of prostate cancer non-coding RNAs 
We compared the assembled prostate cancer transcriptome to the UCSC, 
Ensembl, Refseq, Vega, and ENCODE gene databases to identify and categorize 
transcripts (Figure 2.1c).  While the majority of the transcripts (77.3%) corresponded to 
annotated protein coding genes (72.1%) and non-coding RNAs (5.2%), a significant 
percentage (19.8%) lacked any overlap and were designated “unannotated” (Figure 
2.3a).  These included partially intronic antisense (2.44%), totally intronic (12.1%), and 
intergenic transcripts (5.25%), consistent with previous reports of unannotated 
transcription (21-23).  Due to the added complexity of characterizing antisense or 
partially intronic transcripts without strand-specific RNA-Seq libraries, we focused on 
totally intronic and intergenic transcripts. 
Global characterization of novel intronic and intergenic transcripts demonstrated 
that they were more highly expressed (Figure 2.3b), had greater overlap with expressed 
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sequence tags (ESTs) (Figure 2.4), and displayed a clear but subtle increase in 
conservation over randomly permuted controls (novel intergenic transcripts p = 2.7 x 10-4 
± 0.0002 for 0.4 < ω < 0.8; novel intronic transcripts p = 2.6 x 10-5 ± 0.0017 for 0 < ω < 
0.4, Fisher’s exact test, Figure 2.3c).  By contrast, unannotated transcripts scored lower 
than protein-coding genes for these metrics, which corroborates data in previous reports 
(2, 24).  Interestingly, a small subset of novel intronic transcripts showed a profound 
degree of conservation (Figure 2.3c, insert).  Finally, analysis of coding potential 
revealed that only 5 of 6,144 transcripts harbored a high quality open reading frame 
(ORF), indicating that the vast majority of these transcripts represent ncRNAs (Figure 
2.5). 
To determine whether our unannotated transcripts were supported by histone 
modifications defining active transcriptional units, we used published prostate cancer 
ChIP-Seq data for two prostate cell lines (25), VCaP and LNCaP.  After filtering our 
dataset for transcribed repetitive elements known to display alternative patterns of histone 
modifications (26), we observed a strong enrichment for histone modifications 
characterizing transcriptional start sites (TSSs) and active transcription, including 
H3K4me2, H3K4me3, Acetyl-H3 and RNA polymerase II (Figure 2.3d-g) but not 
H3K4me1, which characterizes enhancer regions (27) (Figures 2.6).  Interestingly, 
intergenic ncRNAs showed greater enrichment compared to intronic ncRNAs in these 
analyses (Figure 2.3d-g). 
To elucidate global changes in transcript abundance in prostate cancer, we 
performed a differential expression analysis for all transcripts.  We found 836 genes 
differentially-expressed between benign samples and localized tumors (FDR < 0.01), 
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with annotated protein-coding and ncRNA genes constituting 82.8% and 7.4% of 
differentially-expressed genes, respectively, including known prostate cancer biomarkers 
such AMACR (28), HPN (29), and PCA3 (14) (Figure 2.3h).  Finally, 9.8% of 
differentially-expressed genes corresponded to unannotated ncRNAs, including 3.2% 
within gene introns and 6.6% in intergenic regions. 
 
Characterization of Prostate Cancer Associated Transcripts 
As ncRNAs may contribute to human disease (6-9), we identified aberrantly 
expressed uncharacterized ncRNAs in prostate cancer.  We found a total of 1,859 
unannotated lncRNAs throughout the human genome.  Overall, these intergenic RNAs 
resided approximately half-way between two protein coding genes (Figures 2.7), and 
over one-third (34.1%) were ≥10kb from the nearest protein-coding gene, which is 
consistent with previous reports (30) and supports the independence of intergenic 
ncRNAs genes. 
A focused analysis of the 1,859 unannotated intergenic RNAs yielded 106 that 
were differentially expressed in localized tumors (FDR < 0.05, Figure 2.8a).  A cancer 
outlier expression analysis similarly nominated numerous unannotated ncRNA outliers 
(Figure 2.8b) as well as known prostate cancer outliers, such as ERG (18), ETV1 (17, 
18), SPINK1 (31) and CRISP3 (32).  Merging these results produced a set of 121 
unannotated transcripts that accurately discriminated benign, localized tumor, and 
metastatic prostate samples by unsupervised clustering (Figure 2.8a).  These 121 
unannotated transcripts were ranked and named as Prostate Cancer Associated 
56 
 
Transcripts (PCATs) according to their fold change in localized tumor versus benign 
tissue (Tables 2.2 and 2.3). 
 
Validation of novel ncRNAs 
To gain confidence in our transcript nominations, we validated multiple 
unannotated transcripts in vitro by reverse transcription PCR (RT-PCR) and quantitative 
real-time PCR (qPCR) (Figure 2.9).  qPCR for four transcripts (PCAT-114, PCAT-14, 
PCAT-43, PCAT-1) on an independent cohort of prostate tissues confirmed predicted 
cancer-specific expression patterns (Figure 2.8c-f).  Interestingly, all four are prostate-
specific, with minimal expression seen by qPCR in breast (n=14) or lung cancer (n=16) 
cell lines or in 19 normal tissue types.  This is further supported by expression analysis of 
these transcripts in our RNA-Seq compendium of 13 tumor types, representing 325 
samples (Figure 2.10).  This tissue specificity was not necessarily due to regulation by 
androgen receptor signaling, as only PCAT-14 expression was induced when androgen 
responsive VCaP and LNCaP cells were treated with the synthetic androgen R1881, 
consistent with previous data from this locus (17) (Figure 2.11). PCAT-1 and PCAT-14 
also showed cancer-specific upregulation when tested on a panel of matched tumor-
normal samples (Figure 2.12). 
Of note, PCAT-114, which ranks as the #5 best outlier, just ahead of ERG (Figure 
2.8b), appears as part of a large, >500 kb locus of expression in a gene desert in Chr2q31.  
We termed this region Second Chromosome Locus Associated with Prostate-1 
(SChLAP1) (Figure 2.13).  Careful analysis of the SChLAP1 locus revealed both 
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discrete transcripts and intronic transcription, highlighting this region as an intriguing 
aspect of the prostate cancer transcriptome. 
 
DISCUSSION 
 This study represents the largest RNA-Seq analysis to date and the first to 
comprehensively analyze a common epithelial cancer from a large cohort of human tissue 
samples.  As such, our study has adapted existing computational tools intended for small-
scale use (3) and developed new methods in order to distill large numbers of 
transcriptome datasets into a single consensus transcriptome assembly that reflects a 
coherent biological picture. 
Among the numerous uncharacterized ncRNA species detected by our study, we 
have focused on 121 prostate cancer-associated PCATs, which we believe represent a set 
of uncharacterized ncRNAs that may have important biological functions in this disease.  
In this regard, these data contribute to a growing body of literature supporting the 
importance of unannotated ncRNA species in cellular biology and oncogenesis (6-12), 
and broadly our study confirms the utility of RNA-Seq in defining functionally-important 
elements of the genome (2-4).  These PCATs reflect a unique aspect of prostate cancer 
biology, as many of them exhibit prostate-specific expression (Figure 2.10), but this is 
typically not due to androgen receptor signaling.  As such, PCATs and other similarly 
lineage-restricted lncRNAs in different cancers may represent rationale candidates for 
biomarker development, since they offer high specificity for distinguishing cancers.  
Furthermore, elucidation of the mechanisms responsible for this lineage-restricted 
expression will likely uncover novel aspects of cancer biology. 
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MATERIALS AND METHODS 
RNA-Seq Library Preparation. 
Next generation sequencing of RNA was performed on 21 prostate cell lines, 20 
benign adjacent prostates, 47 localized tumors, and 14 metastatic tumors according to 
Illumina’s protocol using 2ug of RNA.  RNA integrity was measured using an Agilent 
2100 Bioanalyzer, and only samples with a RIN score >7.0 were advanced for library 
generation.  2µg total RNA was selected for polyA+ RNA using Sera-Mag oligo(dT) 
beads (Thermo Scientific), fragmented with the Ambion Fragmentation Reagents kit 
(Ambion, Austin, TX).  cDNA synthesis, end-repair, A-base addition, and ligation of the 
Illumina PCR adaptors (single read or paired-end where appropriate) were performed 
according to Illumina’s protocol as previously described (33-35).  Libraries were then 
size-selected for 250-300 bp cDNA fragments on a 3.5% agarose gel and PCR-amplified 
using Phusion DNA polymerase (Finnzymes) for 15 –18 PCR cycles.  PCR products 
were then purified on a 2% agarose gel and gel-extracted.  Library quality was 
credentialed by assaying each library on an Agilent 2100 Bioanalyzer of product size and 
concentration.  Libraries were sequenced as 36-45mers on an Illumina Genome Analyzer 
I or Genome Analyzer II flowcell according to Illumina’s protocol.  All single read 
samples were sequenced on a Genome Analyzer I, and all paired-end samples were 
sequenced on a Genome Analyzer II. 
 
Bioinformatic analyses 
To achieve an ab initio prediction of the prostate cancer transcriptome we 
leveraged existing publicly tools for mapping, assembly, and quantification of transcripts, 
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and supplemented these tools with additional informatics filtering steps to enrich the 
results for the most robust transcript predictions (Figure 2.1).  Transcripts were then 
identified and classified by comparing them against gene annotation databases (Figure 
2.1).  Details of the bioinformatics analyses are provided below. 
Mapping reads with TopHat:   Reads were aligned using TopHat v1.0.13 (Feb 5, 
2010) (19), a gapped aligner capable of discovering splice junctions ab initio. Briefly, 
TopHat aligns reads to the human genome using Bowtie(36) to determine a set of 
"coverage islands" that may represent putative exons.  TopHat uses these exons as well as 
the presence of GT-AG genomic splicing motifs to build a second set of reference 
sequences spanning exon-exon junctions.  The unmapped reads from the initial genome 
alignment step are then remapped against this splice junction reference to discover all the 
junction-spanning reads in the sample.  TopHat outputs the reads that successfully map to 
either the genome or the splice junction reference in SAM format for further analysis. For 
this study we used a maximum intron size of 500kb, corresponding to over 99.98% of 
RefSeq introns (37).  This may limit sensitivity to detect read-through chimeras at the 
expense of increased specificity of splice junction calls.  For sequencing libraries we 
determined the insert size using an Agilent 2100 Bioanalyzer prior to data analysis, and 
found that this insert size agreed closely with software predictions (data not shown).  An 
insert size standard deviation of 20 bases was chosen in order to match the most common 
band size cut from gels during library preparation. 
In total, 1.723 billion fragments were generated from 201 lanes of sequencing on 
the Illumina Genome Analyzer and Illumina Genome Analyzer II.  Reads were mapped 
to the human genome (hg18) downloaded from the UCSC genome browser website (38, 
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39).  We obtained 1.418 billion unique alignments including 114.4 million splice 
junctions for use in transcriptome assembly.  Reads with multiple alignments with less 
than two mismatches were discarded. 
Ab initio assembly and quantification with Cufflinks:  Aligned reads from TopHat 
were assembled into sample-specific transcriptomes with Cufflinks version 0.8.2 (March 
26, 2010) (3).  Cufflinks assembles exonic and splice-junction reads into transcripts using 
their alignment coordinates.  To limit false positive assemblies we used a maximum 
intronic length of 300kb, corresponding to the 99.93% percentile of known introns.  After 
assembling transcripts, Cufflinks computes isoform-level abundances by finding a 
parsimonious allocation of reads to the transcripts within a locus.  We filtered transcripts 
with abundance less than 15% of the major transcript in the locus, and minor isoforms 
with abundance less than 5% of the major isoform.  Default settings were used for the 
remaining parameters. 
The Cufflinks assembly stage yielded a set of transcript annotations for each of 
the sequenced libraries.  We partitioned the transcripts by chromosome and used the 
Cuffcompare utility provided by Cufflinks to merge the transcripts into a combined set of 
annotations.  The Cuffcompare program performs a union of all transcripts by merging 
transcripts that share all introns and exons.  The 5' and 3' exons of transcripts were 
allowed to vary by up to 100nt during the comparison process. 
Distinguishing transcripts from background signal:  Cuffcompare reported a total 
of 8.25 million distinct transcripts.  Manual inspection of these transcripts in known 
protein coding gene regions suggested that most of the transcripts were likely to be poor 
quality reconstructions of overlapping larger transcripts.  Also, many of the transcripts 
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were unspliced and had a total length smaller than the size selected fragment length of 
approximately ~250nt.  Furthermore, many of these transcripts were only present in a 
single sample.  Therefore, we reasoned that the vast majority of predicted loci probably 
corresponded to stochastic transcriptional "noise", subtle amounts of genomic DNA 
present in the sample, or artifacts due to errors in read alignment. 
Here, we designed a statistical classifier to predict transcripts over background 
signal with the goal of identifying highly recurrent transcripts that may be altered in 
prostate cancer.  This approach rests on the premise that a manually curated gene 
database could represent a reliable set of "true" positives on which to train a statistical 
learning algorithm.  We used the AceView annotations (20) which we believe have an 
adequate representation of low abundance ncRNA transcripts that may be cell-type 
specific in addition to protein coding gene isoforms.  For each transcript predicted by 
Cufflinks we collected the following statistics: length (bp), number of exons, recurrence 
(number of samples in which the transcript was predicted), 95th percentile of abundance 
(measured in Fragments per Kilobase per Million reads (FPKM)) across all samples, and 
uniqueness of genomic DNA harboring the transcript transcript (measured using the 
Rosetta uniqueness track from UCSC (40)).  Using this information, we used recursive 
partitioning and regression trees in R (package rpart) to predict, for each transcript, 
whether its expression patterns and structural properties resembled those of annotated 
genes. Classification was performed independently for each chromosome in order to 
incorporate the effect of gene density variability on expression thresholds. Transcripts 
that were not classified as annotated genes were discarded, and the remainder were 
subjected to additional analysis and filtering steps. By examining the decision tree results 
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we observed that the 95th percentile of expression across all samples as well as the 
recurrence of each transcript were most frequently the best predictors of expressed versus 
background transcripts (Figure 2.1b,c). 
Refinement of transcript fragments:  The statistical classifier predicted a total 2.88 
million (34.9%) transcript fragments as “expressed” transcripts.  We then developed a 
program to extend and merge intron-redundant transcripts to produce a minimum set of 
transcripts that could possibly explain the assemblies produced by Cufflinks.  By merging 
transcripts in this manner we relinquished the ability to detect some types of alternative 
TSSs, but drastically reduced the total number of independent transcripts in our 
assembly.  We believe merging all intron-redundant transcripts is suitable for qualitative 
detection of transcriptionally active regions, but more sophisticated methods would be 
necessary for the study of alternative splicing, alternative TSSs, and alternative poly-
adenylation site usage within well characterized regions.  The merging step produced a 
total of 123,554 independent transcripts. We then re-computed transcript abundance 
levels for these revised transcripts in Reads per Kilobase per Million (RPKM) units.  
These expression levels were used for the remainder of the study. 
We applied several additional filtering steps to isolate the most robust transcripts.  
First, we discarded transcripts with a total length less than 200nt.  Our size selection 
protocol isolates RNA molecules larger than this, and small RNA sequencing protocols 
would likely be needed to quantify smaller molecules with high confidence.  Second, we 
discarded single exon transcripts with greater than 75% overlap to another longer 
transcript.  We believe many of these are produced from unspliced pre-mRNA molecules 
and do not represent functional RNA products.  Third, we removed transcripts that lacked 
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a completely unambiguous genomic DNA stretch of at least 40nt.  We measured genomic 
uniqueness using the Rosetta uniqueness track downloaded from the UCSC genome 
browser website.  We believe transcripts spanning poorly mappable regions are more 
likely to occur due to mapping artifacts and the availability of longer reads would 
alleviate the need for this filtering step.  Finally, we retained transcripts that were not 
present in at least 5% of our cohort (>5 samples) at more than 5.0 RPKM.  It is possible 
that certain subtypes of prostate cancer may express highly specific transcripts, and future 
studies to characterize these transcripts could provide additional insight into the biology 
of tumor subtypes. 
In certain instances we observed transcripts that were interrupted by poorly 
mappable genomic regions.  Additionally, for low abundance genes we observed 
fragmentation due to the lack of splice junction or paired-end read evidence needed to 
connect nearby fragments.  We reasoned that expression profiles of these fragmented 
transcripts should be highly correlated.  To demonstrate this, we measured the difference 
in the Pearson correlation between expression of randomly chosen exons on the same 
transcript versus expression of spatially proximal exons on different transcripts.  We 
found that in our cohort, a Pearson correlation >0.8 had a positive predictive value (PPV) 
of >95% for distinct exons to be part of the same transcript.  Using this criteria, we 
performed hierarchical agglomerative clustering to extend transcript fragments into larger 
transcriptional units. Pairs of transcripts further than 100kb apart, transcripts on opposite 
strands, and overlapping transcripts were not considered for clustering. Groups of 




Comparison with gene annotation databases: The 44,534 transcripts produced by the 
bioinformatics pipeline were classified by comparison with a comprehensive list of 
“annotated” transcripts from UCSC, RefSeq, ENCODE, Vega, and Ensembl.  First, 
transcripts corresponding to processed pseudogenes were separated.  This was done to 
circumvent a known source of bias in the TopHat read aligner.  TopHat maps reads to 
genomic DNA in its first step, predisposing exon-exon junction reads to align to their 
spliced retroposed pseudogene homologues. Future improvements to splice junction 
mapping algorithms could improve accuracy and eliminate this bias. 
Next, transcripts with >1bp of overlap with at least one annotated gene on the 
correct strand were designated “annotated”, and the remainder were deemed 
“unannotated”.  Transcripts with no overlap with protein coding genes were subdivided 
into intronic, intergenic, or partially intronic antisense categories based on their relative 
genomic locations. 
Informatics filtering of unspliced pre-mRNA isoforms:  We observed a significant 
increase in the percentage of intronic transcripts in our assembly relative to known 
intronic ncRNAs.  This led us to observe that in many cases unspliced pre-mRNAs may 
appear at sufficient levels to escape the filtering steps employed by Cufflinks during the 
assembly stage. We then removed intronic and antisense transcripts that were correlated 
(Pearson correlation >0.5) to their overlapping protein coding genes in order to better 
approximate the true number of intronic or antisense transcripts in the transcriptome.  
This effectively removed transcripts within genes such as PCA3 and HPN that were 
obvious pre-mRNA artifacts, while leaving truly novel intronic transcripts – such as those 
within FBXL7 and CDH13 – intact.  While this informatics approach may conservatively 
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predict intronic and antisense transcription, it enriched our results for the most 
independent transcripts. 
In effect, these steps produced a consensus set of 35,415 transcripts supporting 
long poly-adenylated RNA molecules in human prostate tissues and cell lines.  Per 
chromosome transcript counts closely mirrored known transcript databases (Table 2.2), 
suggesting that the informatics procedures employed here compensate well for gene 
density variability across chromosomes. Overall we detected a similar number of 
transcripts as present in the either the RefSeq or UCSC databases (37). 
Coding potential analysis:  To analyze coding potential, we extracted the DNA 
sequences for each transcript and searched for open reading frames (ORFs) using the 
txCdsPredict program from the UCSC source tool set (39). This program produces 
a score corresponding to the protein coding capacity of a given sequence, and scores 
>800 are ~90% predictive of protein coding genes.  We used this threshold to count 
transcripts with coding potential, and found only 5 of 6,641 unannotated genes with 
scores >800, compared with 1,669 of 25,414 protein coding transcripts. Additionally, we 
observed that protein coding genes possess consistently longer ORFs than either 
unannotated or annotated ncRNA transcripts, suggesting that these unannotated 
transcripts represent ncRNAs (Figure 2.5). 
Separation of transcripts into repetitive and non-repetitive categories:  To 
separate transcripts into “repeat” and “non-repeat” transcripts, we extracted the genomic 
DNA corresponding to the transcript exons and calculated the fraction of repeat-masked 
nucleotides in each sequence.  For the designation of repeat classes, we used the 
RepMask 3.2.7 UCSC Genome Browser track (39). After examining various thresholds, 
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we chose to separate transcripts containing >25% repetitive DNA for the purposes of the 
ChIP-seq and conservation analyses discussed below. 
Conservation Analysis:  We used the SiPhy package (41) to estimate the locate 
rate of variation (ω) of all non-repetitive transcript exons across 29 placental mammals.  
The program was run as described on the SiPhy website: 
(http://www.broadinstitute.org/genome_bio/siphy/documentation.html). 
ChIP-Seq datasets:  We employed published ChIP-Seq datasets for H3K4me1, 
H3K4me2, H3K4me3, Acetylated H3, Pan-H3, and H3K36me3 generated in our 
laboratory (25).  These data are publically available through the NCBI Geo Omnibus 
(GEO GSM353632).  We analyzed the raw ChIP-Seq data using MACS (42) (H3K4me1, 
H3K4me2, H3K4me3, Acetylated H3, and Pan-H3) or SICER (43) (H3K36me3) peak 
finder programs using default settings.  These peak finders were used based upon their 
preferential suitability to detect different types of histone modifications (44). The 
H3K4me3-H3K36me3 chromatin signature used to identify lncRNAs was determined 
from the peak coordinates by associating each H3K4me3 peak with the closest 
H3K36me3-enriched region up to a maximum of 10kb away.  The enhancer signature 
(H3K4me1 but not H3K4me3) was determined by subtracting the set of overlapping 
H3K4me3 peaks from the entire set of H3K4me1 peaks.  These analyses were performed 
with the bx-python libraries distributed as part of the Galaxy bioinformatics infrastructure 
(45). 
Differential Expression Analysis:  To predict differentially expressed transcripts 
we first prepared a matrix of log-transformed, normalized RPKM expression values. We 
used the base 2 logarithm after adding 0.1 to all RPKM values.  The data were first 
67 
 
centered by subtracting the median expression of the benign samples for each transcript.  
We then used the Significance Analysis of Microarrays (SAM) method (46) with 250 
permutations of the Tusher et al. S0 selection method to predict differentially expressed 
genes.  We chose a delta value corresponding to the 90th percentile FDR desired for 
individual analyses.  The MultiExperiment Viewer application (47) was used to run SAM 
and generate heatmaps.  We confirmed that the results matched expected results through 
comparison with microarrays and known prostate cancer biomarkers (data not shown). 
Outlier Analysis:  A modified COPA analysis (18, 48) was performed on the 81 
tissue samples in the cohort.  RPKM expression values were used and shifted by 1.0 in 
order to avoid division by zero. The COPA analysis had the following steps: 1) gene 
expression values were median centered, using the median expression value for the gene 
across the all samples in the cohort. This sets the gene’s median to zero. 2) The median 
absolute deviation (MAD) was calculated for each gene, and then each gene expression 
value was scaled by its MAD. 3) The 80, 85, 90, 98 percentiles of the transformed 
expression values were calculated for each gene and the average of those four values was 
taken. Then, genes were rank ordered according to this “average percentile”, which 
generated a list of outliers genes arranged by importance. 4) Finally, genes showing an 
outlier profile in the benign samples were discarded.  Six novel transcripts ranked as both 
outliers and differentially-expressed genes in our analyses.  These six were manually 
classified either as differentially-expressed or outlier status based on what each 







Figure 2.1: Analysis of transcriptome data for the detection of unannotated 
transcripts. (a) A schematic overview of the methodology employed in this study.  (b) A 
graphical representation showing the bioinformatics filtration model used to merge 
individual transcriptome libraries into a single consensus transcriptome. (c) Following 
informatic processing and filtration of the sequencing data, transcripts were categorized 











Figure 2.2: Transcript assembly of known genes.  We employed ab initio transcript 
assembly on prostate transcriptome sequencing data to reconstruct the known prostate 
transcriptome.  Four examples of transcriptome reassembly are displayed above.  (a)  
SPINK1, a biomarker for prostate cancer.  (b)  PRUNE2 with the PCA3 non-coding RNA 
within its intronic regions.  Note that PCA3 is a prostate cancer biomarker while 





Figure 2.3: Prostate cancer transcriptome sequencing reveals dysregulation of novel 
transcripts. (a) A global overview of transcription in prostate cancer.  The left pie chart 
displays transcript distribution in prostate cancer.   The upper and lower right pie charts 
display unannotated or annotated ncRNAs, respectively categorized as sense transcripts 
(intergenic and intronic) and antisense transcripts.  (b) A line graph showing that 
unannotated transcripts are more highly expressed (RPKM) than control regions. 
Negative control intervals were generated by randomly permuting the genomic positions 
of the transcripts.  (c) Conservation analysis comparing unannotated transcripts to known 
genes and intronic controls shows a subtle degree of purifying selection among 
unannotated transcripts.  The insert on the right shows an enlarged view.  (d-g) 
 Intersection plots displaying the fraction of unannotated transcripts enriched for 
H3K4me2 (d), H3K4me3 (e), Acetyl-H3 (f) or RNA polymerase II (g) at their 
transcriptional start site (TSS) using ChIP-Seq and RNA-Seq data for the VCaP prostate 
cancer cell line.  The legend for these plots (b-g) is shared and located below (f) and (g). 
 (h) A pie chart displaying the distribution of differentially expressed transcripts in 









Figure 2.4: Analysis of EST support for novel transcripts. ESTs from the UCSC 
database table “Human ESTs” were used to evaluate the amount of overlap between 
ESTs and novel transcripts.  (a) A line graph showing the fraction of genes whose 
transcripts are supported by a particular fraction of ESTs.  Over 20% of novel transcripts 
have no support by ESTs.  (b)  A table displaying the number of ESTs supporting each 
class of transcripts.  Percent of all ESTs was calculated using the total number of 
annotated ESTs (8,089,356), not the total number of observed ESTs in the transcriptome 



















Figure 2.5: Analysis of coding potential of unannotated transcripts.  DNA sequences 
for each transcript were extracted and searched for open reading frames (ORFs) using the 
txCdsPredict program from the UCSC source tool set.  Using these methods, novel 
transcripts showed poor protein-coding capacity compared to protein-coding genes, and 
novel transcripts scored similarly to known ncRNAs, suggesting that the vast majority of 









Figure 2.6:  Overlap of unannotated transcripts with ChIP-Seq data.  Perviously 
published ChIP-Seq data for VCaP and LNCaP prostate cancer cells were intersected 
with unannotated prostate cancer transcripts and annotated control genes.  Non-coding 
RNAs were divided into intergenic and intronic.  (a)  H3K4me1 (left) and H3K36me3 
(right) in VCaP. H3K4me1 was not enriched in any samples. (b) ChIP-seq data in LNCaP 
cells.  Overlap between transcription start sites and H3K4me2, H3K4me3, Acetyl-H3, 
H3K36me3, and RNA polymerase II.  Intergenic ncRNAs tend to show higher 
enrichment than intronic ncRNAs for both annotated and unannotated transcripts.  
H3K4me1 was not enriched in any samples, and H3K36me3 showed enrichment over a 

































Figure 2.7: Intergenic unannotated genes are located halfway between annotated 
genes.  The distance between intergenic unannotated ncRNAs to the closest protein-
coding gene was calculated, forming a normal distribution around a mean of 4,292 kb.  
For comparison the distance between protein-coding genes was likewise calculated, 
forming a normal distribution around a mean of 8,559 kb.  These data suggest that, on 








Figure 2.8: Unannotated intergenic transcripts differentiate prostate cancer and 
benign prostate samples.  (a) Unsupervised clustering analyses of differentially-
expressed or outlier unannotated intergenic transcripts clusters benign samples, localized 
tumors, and metastatic cancers. Expression is plotted as log2 fold change relative to the 
median of the benign samples.  The four transcripts detailed in this study are indicated on 
the side.  (b) Cancer outlier expression analysis for the prostate cancer transcriptome 
ranks unannotated transcripts prominently.  (c-f) qPCR on an independent cohort of 
prostate and non-prostate samples (Benign (n=19), PCA (n=35), MET (n=31), prostate 
cell lines (n=7), breast cell lines (n=14), lung cell lines (n=16), other normal samples 
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(n=19)) measures expression levels of four nominated ncRNAs—PCAT-1, PCAT-43, 
PCAT-114, and PCAT-14—upregulated in prostate cancer.  Inset tables on the right 
quantify “positive” and “negative” expressing samples using the cut-off value (shown as 
a black dotted line).  Statistical significance was determined using a Fisher’s exact test. 
 (c) PCAT-14. (d) PCAT-43. (e) PCAT-114 (SChLAP1). (f) PCAT-1. qPCR analysis was 



























Figure 2.9: Validation of novel transcripts in prostate cell lines.  11/14 unannotated 
transcripts selected for validation by RT-PCR and qPCR were confirmed in cell line 
models.  (a) RT-PCR gels showing expected bands for the 11 transcripts that validated.  
GAPDH and a genomic region upstream of MAN1A1 were used as positive and negative 
control, respectively.  Representative PCR bands from all validated transcripts were 
Sanger-sequenced.  Transcripts were confirmed by multiple independent primer pairs 
(See table S10)  (b)  Representative qPCR results using primers selected from (a)  The 







Figure 2.10: Prostate-specificity of PCATs in RNA-Seq compendium.  RNA-Seq was 
performed on a compendium of 325 cell lines and tissues, and gene expression was 
quantified in RPKM.  Evaluation of expression levels for PCAT-1, PCAT-14, PCAT-114, 











Figure 2.11: PCAT-14 is upregulated by androgen signaling.  VCaP and LNCaP cells 
were grown in charcoal-stripped serum for 48 hours prior to treatment with 5nM R1881 
or vehicle (ethanol) control.  24 hours after treatment, cells were harvested, total RNA 
and cDNA were generated, and cells were assayed for expression levels of unannotated 
non-coding RNAs.  No consistent change is seen in PCAT-1, PCAT-43 and PCAT-114 
expression upon addition of R1881.  However, PCAT-14 shows consistent upregulation 
in both VCaP and LNCaP cells treated with R1881.  TMPRSS2 serves as a control 
androgen-regulated gene.  All experiments are normalized to GAPDH and the relative 












Figure 2.12: PCAT-1 and PCAT-14 are upregulated in matched tumor tissues.   Four 
matched tumor-normal patient tissue samples were assayed for PCAT-1 and PCAT-14 
expression by qPCR.  Expression levels were normalized to GAPDH and to the median 








Figure 2.13: The SChLAP1 locus spans >500 kb.  Visualization of transcriptome 
sequencing data in the UCSC genome browser indicates that a large, almost 1 Mb section 
of chromosome 2 is highly activated in cancer, contributing to many individual 
transcripts regulated in a coordinated fashion.  For reference, the two flanking protein-
coding genes, UBE2E3 and CWC22, are shown.  Neither UBE2E3 nor CWC22 appears 






























chr1  759121  272072  12701  5030  4489  3652  2499  3334 
chr2  581574  206281  9353  3224  2856  2361  1579  2023 
chr3  518621  167071  5706  2917  2560  2053  1312  1816 
chr4  329950  103113  5160  2019  1731  1444  977  1238 
chr5  380613  126139  5833  2365  2067  1694  1104  1465 
chr6  396848  145607  7580  2590  2309  1874  1370  1667 
chr7  432152  134051  6432  2355  2132  1703  1326  1583 
chr8  308935  97724  4226  1729  1529  1243  848  1210 
chr9  359300  122626  4069  1937  1767  1402  1114  1272 
chr10  354625  103512  3509  1672  1508  1226  998  1382 
chr11  424606  165211  6909  2922  2640  2102  1566  2023 
chr12  425280  138650  6872  2653  2373  1858  1233  1668 
chr13  159649  68284  3616  1118  908  751  425  549 
chr14  261497  123741  4842  1806  1619  1308  885  1102 
chr15  291241  108058  5816  1884  1626  1321  1362  1127 
chr16  364747  124182  3968  2002  1835  1386  1093  1311 
chr17  473261  168469  5581  2780  2582  1950  1480  1907 
chr18  144300  49112  2504  785  682  539  377  459 
chr19  494738  189411  7209  3543  3239  2269  1668  2314 
chr20  217223  70308  3059  1243  1158  907  659  926 
chr21  113368  29728  939  495  436  354  306  427 
chr22  223385  73509  2401  1156  1068  798  633  771 
chrX  222743  94591  4997  1516  1349  1161  959  1841 
chrY  15190  4039  272  81  71  59  148  254 








Table 2.2: A list of Prostate Cancer Associated Transcripts (PCATs) differentially 

















128095202  ‐2.265  5.444  6.907  0 
PCAT‐10  TU_0078296_0  chr12:32394534‐32405549  ‐1.594  3.690  3.085  0 
PCAT‐100  TU_0049213_0 
chr4:102461960‐
102476087  ‐1.273  2.367  1.888  0.71247 
PCAT‐101  TU_0093070_0  chr11:64945809‐64961189  ‐1.295  2.365  1.913  0.71247 
PCAT‐102  TU_0051063_0 
chr4:187244297‐
187244767  1.892  ‐2.849  0.510  0.73226 
PCAT‐103  TU_0098190_0  chr8:61704765‐61708199  1.983  ‐2.861  0.403  0.73226 
PCAT‐104  TU_0038811_0  chr3:57890130‐57890834  1.962  ‐2.884  0.444  0.73226 
PCAT‐105  TU_0020914_0  chr19:9718612‐9721799  1.643  ‐2.924  0.506  0.73226 
PCAT‐106  TU_0112056_0  chr15:69658838‐69678469  1.838  ‐3.036  0.462  0 
PCAT‐107  TU_0036396_0 
chr14:104617328‐
104619095  1.850  ‐3.119  0.455  0 
PCAT‐108  TU_0095765_0 
chr11:117640504‐
117642734  2.100  ‐3.263  0.382  0 
PCAT‐109  TU_0050224_0 
chr4:147115887‐
147190781  2.198  ‐3.298  0.286  0 
PCAT‐11  TU_0078290_0  chr12:32394534‐32410898  ‐1.534  3.675  3.157  0 
PCAT‐110  TU_0112059_0  chr15:69667695‐69691724  1.815  ‐3.382  0.437  0 
PCAT‐111  TU_0098382_0  chr8:68494189‐68495887  2.541  ‐4.059  0.308  0 
PCAT‐12  TU_0002597_0  chr6:34335202‐34338521  ‐1.626  3.647  3.352  0 
PCAT‐13  TU_0049368_0 
chr4:106772318‐
106772770  ‐1.689  3.608  2.830  0 
PCAT‐14  TU_0106548_0  chr22:22209111‐22212055  ‐1.939  3.591  5.963  0 
PCAT‐15  TU_0078293_0  chr12:32396393‐32414822  ‐1.521  3.571  2.922  0 
PCAT‐16  TU_0099884_0 
chr8:128301493‐
128307576  ‐1.445  3.566  2.517  0 
PCAT‐17  TU_0112014_0  chr15:67722165‐67739990  ‐1.633  3.562  3.659  0 
PCAT‐18  TU_0084306_0  chr5:15896315‐15947088  ‐1.845  3.560  5.747  0 
PCAT‐19  TU_0114240_0  chr2:1534883‐1538193  ‐1.697  3.523  4.340  0 
PCAT‐2  TU_0090142_0  chr11:4748677‐4760303  ‐2.440  4.678  11.397  0 
PCAT‐20  TU_0008499_0  chr7:24236191‐24236455  ‐1.830  3.507  6.682  0 
PCAT‐21  TU_0078299_0  chr12:32290896‐32292169  ‐1.730  3.506  3.292  0 
PCAT‐22  TU_0000033_0  chr6:1619606‐1668581  ‐1.768  3.494  2.247  0 
PCAT‐23  TU_0096472_0 
chr11:133844590‐
133862924  ‐1.878  3.410  5.985  0 
84 
 
PCAT‐24  TU_0114259_0  chr2:1606782‐1607314  ‐1.666  3.392  5.061  0 
PCAT‐25  TU_0096473_0 
chr11:133844590‐
133862995  ‐1.896  3.386  6.107  0 
PCAT‐26  TU_0100361_0 
chr8:144914456‐
144930753  ‐1.652  3.381  3.842  0 
PCAT‐27  TU_0040394_0 
chr3:133418632‐
133441282  ‐1.621  3.320  2.972  0 
PCAT‐28  TU_0043432_0  chr13:34032994‐34050503  ‐1.674  3.204  3.209  0 
PCAT‐29  TU_0112020_0  chr15:67764259‐67801825  ‐1.560  3.194  3.594  0 
PCAT‐3  TU_0054603_0  chr16:82380933‐82394836  ‐2.179  4.461  5.892  0 
PCAT‐30  TU_0042717_0  chr13:23149908‐23200198  ‐2.065  3.169  4.970  0 
PCAT‐31  TU_0078292_0  chr12:32290485‐32406307  ‐1.450  3.151  2.891  0 
PCAT‐32  TU_0084146_0  chr5:14025126‐14062770  ‐1.645  3.126  2.619  0 
PCAT‐33  TU_0056168_0  chr18:22477042‐22477666  ‐1.538  3.056  3.195  0 
PCAT‐34  TU_0040383_0 
chr3:133360541‐
133429262  ‐1.556  3.042  3.748  0 
PCAT‐35  TU_0112025_0  chr15:67780574‐67782345  ‐1.682  3.041  3.433  0 
PCAT‐36  TU_0041688_0 
chr3:186741299‐
186741933  ‐1.475  3.006  2.543  0 
PCAT‐37  TU_0103642_0 
chr9:109187089‐
109187455  ‐1.739  2.999  6.612  0 
PCAT‐38  TU_0040375_0 
chr3:133280694‐
133394609  ‐1.547  2.975  3.907  0 
PCAT‐39  TU_0047312_0  chr4:39217669‐39222163  ‐1.639  2.912  3.612  0 
PCAT‐4  TU_0090140_0  chr11:4748163‐4759145  ‐2.115  4.435  7.200  0 
PCAT‐40  TU_0106545_0  chr22:22218478‐22219162  ‐1.759  2.890  3.736  0 
PCAT‐41  TU_0054541_0  chr16:79408800‐79435066  ‐1.749  2.870  6.648  0 
PCAT‐42  TU_0060446_0  chr1:28438629‐28450156  ‐1.488  2.857  1.982  0 
PCAT‐43  TU_0054537_0  chr16:79406933‐79430041  ‐1.780  2.847  7.261  0 
PCAT‐44  TU_0072907_0  chr20:55759486‐55771563  ‐1.525  2.797  2.812  0 
PCAT‐45  TU_0043403_0  chr13:33844637‐33845921  ‐1.579  2.792  3.640  0 
PCAT‐46  TU_0038678_0  chr3:53515951‐53517078  ‐1.705  2.786  3.691  0 
PCAT‐47  TU_0101706_0  chr9:3408690‐3415374  ‐1.478  2.782  3.307  0 
PCAT‐48  TU_0074308_0  chr10:42652247‐42653596  ‐1.993  2.773  8.825  0 
PCAT‐49  TU_0054538_0  chr16:79408946‐79450819  ‐1.713  2.763  7.094  0 
PCAT‐5  TU_0078288_0  chr12:32393283‐32405731  ‐1.916  4.313  3.566  0 
PCAT‐50  TU_0101709_0  chr9:3411967‐3415374  ‐1.465  2.762  3.189  0 
PCAT‐51  TU_0106544_0  chr22:22210421‐22220506  ‐1.615  2.758  3.742  0 
PCAT‐52  TU_0046121_0  chr4:766363‐766599  ‐1.570  2.757  1.436  0 
PCAT‐53  TU_0106542_0  chr22:22211315‐22220506  ‐1.610  2.756  3.378  0 
PCAT‐54  TU_0106541_0  chr22:22209111‐22219162  ‐1.659  2.734  3.664  0 
PCAT‐55  TU_0044453_0  chr13:51505777‐51524522  ‐1.342  2.732  2.537  0 
PCAT‐56  TU_0054540_0  chr16:79419351‐79423673  ‐1.817  2.728  7.285  0 
PCAT‐57  TU_0104717_0 
chr9:130697833‐
130698832  ‐1.294  2.722  2.334  0 
PCAT‐58  TU_0089014_0 
chr5:176014905‐
176015351  ‐1.397  2.705  1.780  0 





128103681  ‐1.721  4.266  3.900  0 
PCAT‐60  TU_0112003_0  chr15:67645590‐67775246  ‐1.439  2.668  3.045  0 
PCAT‐61  TU_0078286_0  chr12:32395588‐32405731  ‐1.358  2.666  2.612  0 
PCAT‐62  TU_0078303_0  chr12:32274210‐32274530  ‐1.502  2.659  3.331  0 
PCAT‐63  TU_0112004_0  chr15:67644390‐67650387  ‐1.518  2.651  2.993  0 
PCAT‐64  TU_0071087_0  chr20:21428679‐21429454  ‐1.492  2.649  4.648  0 
PCAT‐65  TU_0072906_0  chr20:55759768‐55770657  ‐1.506  2.645  2.958  0 
PCAT‐66  TU_0054240_0  chr16:70155175‐70173873  ‐1.472  2.644  3.531  0 
PCAT‐67  TU_0047330_0  chr4:39217641‐39222163  ‐1.514  2.628  3.070  0 
PCAT‐68  TU_0055435_0  chr18:6718938‐6719172  ‐1.605  2.617  2.922  0 
PCAT‐69  TU_0054542_0  chr16:79420131‐79423590  ‐1.791  2.610  7.664  0 
PCAT‐7  TU_0084308_0  chr5:15938753‐15949124  ‐1.964  4.124  4.748  0 
PCAT‐70  TU_0079791_0  chr12:54971063‐54971481  ‐1.442  2.601  2.014  0 
PCAT‐71  TU_0043411_0  chr13:33918267‐33926769  ‐1.495  2.599  3.386  0 
PCAT‐72  TU_0056121_0  chr18:20196762‐20197522  ‐1.253  2.594  1.719  0 
PCAT‐73  TU_0043412_0  chr13:33918267‐33935946  ‐1.589  2.590  4.280  0 
PCAT‐74  TU_0065837_0 
chr1:149791252‐
149795934  ‐1.385  2.588  2.934  0 
PCAT‐75  TU_0043401_0  chr13:33825711‐33845275  ‐1.599  2.585  4.346  0 
PCAT‐76  TU_0006463_0 
chr6:144659819‐
144660143  ‐1.499  2.574  2.201  0 
PCAT‐77  TU_0048506_0  chr4:80329017‐80348259  ‐1.574  2.569  2.802  0 
PCAT‐78  TU_0084140_0  chr5:14003669‐14054874  ‐1.404  2.547  2.598  0 
PCAT‐79  TU_0082982_0 
chr12:121776584‐
121777370  ‐1.529  2.546  2.620  0 
PCAT‐8  TU_0084303_0  chr5:15899476‐15955226  ‐2.025  4.052  7.104  0 
PCAT‐80  TU_0013212_0 
chr7:138990883‐
139001515  ‐1.230  2.544  1.688  0 
PCAT‐81  TU_0072912_0  chr20:55779532‐55780817  ‐1.430  2.541  3.865  0 
PCAT‐82  TU_0112281_0  chr15:70586704‐70590792  ‐1.459  2.538  2.429  0 
PCAT‐83  TU_0048767_0  chr4:88120066‐88124880  ‐1.374  2.532  2.233  0 
PCAT‐84  TU_0108455_0  chr15:19358326‐19365341  ‐1.565  2.526  1.946  0 
PCAT‐85  TU_0091997_0  chr11:58560356‐58573012  ‐1.315  2.519  2.118  0 
PCAT‐86  TU_0121655_0 
chr2:202985284‐
202998634  ‐1.401  2.476  2.219  0.85961 
PCAT‐87  TU_0071798_0  chr20:33775260‐33778511  ‐1.336  2.465  1.657  0.85037 
PCAT‐88  TU_0049200_0 
chr4:102469973‐
102476087  ‐1.322  2.457  1.946  0.84132 
PCAT‐89  TU_0121714_0 
chr2:203295212‐
203314868  ‐1.346  2.450  1.762  0.83247 
PCAT‐9  TU_0082746_0 
chr12:120197102‐
120197416  ‐1.861  3.755  5.143  0 
PCAT‐90  TU_0098937_0  chr8:95748751‐95751321  ‐1.453  2.422  2.233  0.8238 
PCAT‐91  TU_0108453_0  chr15:19356996‐19364013  ‐1.803  2.409  3.840  0.76781 
PCAT‐92  TU_0114170_0  chr15:99659312‐99669199  ‐1.436  2.406  2.125  0.76781 
PCAT‐93  TU_0089906_0  chr11:1042845‐1045705  ‐1.390  2.402  2.639  0.76781 





160016453  ‐1.175  2.399  2.052  0.76781 
PCAT‐96  TU_0078294_0  chr12:32395632‐32413064  ‐1.456  2.397  2.186  0.76781 
PCAT‐97  TU_0044933_0  chr13:94755992‐94760688  ‐1.291  2.397  2.190  0.76781 
PCAT‐98  TU_0017730_0  chr17:52346638‐52346880  ‐1.417  2.387  1.471  0.76043 

























Table 2.3: A list of Prostate Cancer Associated Transcripts (PCATs) nominated by 











PCAT‐112  TU_0029004_0  chrX:66691350‐66692032  130.7349  1.000  90.921 
PCAT‐113  TU_0054542_0  chr16:79420131‐79423590  127.0431  5.610  135.850 
PCAT‐114  TU_0120899_0  chr2:180689090‐180696402  123.5416  1.053  94.693 
PCAT‐115  TU_0054540_0  chr16:79419351‐79423673  119.0908  4.162  94.446 
PCAT‐116  TU_0120918_0  chr2:181297540‐181400892  112.7101  1.453  92.180 
PCAT‐117  TU_0054538_0  chr16:79408946‐79450819  98.0185  1.830  93.121 
PCAT‐118  TU_0059541_0  chr1:20685471‐20686432  68.3573  1.783  1375.150 
PCAT‐119  TU_0120924_0  chr2:181331111‐181427485  63.9546  1.389  365.202 
PCAT‐120  TU_0074308_0  chr10:42652247‐42653596  60.9184  1.394  65.771 
PCAT‐121  TU_0049192_0  chr4:102257900‐102306678  59.2500  1.385  69.242 
PCAT‐122  TU_0054537_0  chr16:79406933‐79430041  58.0448  1.853  42.751 
PCAT‐123  TU_0120900_0  chr2:180926864‐180985967  55.8439  1.000  67.658 
PCAT‐124  TU_0114527_0  chr2:10858318‐10858530  54.7646  1.297  35.006 
PCAT‐125  TU_0112020_0  chr15:67764259‐67801825  53.8828  2.028  88.990 
PCAT‐126  TU_0120923_0  chr2:181328093‐181419226  52.9793  1.282  232.556 
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High-throughput methodologies have enabled a detailed dissection of the cancer 
transcriptome, nominating thousands of long non-coding RNAs (lncRNAs) in disease.  
However, the functional role, if any, of these lncRNAs is largely unexplored.  Here, we 
describe the functional characterization of PCAT-1, a prostate-specific lncRNA 
discovered by transcriptome sequencing of prostate cancers.  We find that PCAT-1 
expression in prostate cancer promotes cell proliferation by coordinating a repressive 
signature of gene expression regulation.  Interestingly, we identified EZH2 as a negative 
regulator of PCAT-1 and observed that PCAT-1-regulated genes were antagonized by 
EZH2 in vitro and this gene signature stratified human prostate cancer tissues into PCAT-
1-like and EZH2-like biological subgroups.  This gene signature was enriched for genes 
participating in DNA structural maintenance and DNA damage repair, suggesting a 
functional contribution of PCAT-1 to these biological processes.  Taken together, the 
findings presented herein identify PCAT-1 as a novel transcriptional repressor implicated 





High-throughput sequencing of RNA (RNA-seq) has facilitated rapid discovery of 
thousands of unannotated non-coding RNA transcripts.  Yet, the biological function of 
many of these ncRNAs is unknown.  One class of ncRNAs, long non-coding RNAs 
(lncRNAs) >200 bp in length, has been implicated in widespread biological roles, 
including cancer biology.  While several types of ncRNAs appear to be derived from 
protein-coding genes, thus complicating the interpretation of their biological significance,  
lncRNAs are characterized by independent gene promoters and their gene structure 
mirrors that of protein-coding genes, commonly exhibiting splicing of multiple exons and 
a 3’ polyadenylation signal. 
We employed RNA-seq on >100 prostate cancer tissues and cell lines and 
identified >1,800 intergenic lncRNAs, of which 121 demonstrated dysregulated 
expression in prostate cancer and were termed PCATs.  Here, we identify PCAT-1 as a 
novel prostate cancer gene that serves to promote cell proliferation by coordinating 
repression of specific target genes.  Moreover, we describe an antagonist PCAT-1-EZH2 









PCAT-1, a novel prostate cancer lncRNA 
We previously nominated and validated numerous novel lncRNAs found in 
prostate cancer tissues and cell lines.  To explore several transcripts more closely, we 
performed 5’ and 3’ rapid amplification of cDNA ends (RACE) for PCAT-1 and PCAT-
14.  Interestingly, the PCAT-14 locus contained components of viral ORFs from the 
HERV-K endogenous retrovirus family, whereas PCAT-1 incorporates portions of a 
mariner family transposase (1, 2), an Alu, and a viral long terminal repeat (LTR) 
promoter region (Figure 3.1 and 3.2a).  While PCAT-14 was upregulated in localized 
prostate cancer but largely absent in metastases (Figure 2.8), PCAT-1 was strikingly 
upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers 
(Figure 2.8f).  Because of this notable profile, we hypothesized that PCAT-1 may have 
coordinated expression with the oncoprotein EZH2, a core PRC2 protein that is 
upregulated in solid tumors and contributes to a metastatic phenotype (3, 4). 
 Surprisingly, we found that PCAT-1 and EZH2 expression were nearly mutually 
exclusive (Figure 3.2b), with only one patient showing outlier expression of both.  This 
suggests that outlier PCAT-1 and EZH2 expression may define two subsets of high-grade 
disease. 
PCAT-1 is located in the chromosome 8q24 gene desert approximately 725 kb 
upstream of the c-MYC oncogene.  To confirm that PCAT-1 is a non-coding gene, we 
cloned the full-length PCAT-1 transcript and performed in vitro translational assays, 
which were negative as expected (Figure 3.3).  Next, since Chr8q24 is known to harbor 
prostate cancer-associated single nucleotide polymorphisms (SNPs) and to exhibit 
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frequent chromosomal amplification (5-10), we evaluated whether the relationship 
between EZH2 and PCAT-1 was specific or generalized.  To address this, we measured 
expression levels of c-MYC and NCOA2, two proposed targets of Chr8q amplification (7, 
10), by qPCR.  Neither c-MYC nor NCOA2 levels showed striking expression 
relationships to PCAT-1, EZH2, or each other (Figure 3.4).  Likewise, PCAT-1 outlier 
expression was not dependent on Chr8q24 amplification, as highly expressing localized 
tumors often did not have 8q24 amplification and high copy number gain of 8q24 was not 
sufficient to upregulate PCAT-1 (Figure 3.5).  
 
PCAT-1 Function and Regulation 
Despite reports showing that upregulation of the ncRNA HOTAIR participates in 
PRC2 function in breast cancer(11), we do not observe strong expression of this ncRNA 
in prostate (Figure 3.6), suggesting that other ncRNAs may be important in this cancer.  
To determine the mechanism for the expression profiles of PCAT-1 and EZH2, we 
inhibited EZH2 activity in VCaP cells, which express low-to-moderate levels of PCAT-1. 
 Knockdown of EZH2 by shRNA or pharmacologic inhibition of EZH2 with the inhibitor 
3-deazaneplanocin A (DZNep) caused a dramatic upregulation in PCAT-1 expression 
levels (Figure 3.2c,d), as did treatment of VCaP cells with the demethylating agent 
5’deoxyazacytidine, the histone deacetylase inhibitor SAHA, or both (Figure 3.2e). 
 Chromatin immunoprecipitation (ChIP) assays also demonstrated that SUZ12, a core 
PRC2 protein, directly binds the PCAT-1 promoter approximately 1kb upstream of the 
TSS (Figure 3.2f).  Interestingly, RNA immunoprecipitation (RIP) similarly showed 
binding of PCAT-1 to SUZ12 protein in VCaP cells (Figure 3.7a).  RIP assays followed 
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by RNase A, RNase H, or DNase I treatment either abolished, partially preserved, or 
totally preserved this interaction, respectively (Figure 3.7b).  This suggests that PCAT-1 
exists primarily as a single-stranded RNA and secondarily as a RNA/DNA hybrid. 
To explore the functional role of PCAT-1 in prostate cancer, we stably 
overexpressed full length PCAT-1 or controls in RWPE benign immortalized prostate 
cells.  We observed a modest but consistent increase in cell proliferation when PCAT-1 
was overexpressed at physiological levels (Figure 3.8).  Next, we designed siRNA oligos 
to PCAT-1 and performed knockdown experiments in LNCaP cells, which lack PRC2-
mediated regulation of PCAT-1 (Figure 3.9).  Supporting our overexpression data, 
knockdown of PCAT-1 with three independent siRNA oligos resulted in a 25% - 50% 
decrease in cell proliferation in LNCaP cells (Figure 3.8), but not control DU145 cells 
lacking PCAT-1 expression (Figure 3.8) or VCaP cells, in which PCAT-1 is expressed 
but repressed by PRC2 (Figure 3.8). 
Gene expression profiling of LNCaP knockdown samples on cDNA microarrays 
indicated that PCAT-1 modulates the transcriptional regulation of 370 genes (255 
upregulated, 115 downregulated; FDR ≤ 0.01) (Appendix 2).  Gene ontology analysis of 
the upregulated genes showed preferential enrichment for cellular processes such as 
mitosis and cell cycle, whereas the downregulated genes had no concepts showing 
statistical significance (Figure 3.8and Table 3.1).  These results suggest that PCAT-1’s 
function is predominantly repressive in nature, similar to other lncRNAs.  We next 
validated expression changes in three key PCAT-1 target genes (BRCA2, CENPE and 
CENPF) whose expression is upregulated upon PCAT-1 knockdown (Figure 3.10a) in 
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LNCaP and VCaP cells, the latter of which appear less sensitive to PCAT-1 knockdown 
likely due to lower overall expression levels of this transcript.   
 
PCAT-1 signatures in prostate cancer 
Because of the regulation of PCAT-1 by PRC2 in VCaP cells, we hypothesized 
that knockdown of EZH2 would also downregulate PCAT-1 targets as a secondary 
phenomenon due to the subsequent upregulation of PCAT-1.  Simultaneous knockdown 
of PCAT-1 and EZH2 would thus abrogate expression changes in PCAT-1 target genes.  
Performing this experiment in VCaP cells demonstrated that PCAT-1 target genes were 
indeed downregulated by EZH2 knockdown, and that this change was either partially or 
completely reversed using siRNA oligos to PCAT-1 (Figure 3.10a), lending support to 
the role of PCAT-1 as a transcriptional repressor.  Taken together, these results suggest 
that PCAT-1 biology may exhibit two distinct modalities: one in which PRC2 represses 
PCAT-1 and a second in which active PCAT-1 promotes cell proliferation.  PCAT-1 and 
PRC2 may therefore characterize distinct subsets of prostate cancer. 
To examine our clinical cohort, we used qPCR to measure expression of BRCA2, 
CENPE, and CENPF in our tissue samples.  Consistent with our model, we found that 
PCAT-1-expressing samples tended to have low expression of PCAT-1 target genes 
(Figure 3.10b).  Moreover, comparing EZH2-outlier and PCAT-1-outlier patients (see 
Figure 3.2b), we found that two distinct patient phenotypes emerged: those with high 
EZH2 tended to have high levels of PCAT-1 target genes; and those with high PCAT-1 
expression displayed the opposite expression pattern (Figure 3.10c).  Network analysis 
of the top 20 upregulated genes following PCAT-1 knockdown with the HefaLMP tool 
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(12) further suggested that these genes form a coordinated network (Figure 3.10d), 
corroborating our previous observations.  Taken together, these results provide initial 
data into the composition and function of the prostate cancer ncRNA transcriptome. 
 
DISCUSSION 
Our discovery of the prostate-specific ncRNA gene PCAT-1, which is markedly 
overexpressed in a subset of prostate cancers, particularly metastases, provides the first 
example of a novel lncRNA being discovered by large-scale RNA-seq analyses of human 
tissues.  Our results suggest that PCAT-1 may contribute to cell proliferation in a subset 
of prostate cancers.  It is also notable that PCAT-1 resides in the 8q24 “gene desert” 
locus, in the vicinity of well-studied prostate cancer risk SNPs and the c-MYC oncogene, 
suggesting that this locus—and its frequent amplification in cancer—may be linked to 
additional aspects of cancer biology.  In addition, the interplay between PRC2 and PCAT-
1 further suggests that this ncRNA may have an important role in prostate cancer 
progression (Figure 3.10e).  Other ncRNAs identified by this analysis may similarly 
contribute to prostate cancer as well.  Furthermore, recent pre-clinical efforts to detect 
prostate cancer non-invasively through the collection of patient urine samples have 
shown promise for several urine-based prostate cancer biomarkers, including the ncRNA 
PCA3 (13, 14).  While additional studies are needed, our identification of ncRNA 
biomarkers for prostate cancer suggests that urine-based assays for these ncRNAs may 




Taken together, our findings support an important role for tissue-specific ncRNAs 
in prostate cancer and suggest that cancer-specific functions of these ncRNAs may help 
to “drive” tumorigenesis.  We further speculate that specific ncRNA signatures may 
occur universally in all disease states and applying these methodologies to other diseases 





















MATERIALS AND METHODS 
Experimental studies 
Cell lines: The benign immortalized prostate cell line RWPE as well as PC3, Du145, 
LNCaP, VCaP, 22Rv1, CWR22, C4-2B, NCI-660, MDA PCa 2b, WPMY-1, and LAPC-
4  prostate cell lines were obtained from the American Type Culture Collection 
(Manassas, VA).  Benign non-immortalized prostate epithelial cells (PrEC) and prostate 
smooth muscle cells (PrSMC) were obtained from Lonza (Basel, Switzerland).   
PC3, Du145, LNCaP, 22Rv1, and CRW22 cells were grown in RPMI 1640 
(Invitrogen) and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin.  LNCaP CDS parent cells were grown in RPMI 1640 lacking phenol red 
(Invitrogen) supplemented with 10% charcoal-dextran stripped FBS (Invitrogen) and 1% 
penicillin-streptomycin.  LNCaP CDS 1, 2, and 3 are androgen-independent subclones 
derived from extended cell culture in androgen-depleted media.  VCaP and WPMY-1 
cells were grown in DMEM (Invitrogen) and supplemented with 10% fetal bovine serum 
(FBS) with 1% penicillin-streptomycin.  NCI-H660 cells were grown in RPMI 1640 
supplemented with 0.005 mg/ml insulin, 0.01 mg/ml transferrin, 30 nM sodium selenite, 
10 nM hydrocortisone, 10 nM beta-estradiol, 5% FBS and an extra 2 mM of L-glutamine 
(for a final concentration of 4 mM).  MDA PCa 2b cells were grown in F-12K medium 
(Invitrogen) supplemented with 20% FBS, 25 ng/ml cholera toxin, 10ng/ml EGF, 0.005 
mM phosphoethanolamine, 100 pg/ml hydrocortisone, 45 nM selenious acid, and 0.005 
mg/ml insulin.  LAPC-4 cells were grown in Iscove’s media (Invitrogen) supplemented 
with 10% FBS and 1 nM R1881.  C4-2B cells were grown in 80% DMEM supplemented 
with 20% F12, 5% FBS, 3 g/L NaCo3, 5ug/ml insulin, 13.6 pg/ml triiodothyonine, 
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5ug/ml transferrin, 0.25ug/ml biotin, and 25 ug/ml adenine.  PrEC cells were grown in 
PrEGM supplemented with 2ml BPE, 0.5 ml hydrocortisone, 0.5ml EGF, 0.5 ml 
epinephrine, 0.5 ml transferrin, 0.5 ml insulin, 0.5 ml retinoic acid, and 0.5 ml 
triiodothyronine, as part of the PrEGM BulletKit (Lonza).  PrSMC cells were grown in 
SmGM-2 media supplemented with 2ml BPE, 0.5 ml hydrocortisone, 0.5ml EGF, 0.5 ml 
epinephrine, 0.5 ml transferrin, 0.5 ml insulin, 0.5 ml retinoic acid, and 0.5 ml 
triiodothyronine, as part of the SmGM-2 BulletKit (Lonza). 
For androgen treatment experiments, LNCaP and VCaP cells were grown in 
androgen-depleted media lacking phenol red and supplemented with 10% charcoal-
stripped serum and 1% penicillin-streptomycin.  After 48 hours, cells were treated with 
5nM methyltrienolone (R1881, NEN Life Science Products) or an equivalent volume of 
ethanol.  Cells were harvested for RNA at 6, 24, and 48 hours post-treatment.  
Prostate tissues were obtained from the radical prostatectomy series and Rapid 
Autopsy Program (15) at the University of Michigan tissue core.  These programs are 
part of the University of Michigan Prostate Cancer Specialized Program Of Research 
Excellence (S.P.O.R.E.). All tissue samples were collected with informed consent under 
an Institutional Review Board (IRB) approved protocol at the University of Michigan. 
 (SPORE in Prostate Cancer (Tissue/Serum/Urine) Bank Institutional Review Board # 
1994-0481).  
 
RNA isolation and cDNA synthesis:  Total RNA was isolated using Trizol and an RNeasy 
Kit (Invitrogen) with DNase I digestion according to the manufacturer’s instructions. 
  RNA integrity was verified on an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo 
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Alto, CA).  cDNA was synthesized from total RNA using Superscript III (Invitrogen) and 
random primers (Invitrogen). 
 
Quantitative Real-time PCR: Quantitative Real-time PCR (qPCR) was performed using 
Power SYBR Green Mastermix (Applied Biosystems, Foster City, CA) on an Applied 
Biosystems 7900HT Real-Time PCR System. All oligonucleotide primers were obtained 
from Integrated DNA Technologies (Coralville, IA) and are listed in Appendix 1.  The 
housekeeping gene, GAPDH, was used as a loading control.  Fold changes were 
calculated relative to GAPDH and normalized to the median value of the benign samples. 
 
Reverse-transcription PCR: Reverse-transcription PCR (RT-PCR) was performed for 
primer pairs using Platinum Taq High Fidelity polymerase (Invitrogen).  PCR products 
were resolved on a 1.5% agarose gel.  PCR products were either sequenced directly (if 
only a single product was observed) or appropriate gel products were extracted using a 
Gel Extraction kit (Qiagen) and cloned into pcr4-TOPO vectors (Invitrogen).  PCR 
products were bidirectionally sequenced at the University of Michigan Sequencing Core 
using either gene-specific primers or M13 forward and reverse primers for cloned PCR 
products.  All oligonucleotide primers were obtained from Integrated DNA Technologies 
(Coralville, IA) and are listed in Appendix 2. 
   
RNA-ligase-mediated rapid amplification of cDNA ends (RACE): 5’ and 3’ RACE was 
performed using the GeneRacer RLM-RACE kit (Invitrogen) according to the 
manufacturer’s instructions.  RACE PCR products were obtained using Platinum Taq 
101 
 
High Fidelity polymerase (Invitrogen), the supplied GeneRacer primers, and appropriate 
gene-specific primers indicated in Appendix 2.  RACE-PCR products were separated on 
a 1.5% agarose gels.  Gel products were extracted with a Gel Extraction kit (Qiagen), 
cloned into pcr4-TOPO vectors (Invitrogen), and sequenced bidirectionally using M13 
forward and reverse primers at the University of Michigan Sequencing Core.  At least 
three colonies were sequenced for every gel product that was purified. 
 
siRNA knockdown studies:  Cells were plated in 100mM plates at a desired concentration 
and transfected with 20uM experimental siRNA oligos or non-targeting controls twice, at 
12 hours and 36 hours post-plating.  Knockdowns were performed with Oligofectamine 
in OptiMEM media.  Knockdown efficiency was determined by qPCR.  siRNA 
sequences (in sense format) for PCAT-1 knockdown were as follows: siRNA 1 
UUAAAGAGAUCCACAGUUAUU; siRNA 2 GCAGAAACACCAAUGGAUAUU; 
siRNA 3 AUACAUAAGACCAUGGAAAU; siRNA 4 GAACCUAACUGG-
ACUUUAAUU.  For EZH2 siRNA, the following sequence was used: 
GAGGUUCAGACGAGCUGAUUU.   72 hours post-transfection, cells were trypsinized, 
counted with a Coulter counter, and diluted to 1 million cells/mL.  
For proliferation assays, 10,000 cells were plated in 24-well plates and grown in 
regular media.  48 and 96 hours post-plating, cells were harvested and counted using a 
Coulter counter.  
 
shRNA knockdown: The prostate cancer cell line VCaP was seeded at 50-60% confluency 
and allowed to attach over night.  Cells were transfected with EZH2 or non-targeting 
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shRNA lentiviral constructs as described previously for 48 hours.  GFP+ cells were drug-
selected using 1 ug/mL puromycin for 72 hours.  48 hours post-selection cells were 
harvested for protein and RNA using RIPA buffer or trizol, respectively.  RNA was 
processed as described above.  Protein lysates were boiled in sample buffer, and 10 ug 
protein was loaded onto a SDS-PAGE gel and run for separation of proteins.  Proteins 
were transferred onto Polyvinylidene Difluoride membrane (GE Healthcare) and blocked 
for 90 minutes in blocking buffer (5% milk, 0.1% Tween, Tri-buffered saline (TBS-T)). 
 Membranes were incubated overnight at 4C with either EZH2 mouse monoclonal 
(1:1000, in dilution buffer, BD Biosciences, no. 612666), or B-Actin (Abcam, ab8226) for 
equal loading.  Following 3 washes with TBS-T, and one wash with TBS, the blot was 
incubated with horseradish peroxidase-conjugated secondary antibody and the signals 
visualized by enhanced chemiluminescence system as described by the manufacturer (GE 
Healthcare). 
 
Gene expression profiling: Expression profiling was performed using the Agilent Whole 
Human Genome Oligo Microarray (Santa Clara, CA), according to previously published 
protocols (16).  All samples were run in technical triplicates comparing knockdown 
samples treated with PCAT1 siRNA compared to treatments with non-targeting control 
siRNA.  Expression array data were processed using the SAM method (17) with an FDR 
≤ 0.01.  For gene ontology analysis, up- and down-regulated probes were separated and 
probe lists were analyzed using the DAVID bioinformatics platform (18) with the 




Drug treatments:  VCaP cells were plated at equal cell densities in 100mm2 plates and 
allowed to attach for 48 hours.  Cells were then treated with DMSO (vehicle control), 
20uM 5’deoxyazacytidine (Sigma), 500nM HDAC inhibitor suberoylanilide hydroxamic 
acid (SAHA) (Biovision Inc.), or both 5’deoxyazacytidine and SAHA. 
 5’deoxyazacytidine treatments were performed for 6 days with media and drug re-
applied every 48 hours.  SAHA treatments were performed for 48 hours.  DMSO 
treatments were performed for 6 days.  Total RNA was collected using Trizol and 
extracted as described above. 
For pharmacological inhibition of EZH2, VCaP cells were plated and grown 
overnight in 6 well plates. Following plating and attachment, cells were treated with 
either 0.1uM 3-deazaneplanocin A (DZNep) or DMSO vehicle control.  Cell media and 
drug treatments were refreshed every 48 hours.  RNA from cells was harvested at 72 
hours and 144 hours post-treatment. 
 
Chromatin immunoprecipitation :ChIP assays were performed as described previously 
(19).  Antibodies used for ChIP were rabbit polyclonal IgG (Millipore, PP64), SUZ12 
(Cell Signaling, 3737), and SUZ12 (Abcam, ab12073), using 4 - 7 ug of antibody per 
ChIP reaction.  ChIP-PCR reactions were performed using SybrGreen as described above 
using 1:150th of the ChIP product per reaction.  All ChIP-PCR reactions were performed 






RNA immunoprecipitation: RIP assays were performed using a Millipore EZ-Magna RIP 
RNA-Binding Protein Immunoprecipitation kit (Millipore, #17-701) according to the 
manufacturer’s instructions.  Input lysates were fractionated into cytoplasmic and nuclear 
fractions using a NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo-
Scientific/Pierce, #78835), and nuclear fractions were used for RIP assays.  RIP-PCR was 
performed as RT-PCR, as described above, using total RNA as input controls. 1:150th of 
RIP RNA product was used per PCR reaction. Antibodies used for RIP were Rabbit 
polyclonal IgG (Millipore, PP64), SNRNP70 (Millipore, CS203216), and SUZ12 
(Abcam, ab12073), using 4 – 7 ug of antibody per RIP reaction.  Treatment of RIP RNA 
product was performed using 5 ug of RNase A (Invitrogen), 5 ug of RNase H 
(Invitrogen), or 5 ug of DNase I (Qiagen) and incubating at 37C for 15-20 minutes.  All 
RIP assays were performed in biological duplicate. 
 
Overexpression studies: PCAT-1 full length transcript was amplified from LNCaP cells 
and cloned into the pLenti6 vector (Invitrogen) along with RFP and LacZ controls.  Insert 
sequences were confirmed by Sanger sequencing at the University of Michigan 
Sequencing Core.  Lentiviruses were generated at the University of Michigan Vector 
Core.  The benign immortalized prostate cell line RWPE was infected with lentiviruses 
expressing PCAT-1, RFP, or LacZ and stable pools and clones were generated by 
selection with blasticidin (Invitrogen).  For cell proliferation assays, 10,000 cells were 
plated in 12-well plates and allowed to attach overnight.  Cells were harvested and 




In vitro translation:  Full length PCAT-1, Halo-tagged ERG or GUS positive control were 
cloned into the PCR2.1 entry vector (Invitrogen).  Insert sequences were confirmed by 
Sanger sequencing at the University of Michigan Sequencing Core.  In vitro translation 
assays were performed with the TnT Quick Coupled Transcription/Translation System 
(Promega) with 1mM methionine and Transcend Biotin-Lysyl-tRNA (Promega) 
according to the manufacturer’s instructions. 
 
Statistical analyses for experimental studies: All data are presented as means ± S.E.M. 
 All experimental assays were performed in duplicate or triplicate.  Statistical analyses 


















Figure 3.1: Analysis of PCAT-1 and PCAT-14 transcript structure.  (a) 5’ and 3’ 
RACE experiments for PCAT-1 showed a ncRNA transcript containing two exons, each 
of which harbored portions of ancestral repetitive elements.  (b) 5’ and 3’ RACE analysis 
of PCAT-14. Expressed nucleotides are indicated in uppercase; genomic nucleotides are 




Figure 3.2: PCAT-1 is a marker of aggressive cancer and a PRC2-repressed ncRNA. 
 (a) The genomic location of PCAT-1 determined by 5’ and 3’ RACE, with DNA 
sequence features indicated by the colored boxes  (b) qPCR for PCAT-1 (Y-axis) and 
EZH2 (X-axis) on a cohort of benign (n=19), localized tumor (n=35) and metastatic 
cancer (n=31) samples.  The inset table quantifies patient subsets demarcated by the gray 
dotted lines.  (c) Knockdown of EZH2 in VCaP resulted in upregulation of PCAT-1. 
 Data were normalized to GAPDH and represented as fold change.  ERG and B-Actin 
serve as negative controls.  The inset Western blot indicates EZH2 knockdown. 
 (d) Treatment of VCaP cells with 0.1 µM of the EZH2 inhibitor DZNep or vehicle 
control (DMSO) shows increased expression of PCAT-1 transcript following EZH2 
inhibition.  (e) PCAT-1 expression is increased upon treatment of VCaP cells with the 
demethylating agent 5’Azacytidine, the histone deacetylase inhibitor SAHA, or a 
combination of both.  qPCR data were normalized to the average of (GAPDH+B-Actin) 
and represented as fold change.  GSTP1 and FKBP5 are positive and negative controls, 
respectively.  (f) ChIP assays for SUZ12 demonstrated direct binding of SUZ12 to the 
PCAT-1 promoter.  Primer locations are indicated (boxed numbers) in the PCAT-1 



















Figure 3.3: In vitro translation of PCAT-1 confirms ncRNA status. Full length PCAT-
1 transcript was cloned into the PCR2.1 vector (Invitrogen) and expressed using the TnT 
Quick Coupled Transcription/Translation System (Promega).  Western blot analysis 
resolving the proteins by SDS-PAGE indicated that PCAT-1 is a non-coding RNA with 





Figure 3.4: PCAT-1 and EZH2 expression is not exclusive with other Chr8q genes.  
qPCR was performed for c-MYC, NCOA2, PCAT-1, and EZH2.  Patterns of expression 
were compared as above: (a) PCAT-1 vs, c-MYC; (b) PCAT-1 vs NCOA2; (c) NCOA2 vs. 

























Figure 3.5: Genomic amplification of Chr8q is not required for PCAT-1 
upregulation.  Left: qPCR for PCAT-1 in the two prostate tissue cohorts shown in log10 
scale.  qPCR data is normalized to GAPDH and the median of the benign samples.  Right: 
Matched copy-number data (array CGH) for two patients.  The top panel indicates a 
patient with high Chr8q copy number gain and low expression of PCAT-1.  The lower 
panel indicates a patient with high expression of PCAT-1 but no copy number gain of 
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Chr8q.  Samples were run against genomic DNA from a normal human reference pool on 
Agilent Human Genome CGH 105K oligo arrays (Agilent Technologies, Santa Clara, 
























Figure 3.6: HOTAIR is not upregulated in prostate cancer. (a) qPCR analysis of a 
panel of breast cell lines and prostate cell lines for HOTAIR expression shows 
upregulation of HOTAIR in numerous breast cancer cell lines but not prostate cancer cell 
lines.  Expression levels are normalized to GAPDH and the median expression of benign 
breast cell lines.  (b)  RPKM expression levels of HOTAIR in the prostate RNA-Seq 













Figure 3.7: PCAT-1 transcript associates with the PRC2 complex in VCaP cells.  
 (a) RIP assays for SUZ12 indicate binding of PCAT-1 transcript to SUZ12 protein. 
 SNRNP70 serves as a control specifically binding to the U1 RNA.  Treating cells with 
IgG or no antibody serve as the negative controls.  (b) The PRC2/PCAT-1 interaction is 
stable to DNase I treatment but is abolished by RNase A treatment and partially degraded 
















Figure 3.8: PCAT-1 promotes cell proliferation. (a) Full length PCAT-1 transcript was 
cloned into a lentiviral vector, and, following lentivirus production, RWPE benign 
immortalized prostate cells stably overexpressing PCAT-1 were generated by selection 
with blasticidin. PCAT-1 overexpression compared to the LacZ control cells was 
confirmed by qPCR.  LNCaP serves as a positive control. (b) Cell proliferation assays for 
RWPE benign immortalized prostate cells stably infected with PCAT-1 lentivirus or RFP 
and LacZ control lentiviruses. An asterisk (*) indicates p ≤ 0.02 by a two-tailed Students 
t-test.  (c) Cell proliferation assays in LNCaP using PCAT-1 siRNAs. An asterisk (*) 
indicates p ≤ 0.005 by a two-tailed Students t-test.  (d) Gene ontology analysis of PCAT-
1 knockdown microarray data using the DAVID program.  Blue bars represent the top 
hits for upregulated genes.  Red bars represent the top hits for downregulated genes.  All 











Figure 3.9: PCAT-1 is not a PRC2 target in LNCaP cells.  (a) LNCaP cells were 
infected with lentivirus for EZH2 or scrambled control.  qPCR showed no change in 
PCAT-1 expression.  IGFBP3 and HMBS serve as positive and negative controls, 
respectively.  (b) ChIP analysis of SUZ12 in LNCaP cells does not show direct binding of 
PRC2 proteins upstream of the PCAT-1 transcriptional start site (refer to fig. 3E for 
comparison).  KRT17 serves as a positive control.  (c) RNA-IP analysis of in LNCaP cells 
does not indicate binding of PCAT-1 transcript to PRC2.  lincGARS serves as a positive 
control. (d) A representative image of SUZ12 RNA-IP pulldown efficiency.  Equal 
fractions of LNCaP nuclear lysate were treated with either IgG or SUZ12 antibodies and, 
following washing, probed for SUZ12 protein.  Treating nuclear lysates with no antibody 





Figure 3.10: Prostate cancer tissues recapitulate PCAT-1 signaling. (a) qPCR 
expression of three PCAT-1 target genes after PCAT-1 knockdown in VCaP and LNCaP 
cells, as well as following EZH2 knockdown or dual EZH2 and PCAT-1 knockdown in 
VCaP cells.  qPCR data were normalized to the average of (GAPDH+B-Actin) and 
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represented as fold change.  Error bars represent mean ± S.E.M.  (b) Standardized log2-
transformed qPCR expression of a set of tumors and metastases with outlier expression of 
either PCAT-1 or EZH2.  The shaded squares in the lower left show Spearman correlation 
values between the indicated genes (* indicates p < 0.05).  Blue and red indicate negative 
or positive correlation, respectively.  The upper squares show the scatter plot matrix and 
fitted trendlines for the same comparisons.  (c) A heatmap of PCAT-1 target genes 
(BRCA2, CENPF, CENPE) in EZH2-outlier and PCAT-1-outlier patient samples (see Fig. 
4b).  Expression was determined by qPCR and normalized as in (b).  (d) A predicted 
network generated by the HefaLMP program for 7 of 20 top upregulated genes following 
PCAT-1 knockdown in LNCaP cells.  Gray nodes are genes found following PCAT-1 
knockdown.  Red edges indicate co-expressed genes; black edges indicate predicted 
protein-protein interactions; and purple edges indicate verified protein-protein 
interactions. (e) A proposed schematic representing PCAT-1 upregulation, function, and 













Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_BP_FAT  GO:0022403~cell cycle phase  2.71E‐16  6.02522351  3.03E‐13  3.03E‐13  3.66E‐13 
GOTERM_BP_FAT  GO:0000279~M phase  2.25E‐15  6.67546375  3.03E‐12  1.51E‐12  3.64E‐12 
GOTERM_BP_FAT  GO:0022402~cell cycle process  1.01E‐14  4.80692371  1.38E‐11  4.59E‐12  1.66E‐11 
SP_PIR_KEYWORDS  mitosis  6.82E‐13  9.12491342  1.66E‐10  8.29E‐11  8.82E‐10 
GOTERM_BP_FAT  GO:0000278~mitotic cell cycle  2.57E‐12  5.49083562  3.51E‐09  8.77E‐10  4.23E‐09 
GOTERM_BP_FAT  GO:0007049~cell cycle  3.80E‐12  3.72268142  5.18E‐09  1.04E‐09  6.25E‐09 
GOTERM_BP_FAT  GO:0051301~cell division  6.75E‐12  6.10506469  9.21E‐09  1.53E‐09  1.11E‐08 
SP_PIR_KEYWORDS  cell cycle  7.18E‐12  5.11554227  1.75E‐09  5.82E‐10  9.29E‐09 
SP_PIR_KEYWORDS  cell division  7.26E‐12  6.95774648  1.76E‐09  4.41E‐10  9.39E‐09 
GOTERM_CC_FAT  GO:0015630~microtubule cytoskeleton  1.01E‐11  4.68954996  2.22E‐09  1.11E‐09  1.29E‐08 
GOTERM_BP_FAT  GO:0000280~nuclear division  8.33E‐11  6.85309773  1.13E‐07  1.62E‐08  1.37E‐07 
GOTERM_BP_FAT  GO:0007067~mitosis  8.33E‐11  6.85309773  1.13E‐07  1.62E‐08  1.37E‐07 
GOTERM_BP_FAT 
GO:0000087~M phase of mitotic cell 
cycle  1.14E‐10  6.73017221  1.55E‐07  1.94E‐08  1.87E‐07 
GOTERM_BP_FAT  GO:0048285~organelle fission  1.67E‐10  6.58258071  2.28E‐07  2.53E‐08  2.74E‐07 
GOTERM_CC_FAT  GO:0005819~spindle  1.37E‐09  8.77846791  3.00E‐07  6.01E‐08  1.74E‐06 
GOTERM_CC_FAT  GO:0044430~cytoskeletal part  3.53E‐09  3.23343567  7.74E‐07  9.67E‐08  4.50E‐06 




Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_CC_FAT 
GO:0043232~intracellular non‐
membrane‐bounded organelle  2.96E‐12  2.28855826  6.49E‐10  6.49E‐10  3.77E‐09 
GOTERM_CC_FAT 
GO:0043228~non‐membrane‐bounded 
organelle  2.96E‐12  2.28855826  6.49E‐10  6.49E‐10  3.77E‐09 
GOTERM_CC_FAT  GO:0015630~microtubule cytoskeleton  1.01E‐11  4.68954996  2.22E‐09  1.11E‐09  1.29E‐08 
GOTERM_CC_FAT  GO:0005856~cytoskeleton  3.14E‐09  2.71949761  6.89E‐07  9.84E‐08  4.00E‐06 
GOTERM_CC_FAT  GO:0044430~cytoskeletal part  3.53E‐09  3.23343567  7.74E‐07  9.67E‐08  4.50E‐06 
SP_PIR_KEYWORDS  cytoskeleton  1.95E‐06  3.18068411  4.75E‐04  5.27E‐05  0.00252634 
GOTERM_CC_FAT 
GO:0044450~microtubule organizing 
center part  3.38E‐06  12.2898551  7.41E‐04  6.17E‐05  0.00430253 
GOTERM_CC_FAT  GO:0005813~centrosome  1.01E‐05  5.01514265  0.00221202  1.70E‐04  0.01286134 









Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_CC_FAT  GO:0005819~spindle  1.37E‐09  8.77846791  3.00E‐07  6.01E‐08  1.74E‐06 
GOTERM_CC_FAT  GO:0005874~microtubule  1.69E‐06  4.98237368  3.69E‐04  3.36E‐05  0.00214593 




Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_CC_FAT  GO:0044427~chromosomal part  4.96E‐11  5.47664629  1.09E‐08  3.62E‐09  6.31E‐08 
GOTERM_CC_FAT  GO:0005694~chromosome  3.02E‐10  4.76879077  6.62E‐08  1.66E‐08  3.85E‐07 
GOTERM_CC_FAT 
GO:0000775~chromosome, 
centromeric region  1.67E‐09  9.71294998  3.66E‐07  6.09E‐08  2.12E‐06 
GOTERM_CC_FAT  GO:0000793~condensed chromosome  2.60E‐08  8.73731884  5.70E‐06  6.34E‐07  3.31E‐05 
SP_PIR_KEYWORDS  kinetochore  7.88E‐07  11.9275654  1.92E‐04  2.74E‐05  0.00101965 
GOTERM_CC_FAT 
GO:0000779~condensed chromosome, 
centromeric region  8.38E‐07  11.7312253  1.83E‐04  1.83E‐05  0.00106551 
GOTERM_BP_FAT  GO:0007059~chromosome segregation  1.17E‐06  9.26437285  0.00159144  1.45E‐04  0.00191904 
GOTERM_CC_FAT  GO:0000776~kinetochore  2.87E‐05  8.93807642  0.00626152  3.92E‐04  0.03647611 
GOTERM_CC_FAT 
GO:0000777~condensed chromosome 
kinetochore  5.23E‐05  10.3828086  0.0113946  6.03E‐04  0.06654048 
GOTERM_CC_FAT 
GO:0000940~outer kinetochore of 
condensed chromosome  1.20E‐04  38.2351047  0.02594508  0.00131352  0.15256829 
GOTERM_BP_FAT 
GO:0051493~regulation of cytoskeleton 
organization  0.100330664  2.82110602  1  0.87987522  82.3838413 
GOTERM_BP_FAT 
GO:0070507~regulation of microtubule 
cytoskeleton organization  0.106560286  5.36010144  1  0.87800896  84.2836176 
GOTERM_BP_FAT 
GO:0032886~regulation of microtubule‐




Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_BP_FAT 
GO:0051327~M phase of meiotic cell 
cycle  4.90E‐06  7.8168146  0.0066582  5.57E‐04  0.00804899 
GOTERM_BP_FAT  GO:0007126~meiosis  4.90E‐06  7.8168146  0.0066582  5.57E‐04  0.00804899 
GOTERM_BP_FAT  GO:0051321~meiotic cell cycle  5.82E‐06  7.65728777  0.00789578  6.10E‐04  0.00955096 




Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_BP_FAT 
GO:0007017~microtubule‐based 
process  2.41E‐08  5.53584247  3.29E‐05  3.29E‐06  3.96E‐05 
GOTERM_BP_FAT 
GO:0000226~microtubule cytoskeleton 
organization  1.19E‐04  5.24765176  0.14921239  0.0089372  0.1945143 




Enrichment  Bonferroni  Benjamini  FDR 
SP_PIR_KEYWORDS  atp‐binding  5.12E‐06  2.29972952  0.00124353  1.24E‐04  0.00662221 
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SP_PIR_KEYWORDS  nucleotide‐binding  1.04E‐05  2.0784525  0.00252414  2.11E‐04  0.01344999 
UP_SEQ_FEATURE 
nucleotide phosphate‐binding 
region:ATP  2.40E‐05  2.46666468  0.0183188  0.00614394  0.03666554 
GOTERM_MF_FAT  GO:0005524~ATP binding  3.49E‐05  2.02959734  0.01136867  0.01136867  0.04720456 
GOTERM_MF_FAT 
GO:0032559~adenyl ribonucleotide 
binding  4.61E‐05  2.00323894  0.01499727  0.00752696  0.06238072 
GOTERM_MF_FAT  GO:0032553~ribonucleotide binding  5.56E‐05  1.86793055  0.01806136  0.00454625  0.0752377 
GOTERM_MF_FAT 
GO:0032555~purine ribonucleotide 
binding  5.56E‐05  1.86793055  0.01806136  0.00454625  0.0752377 
GOTERM_MF_FAT  GO:0030554~adenyl nucleotide binding  6.12E‐05  1.95071141  0.01987313  0.0040066  0.08285798 
GOTERM_MF_FAT  GO:0000166~nucleotide binding  7.07E‐05  1.7424561  0.02291439  0.00385605  0.09567995 
GOTERM_MF_FAT  GO:0017076~purine nucleotide binding  7.12E‐05  1.82823052  0.02309376  0.00333224  0.0964374 
GOTERM_MF_FAT  GO:0001883~purine nucleoside binding  8.50E‐05  1.92083453  0.02748603  0.00347779  0.11502619 




Enrichment  Bonferroni  Benjamini  FDR 
SP_PIR_KEYWORDS  chelation  1.32E‐06  52.1830986  3.22E‐04  4.02E‐05  0.0017119 
PIR_SUPERFAMILY  PIRSF002564:metallothionein  3.84E‐06  41.6969697  3.42E‐04  3.42E‐04  0.00417325 
UP_SEQ_FEATURE  region of interest:Alpha  3.93E‐06  41.6690141  0.00301834  0.00301834  0.00599575 
UP_SEQ_FEATURE  region of interest:Beta  3.93E‐06  41.6690141  0.00301834  0.00301834  0.00599575 
INTERPRO 
IPR003019:Metallothionein 
superfamily, eukaryotic  5.75E‐06  38.3942688  0.00227046  0.00227046  0.00801144 
INTERPRO  IPR000006:Metallothionein, vertebrate  5.75E‐06  38.3942688  0.00227046  0.00227046  0.00801144 
INTERPRO 
IPR018064:Metallothionein, vertebrate, 
metal binding site  5.75E‐06  38.3942688  0.00227046  0.00227046  0.00801144 
SP_PIR_KEYWORDS  metal‐thiolate cluster  6.07E‐06  37.9513444  0.00147319  1.34E‐04  0.00784606 
UP_SEQ_FEATURE 
metal ion‐binding site:Divalent metal 
cation; cluster B  6.11E‐06  37.8809219  0.00469478  0.00235015  0.00933359 
UP_SEQ_FEATURE 
metal ion‐binding site:Divalent metal 
cation; cluster A  6.11E‐06  37.8809219  0.00469478  0.00235015  0.00933359 
SP_PIR_KEYWORDS  metal binding  6.61E‐05  21.971831  0.01593785  0.00114693  0.08547079 
SP_PIR_KEYWORDS  cadmium  8.95E‐05  41.7464789  0.02151373  0.00144885  0.11568263 
GOTERM_MF_FAT  GO:0046870~cadmium ion binding  2.18E‐04  31.6836601  0.06889543  0.00711295  0.29434429 
SP_PIR_KEYWORDS  acetylated amino end  0.006365991  5.11181374  0.78815082  0.06261547  7.92750279 
SP_PIR_KEYWORDS  copper  0.029163321  5.9637827  0.99924748  0.20128604  31.8033936 




Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_BP_FAT 
GO:0007017~microtubule‐based 
process  2.41E‐08  5.53584247  3.29E‐05  3.29E‐06  3.96E‐05 
GOTERM_CC_FAT  GO:0005874~microtubule  1.69E‐06  4.98237368  3.69E‐04  3.36E‐05  0.00214593 
GOTERM_BP_FAT 
GO:0007018~microtubule‐based 
movement  1.29E‐05  6.94827964  0.01744449  0.00125624  0.02120218 
SP_PIR_KEYWORDS  microtubule  1.56E‐05  4.86730247  0.00377475  2.91E‐04  0.0201259 
GOTERM_MF_FAT 
GO:0003777~microtubule motor 
activity  4.90E‐05  8.22952211  0.01595905  0.00534824  0.06641223 
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UP_SEQ_FEATURE  domain:Kinesin‐motor  0.001694818  9.69046839  0.72913019  0.22989114  2.55741208 
GOTERM_MF_FAT  GO:0003774~motor activity  0.001980066  4.49413619  0.47800924  0.05273411  2.6488895 
SP_PIR_KEYWORDS  motor protein  0.004866667  4.46145576  0.6944027  0.05245967  6.11445689 
INTERPRO 
IPR019821:Kinesin, motor region, 
conserved site  0.013166214  8.04451346  0.99467421  0.52663331  16.8500322 
INTERPRO  IPR001752:Kinesin, motor region  0.013166214  8.04451346  0.99467421  0.52663331  16.8500322 




Enrichment  Bonferroni  Benjamini  FDR 
SP_PIR_KEYWORDS  meiosis  1.90E‐04  11.1323944  0.04520584  0.00288704  0.24589866 
GOTERM_CC_FAT  GO:0044454~nuclear chromosome part  4.95E‐04  5.68786681  0.10269743  0.00491344  0.62741764 
GOTERM_CC_FAT  GO:0000228~nuclear chromosome  5.47E‐04  4.80907372  0.1129476  0.00519737  0.69370818 
GOTERM_CC_FAT 
GO:0000794~condensed nuclear 




Enrichment  Bonferroni  Benjamini  FDR 
GOTERM_BP_FAT 
GO:0000226~microtubule cytoskeleton 
organization  1.19E‐04  5.24765176  0.14921239  0.0089372  0.1945143 
GOTERM_BP_FAT 
GO:0007052~mitotic spindle 
organization  9.24E‐04  20.0110454  0.7163991  0.05567155  1.50693476 

















1. T. Oosumi, W. R. Belknap, B. Garlick, Nature 378, 672 (Dec 14, 1995). 
2. H. M. Robertson, K. L. Zumpano, A. R. Lohe, D. L. Hartl, Nat Genet 12, 360 
(Apr, 1996). 
3. C. G. Kleer et al., Proc Natl Acad Sci U S A 100, 11606 (Sep 30, 2003). 
4. S. Varambally et al., Nature 419, 624 (Oct 10, 2002). 
5. N. Ahmadiyeh et al., Proc Natl Acad Sci U S A 107, 9742 (May 25, 2010). 
6. A. A. Al Olama et al., Nat Genet 41, 1058 (Oct, 2009). 
7. R. Beroukhim et al., Nature 463, 899 (Feb 18, 2010). 
8. J. Gudmundsson et al., Nat Genet 39, 631 (May, 2007). 
9. J. Sotelo et al., Proc Natl Acad Sci U S A 107, 3001 (Feb 16, 2010). 
10. B. S. Taylor et al., Cancer Cell 18, 11 (Jul 13, 2010). 
11. R. A. Gupta et al., Nature 464, 1071 (Apr 15, 2010). 
12. C. Huttenhower et al., Genome Res 19, 1093 (Jun, 2009). 
13. B. Laxman et al., Cancer Res 68, 645 (Feb 1, 2008). 
14. D. Hessels et al., Eur Urol 44, 8 (Jul, 2003). 
15. M. A. Rubin et al., Clin Cancer Res 6, 1038 (Mar, 2000). 
16. S. A. Tomlins et al., Neoplasia 10, 177 (Feb, 2008). 
17. V. G. Tusher, R. Tibshirani, G. Chu, Proc Natl Acad Sci U S A 98, 5116 (Apr 24, 
2001). 
18. G. Dennis, Jr. et al., Genome Biol 4, P3 (2003). 












A lineage-specific long non-coding RNA controls homologous 





The dysregulation of repair pathways that monitor and process double-stranded 
DNA breaks (DSBs) is essential to tumorigenesis in many cancers.  However, while 
direct mutation of components of the DSB repair machinery is common in hereditary 
cancer, mechanisms of impaired DSB repair in sporadic cancers remains incompletely 
understood (1-3).  Here, we describe the first role for a lineage-specific long noncoding 
RNA (lncRNA) in DSB repair.  We identify PCAT-1, a prostate cancer-specific lncRNA, 
which regulates prostate cell response to genotoxic stress.  PCAT-1 expression results in a 
functional deficiency in homologous recombination (HR) through its repression of the 
BRCA2 tumor suppressor, which, in turn, imparts a high sensitivity to small molecule 
inhibitors of PARP1, both in vitro and in vivo.  These effects were mediated through 
repression of the BRCA2 3’UTR by PCAT-1 in a microRNA-like manner.  Importantly, 
these findings represent lineage-specific functions of PCAT-1 that were not observed in 
breast cancer cells.  Our observations thus identify PCAT-1 as the first example of a 





The uncontrolled accumulation of DSBs represents a putative Achilles heel for 
cancer cells, since these lesions are toxic and their repair requires re-ligation of 
completely detached genetic material (4).  Several mechanisms, such as non-homologous 
end joining (NHEJ), microhomology-mediated end joining (MMEJ) and homologous 
recombination (HR), contribute to DSB repair and are employed variously during the cell 
cycle, depending on whether a specific DSB harbors either large, small, or no stretches 
(NHEJ, MMEJ, and HR, respectively) of complementary DNA sequences on the two 
fragments of broken DNA (4, 5).  In particular, the lethality of excess DSBs has been 
exploited for the therapeutic treatment of breast and ovarian cancers harboring BRCA1/2 
mutations, which leads to defective HR and increased DSBs (6).  These cancers exhibit 
synthetic lethality when treated with small molecule inhibitors of the PARP1 DNA repair 
enzyme, whose inhibition prevents a second method of DNA repair and leads to gross 
collapse of cellular DNA maintenance (7-9). 
Recently, long noncoding RNAs (lncRNAs) have emerged as new layer of cell 
biology, contributing to diverse biological processes such as pluripotency maintenance in 
stem cells (10), X chromosome inactivation in women (11), and neurodegenerative 
disease (12).  In cancer, aberrant expression of lncRNAs is associated with cancer 
progression (13), and overexpression of oncogenic lncRNAs can promote tumor cell 
proliferation and metastasis through transcriptional regulation of target genes (14-16).  
Yet, while previous studies in cancer have identified lncRNAs induced by genotoxic 
stress (17, 18), no study to date has described a role for lncRNAs in the regulation of 
DSB repair.  We have previously reported the systematic discovery of novel lncRNAs in 
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prostate cancer (13).   Of note, we characterized PCAT-1 as a prostate-specific lncRNA 
upregulated in subsets of prostate cancer patients and implicated in tumor growth (13).  
PCAT-1 was found to repress in vitro genes associated with DNA maintenance, DNA 
repair, and mitotic spindle assembly, and negative correlations between PCAT-1 and its 
DNA repair gene targets were similarly observed in human prostate cancer tissues.  Here, 




We noted that PCAT-1 was a repressor of BRCA2, a tumor suppressor gene 
integral to the proper induction of the HR pathway (6).  We hypothesized that PCAT-1-
mediated repression of BRCA2 would lead to impaired HR upon genotoxic stress and 
increased cell susceptibility to PARP-1 inhibitors (Figure 4.1a).  To pursue this 
hypothesis, we generated a panel of four in vitro cell culture model systems: PCAT-1 
overexpression in Du145 prostate cancer cells (which lack endogenous expression of this 
lncRNA), PCAT-1 overexpression in RWPE benign prostate cells (which lack 
endogenous expression of this lncRNA), stable knockdown of PCAT-1 in LNCaP 
prostate cancer cells (which harbor high endogenous levels of PCAT-1 expression), and 
PCAT-1 overexpression in MCF7 breast cancer cells (which lack endogenous expression 
of PCAT-1) (Figure 4.1b). 
Western blot analysis of these four isogenic models uniformly revealed strong 
downregulation of BRCA2 protein levels in RWPE and Du145 prostate cells and 
upregulation of BRCA2 in LNCaP sh-PCAT-1 cells (Figure 4.1c).  Consistent with the 
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lineage-specific expression of PCAT-1 exclusive in prostate(13), MCF7-PCAT-1 cells 
showed no change in BRCA2 levels, suggesting that PCAT-1 also functions in a lineage-
specific manner (Figure 4.1c). 
Importantly, BRCA2 inactivation impairs HR of DSBs and serves as a predictive 
biomarker for response to treatment with inhibitors of the PARP1 DNA repair enzyme 
through synthetic lethality that results from joint inactivation of two DNA repair 
pathways (HR via BRCA2 inactivation, and base excision repair via PARP1 inhibition) 
(19).  Accordingly, treatment of our four isogenic cell lines with either a PARP1 
inhibitor, Olaparib (9) or ABT-888 (20), or radiation, resulted in modulation of RAD51 
foci formation, which is a component of the HR pathway and a marker for engagement of 
the HR machinery (21).  Specifically, PCAT-1 overexpression decreased RAD51 foci 
formation post-therapy and PCAT-1 knockdown increased RAD51 foci formation post-
therapy in prostate cells (Figure 4.1d and Figure 4.2). 
Because PCAT-1 impairs HR, genotoxic stress of PCAT-1-expressing cells should 
lead to an accumulation of DSBs, which can be visualized using phospho-gammaH2AX 
(p-gH2AX) foci, a marker of double-stranded DNA breaks that have not been repaired 
(4).  To test this, we treated our isogenic Du145 and LNCaP cell line models with 
Olaparib, ABT-888, or radiation.  As predicted, PCAT-1 overexpression in Du145 led to 
an increase in p-gH2AX foci under stress conditions (Figure 4.3), indicating that PCAT-1 
impairs DSB repair in these cells.  Similarly, LNCaP cells with PCAT-1 knockdown 
displayed decreased levels of p-gH2AX foci (Figure 4.3).  Finally, we also evaluated the 
ability of our isogenic cell lines to sustain growth in clonogenic survival assays, a gold-
standard assay for cell viability following genotoxic stress, after treatment of cells with 
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PARP1 inhibition or radiation.  We found that PCAT-1 expression led to decreased cell 
survival in Du145 and RWPE cells, whereas PCAT-1 knockdown increased LNCaP cell 
survival, in these assays (Figure 4.4 and Figure 4.5).  MCF7 cells overexpressing PCAT-
1 did not show a change in clonogenic survival in these conditions.  Together, these data 
indicate that PCAT-1 expression may impart cell sensitivity to genotoxic stress by 
decreasing the HR response through downregulation of BRCA2. 
Because PCAT-1 expressing cells exhibit reduced HR efficiency when 
challenged, we investigated whether PARP1 inhibition selectively killed PCAT-1-
expressing cells.  Following treatment with two PARP1 inhibitors (Olaparib or ABT-
888), we observed that knockdown of PCAT-1 in LNCaP cells prevented cell death, 
whereas overexpression of PCAT-1 in Du145 and RWPE prostate cells, but not MCF7 
breast cells, increased cell death in response to PARP inhibition (Figure 4.6a-f).  This 
change in cell sensitivity to PARP1 inhibitors was quite profound, as the IC50 for LNCaP 
and Du145 cells changed by at least five-fold when PCAT-1 expression was either 
exogenously introduced or depleted by knockdown (Figure 4.6a-d).  Similar results were 
observed in RWPE cells overexpressing PCAT-1 (Figure 4.7), and treatment with the 
mTOR inhibitor rapamycin did not produce this effect (Figure 4.8), supporting 
specificity of PCAT-1 in inducing sensitivity to PARP1 inhibitors.  Prostate cell 
sensitivity to PARP1 inhibitors was mediated through BRCA2, as knockdown of BRCA2 
in LNCaP shPCAT-1 cells (which have increased levels of BRCA2) rescued the 
sensitivity of these cells to PARP1 inhibition in a dose-dependent manner according to 
the efficiency of the knockdown (Figure 4.6g) and reduced RAD51 foci post-treatment 
(Figure 4.6g).  To rule out the possibility that altered cell cycle distributions contribute to 
128 
 
our observed phenotypes, we performed flow cytometry on our isogenic RWPE, LNCaP, 
and Du145 cell models, which demonstrated no change in cell cycle in our model 
systems (Figure 4.9). 
To evaluate the contribution of PCAT-1 to PARP inhibitor response in vivo, we 
generated xenografts of Du145 cells expressing either empty vector control or PCAT-1.  
We observed that Du145-PCAT-1 cells grew significantly more rapidly in severe 
combined immunodeficient (SCID) mice, consistent with our previous findings that 
PCAT-1 accelerates prostate cell proliferation in vitro  (Figure 4.10a) (13).  Moreover, 
Du145-PCAT-1 xenografts showed marked susceptibility and tumor regression following 
intra-peritoneal (IP) administration of Olaparib, whereas Du145-control cells showed 
only a subtle change in growth while the drug was administered, indicating that the 
background effect of Olaparib therapy—possibly due to its effects on other members of 
the PARP family (22)—is small (Figure 4.10a).  Mice in all groups of treatment 
maintained their body weights and showed no evidence of weight loss (Figure 4.10b). 
Importantly, Du145 xenografts retained both PCAT-1 expression and BRCA2 
repression (Figure 4.10c).  To investigate PCAT-1 signaling under control-treated 
(DMSO) and Olaparib-treated conditions, we also observed in vivo upregulation of 
PCAT-1-induced target genes (Figure 4.10c) also observed in RWPE-PCAT-1 
overexpressing cells (Figure 4.11) (13).  These data suggest that PCAT-1 is 
mechanistically linked to increased prostate cell sensitivity to PARP1 inhibitors via its 
repression of BRCA2 both in vitro and in vivo. 
While many lncRNAs are noted to regulate gene transcription through epigenetic 
mechanisms (14-16, 23, 24), we did not observe evidence for this possibility with PCAT-
129 
 
1.  Although PCAT-1 regulated BRCA2 transcript levels in vitro (Figure 4.12a), 
treatment of RWPE-LacZ and RWPE-PCAT-1 cells with the DNA methylation inhibitor 
5-azacytidine (5-aza), the histone deacetylase inhibitor TSA, or both did not reveal 
enhanced epigenetic regulation of BRCA2 mRNA in PCAT-1-expressing cells (Figure 
4.12b), although there was a baseline regulation of BRCA2 in both cell lines when 5-aza 
and TSA were combined.  Together, these results suggest that epigenetic repression of 
BRCA2 is not the primary mechanism of PCAT-1.  Similarly, a recent report suggests that 
lncRNAs containing Alu elements in their transcript sequence may utilize these repetitive 
sequences to regulate target gene mRNAs via STAU1-dependent degradation (25).  
Although PCAT-1 harbors an Alu element from bps 1103 – 1402, knockdown of STAU1 
in LNCaP or VCaP cells, which endogenously harbor PCAT-1, did not alter BRCA2 
levels (Figure 4.12c). 
To determine whether PCAT-1 may function in a manner more analogous to 
microRNAs, which regulate mRNA levels post-transcriptionally (26), we generated a 
luciferase construct of the BRCA2 3’UTR (Figure 4.13a).  Surprisingly, we found that 
RWPE-PCAT-1 cells, but not control RWPE-LacZ cells, were able to directly repress the 
activity of the wild-type BRCA2 3’UTR construct (Figure 4.13a).  Further, to map a 
region of PCAT-1 required for repression of the BRCA2 3’UTR, we additionally 
generated a series of PCAT-1 deletion constructs and overexpressed these in RWPE cells 
(Figure 4.13b).  We generated these constructs to establish whether the 3’ end of PCAT-
1, which contains portions of ancestral transposase and Alu repeat elements (Figure 
4.13b) (13), or the 5’ end of PCAT-1, which consists of non-repetitive DNA sequences, 
was required for BRCA2 repression.  We observed that the 5’ end of PCAT-1 was 
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sufficient to downregulate the BRCA2 3’UTR luciferase signal as well as endogenous 
BRCA2 transcript levels (Figure 4.13c,d), and for this regulation, the first 250 bps of the 
PCAT-1 gene were required.  By contrast, the 3’ end of PCAT-1 was expendable for this 
regulation.  Importantly, the 5’ end of PCAT-1 was similarly sufficient to sensitize 
RWPE cells to Olaparib treatment in vitro, resulting in decreased cell survival in cells 
expressing the 5’ end of PCAT-1 (Figure 4.13e).  Together, these results indicate that 
PCAT-1 overexpression is able to directly repress the activity of the BRCA2 3’UTR, and 
that this repression required the 5’ end of PCAT-1. 
Of note, we previously reported that the TMPRSS2-ERG gene fusion in prostate 
cancer may also serve as a biomarker for PARP1 inhibitor therapy, due to physical 
interaction between the ERG protein and PARP-1 (27).  Interestingly, we observed that 
prostate cancer tissue samples with the highest levels of PCAT-1 tended to be ERG-
negative, although this analysis did not reach statistical significance (Figure 4.14).  Thus, 
PCAT-1 may identify a unique set of patients for whom PARP1 inhibitor therapy may 
have a mechanistic basis.  
 
DISCUSSION 
To our knowledge, this is the first report of a lineage-specific lncRNA being 
involved in the DSB repair process.  While several lncRNAs have been reported to be 
transcriptionally induced by genotoxic stress (17, 18), PCAT-1 is the first example of a 
lncRNA implicated in the functional regulation of the DNA repair machinery (Figure 
4.15).  These results expand the potential roles for lncRNAs in cancer biology and 
contrast strikingly with previous reports that lncRNAs operate epigenetically through 
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chromatin modifying complexes (28).  Indeed, epigenetic regulation likely represents 
only a one of numerous mechanisms for lncRNA function (15, 25, 29-31).  Supporting 
this notion, we do not observe compelling evidence that PCAT-1 functions in an 
epigenetic manner, but rather it may exhibit microRNA-like features.  Our 
characterization of a PCAT-1-BRCA2 axis therefore provides the first report of novel 
mechanism of HR regulation in human cancer. 
These data suggest that lncRNAs may have a more widespread role in genome 
maintenance and DNA repair than previously appreciated.  A report in fission yeast found 
that locations of meiotic recombination are enriched for the transcription of local 
ncRNAs (32).  Moreover, lncRNAs such as Xist and HOTTIP have been shown to 
contribute to large-scale genome architecture (23, 33).  A detailed analysis of the 
CDKN1A promoter uncovered a p53-induced lncRNA that contributed to transcriptional 
regulation of pro-apoptotic genes (34), but this gene was not shown to be involved in 
DSB repair.  Of note, however, Adamson et al. nominated the RNA-binding protein 
RBMX as a novel component of the homologous recombination pathway (35), suggesting 
that RNA-protein interactions may be integral to this process. 
This work sheds insight onto potential mechanisms of impaired DSB repair in 
cancers lacking an inactivating mutation in canonical DSB repair proteins.  Thus, our 
studies have uncovered a novel mechanism of “BRCA-ness”—the clinical observation 
that many cancers lacking BRCA1/BRCA2 mutations exhibit the clinical features of 
impaired DSB repair (3, 36).  While PCAT-1 expression and function appear to be 
restricted to prostate cancer cells, we hypothesize that other cancers with a BRCA-like 
phenotype may harbor lineage-specific lncRNAs involved in the regulation and execution 
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of proper HR and other forms of DSB repair.  Finally, future clinical trials examining the 
efficacy of PARP1 inhibitors in prostate cancer will provide critical information as to 























MATERIALS AND METHODS 
Cell lines 
All cell lines were obtained from the American Type Culture Collection 
(Manassas, VA).  Cell lines were maintained using standard media and conditions.  
Du145-derived cell lines were maintained in DMEM supplemented with 10% FBS 
(Invitrogen) and 1% penicillin-streptomycin (Invitrogen) in a 5% CO2 cell culture 
incubator.  RWPE-derived cell lines were maintained in KSF (Invitrogen) supplemented 
with Bovine Pituitary Extract, Epidermal Growth Factor and 1% penicillin-streptomycin 
in a 5% CO2 cell culture incubator.  MCF7-derived cell lines were maintained in DMEM 
supplemented with 10% FBS, 10mg/mL insulin, and 1% penicillin-streptomycin in a 5% 
CO2 cell culture incubator.  LNCAP-derived cell lines were maintained in RPMI 1640 
(Invitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin in a 5% CO2 
cell culture incubator. 
PCAT-1 or control-expressing cell lines were generated by cloning PCAT-1 or 
control LacZ into the pLenti6 vector (Invitrogen).  After confirmation of the insert 
sequence, lentiviruses were generated at the University of Michigan Vector Core and 
transfected intoMCF7, RWPE, or Du145 cells.  Stably-transfected cells were selected 
using blasticidin (Invitrogen). 
For LNCAP cells with stable knockdown of PCAT-1, cells were seeded at 50-
60% confluency, incubated overnight, and transfected with PCAT1 or non-targeting 
shRNA lentiviral constructs for 48 hours.  GFP+ cells were drug-selected using 1 ug/mL 
puromycin.  PCAT1 shRNAs were customed generated by Systems Biosciences using the 
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following sequences: shRNA 1 GCAGAAACACCAAUGGAUAUU; shRNA 2 
AUACAUAAGACCAUGGAAAU. 
 
Cell line treatments 
Cells were plated in 6-well plates and allowed to grow for 24 hours.  For radiation 
experiments, after 24 hours, cells were subjected to 2 Gray (Gy), 4 Gy, or 6 Gy of 
radiation (Philips RT250, Kimtron Medical).  RAD51 and gamma-H2AX staining was 
performed 6 hours or 24 hours post-treatment, and RNA was collected 24 hours post-
treatment. 
For Olaparib or ABT-888 treatments, cells were treated with the indicated doses 
of drug or DMSO control.  RAD51 and gamma-H2AX staining was performed 6 hours 
post-treatment, and RNA was collected 24 hours post-treatment. 
For epigenetic drug treatments, RWPE-LacZ and RWPE-PCAT1 cells were 
treated with 20uM 5’deoxyazacytidine (Sigma), 500 nM HDAC inhibitor Trichostatin A 
(TSA) (Sigma), or both 5’deoxyazacytidine and TSA.  5’deoxyazacytidine treatments 
were performed for 6 days with media and drug re-applied every 48 hours.  TSA 
treatments were performed for 48 hours.  DMSO treatments were performed for 6 days.   
 
RNA isolation; cDNA synthesis; and PCR experiments 
Total RNA was isolated using Trizol and an RNeasy Kit (Invitrogen) with DNase 
I digestion according to the manufacturer’s instructions.   RNA integrity was verified on 
an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).  cDNA was 
synthesized from total RNA using Superscript III (Invitrogen) and random primers 
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(Invitrogen).  Quantitative Real-time PCR (qPCR) was performed using Power SYBR 
Green Mastermix (Applied Biosystems, Foster City, CA) on an Applied Biosystems 
7900HT Real-Time PCR System. 
The relative quantity of the target gene was completed for each sample using the 
ΔΔCt method by the comparing mean Ct of the gene to the average Ct of the geometric 
mean of two housekeeping genes, GAPDH and HMBS. All oligonucleotide primers were 
synthesized by Integrated DNA Technologies (Coralville, IA). The primer sequences for 
the transcript analyzed are provided in Appendix 2. 
 
Xenografts 
Five week-old male SCID mice (CB.17. SCID), were purchased from Charles 
River, Inc. (Charles River Laboratory, Wilmington, MA). 1 x 106 Du145-control or 
Du145-PCAT1 stable cells were resuspended in 100μl of saline with 50% Matrigel (BD 
Biosciences, Becton Drive, NJ) and were implanted subcutaneously into the left and right 
flank regions of the mice. Mice were anesthetized using a cocktail of Xylazine (80-120 
mg/kg, IP) and Ketamine (10mg/kg, IP) for chemical restraint before tumor implantation. 
All tumors were staged for two weeks before starting the drug treatment. At the 
beginning of the third week, mice with tumors (10 tumors per treatment group, average 
size 150-200 mm3) were treated with Olaparib (100mg/kg, IP twice daily five times per 
week) or an equal volume of DMSO control.  Olaparib was obtained from Axon 
Medchem (Groningen, The Netherlands).  Growth in tumor volume was recorded weekly 
by using digital calipers and tumor volumes were calculated using the formula (π/6) (L × 
W2), where L = length of tumor and W = width.  Loss of body weight during the course 
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of the study was also monitored weekly; all changes in mouse weights occurred within 
tolerable limits as set by the University Committee on Use and Care of Animals 
(UCUCA) at the University of Michigan. At the end of the xenograft studies, mice were 
sacrificed, and mouse xenograft tumors were subsequently harvested, maintained in 
formalin, and subsequently embedded in paraffin. All procedures involving mice were 




1 x 105cells were plated on sterile coverslips in 12-well plates and cultured for 24 
hours. After treated for 6 hour or 24 hour, cells were fixed with 4% paraformaldehyde for 
15min at room temperature, and then permeabilized with 0.5% Triton X-100 for 20min.  
Cells were blocked for 1 hour in blocking buffer (0.5% BSA, 2.5% goat serum and 
0.05% Triton X-100 in PBS), and then incubated with primary antibody against 
Rad51(Santa Cruz sc-8349) at 1:400 or gamma-H2AX (Millipore JBW301) at 1:1,000, 
followed by secondary antibody Alexa Fluor 488 goat anti-rabbit IgG(Invitrogen 
A11008) or Alexa Fluor 594 goat anti-mouse IgG(Invitrogen A11005) at 1:2,000.  Nuclei 
were stained with DAPI(4’,6-diamidino-2-phenylindole)(Invitrogen P36931) and 
coverslips were kept in dark overnight. The cells were observed and images were 
recorded by fluorescent microscope (Olympus 1 X 71), with the software Olympus DP 
Controller 2002 (Olympus Optical Co. Ltd). A minimum of 100 cells were analyzed on 
each coverslip and the number of foci on digital images was determined using the image 
analysis software package Image J(version 1.42, available from Research Services 
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Branch of  NIH). The quantitative results were shown as the average cell fraction with 
more than 5 or 10 foci of at least three independent experiments. 
 
Luciferase Assays 
RWPE-LacZ, RWPE-PCAT1 pool, and RWPE-PCAT1 clone 2 cells were 
transfected with full length BRCA2 3’UTR or BRCA2 3’UTR deletion luciferase 
constructs as well as pRL-TK vector as internal control for luciferase activity. Following 
2 days of incubation, the cells were lysed and luciferase assays conducted using the dual 
luciferase assay system (Promega, Madison, WI, USA). Each experiment was performed 
in quadruplicate.  
 
Immunoblot Analysis 
Cells were lysed in RIPA lysis buffer (Sigma, St. Louis, MO) and briefly 
sonicated for homogenization.  Aliquots of each protein extract were boiled in sample 
buffer, size fractionated by SDS-PAGE at 4C, and transferred onto Polyvinylidene 
Difluoride membrane (GE Healthcare, Piscataway, NJ). The membrane was then 
incubated at room temperature for 1-2 hours in blocking buffer [Tris-buffered saline, 
0.1% Tween (TBS-T), 5% nonfat dry milk] and incubated at 4C with the appropriate 
antibody.  Following incubation, the blot was washed 4 times with TBS-T and incubated 
with horseradish peroxidase-conjugated secondary antibody.  The blot was then washed 4 
times with TBS-T and twice with TBS, and the signals visualized by enhanced 




The following antibodies were used for immunoblot analysis: BRCA2 (EMD OP95) and 
B-actin (Sigma A5441). 
 
Chemosensitivity Assays 
Five thousand cells were plated in each well of a 96-well plate in sets of ten. Cells 
were then treated with a single dose of Olaparib or ABT-888 as indicated for 72 hours. 
WST assays (Roche) were performed according to company protocol. Briefly, 10% WST 
was added to each well, the plates were incubated at 37C with 5% CO2 for 4 hours and 
the OD at 450nM was measured. 
 
Cell cycle analysis 
1 x 106 cells were plated on 12-well plates and cultured for 24 hours. Cells were 
collected and fixed with ice-cold 70% ethanol at -20C overnight. For analyzing cell 
cycle, fixed cells were centrifuged at 600g for 6 min and washed with ice-cold PBS, 
resuspended in PBS containing 50ug/ml propidium iodide and 100ug/ml RNAse A 
(Invitrogen), then incubated at room temperature for at least 20min in dark. Samples were 
analyzed at the University of Michigan Flow Cytometry Core. Minimum of 10,000 cells 
were counted for each analysis. 
 
Clonogenic survival assay 
1 x 105 or 1 x 106 cells were plated on 6-well plates or 100mm dish and cultured 
for 24h. After treated with Radiation for 24 hours or PARP inhibitor (Olaparib or ABT-
888) for 72 hours at indicated dose, cells were trypsinized and re-plated at different 
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concentrations on 60mm dishes or Poly-D-Lysine (Sigma P6407) treated 6-well plates in 
fresh media. After cultured for 7-14 days, cell colonies were fixed (Vacetic 
acid:Vmethonal=1:3) and stained with crystal violet. Colony number was counted for 
each condition in at least 3 independent experiments. 
 
siRNA knockdown analysis 
1 x 105 cells were plated on 6-well plates and allowed to attach overnight in 
serum-free media.  Cells were transfected with siRNAs mixed with Optimem (Invitrogen) 
and Oligofectamine (Invitrogen) according to standard protocols for a final concentration 
of siRNA of 10nM.  24 hours post-transfection, media containing 10% FBS was added.  
RNA was harvested 48 hours later.  siRNAs used were:  STAU1-5: 
GCAGGGAGUUUGUGAUGCA; STAU1-7: CGAGUAAAGCCUAGAAUCA; 
STAU1-8: CGGAUGCAGUCCACCUAUA 
 
Statistical analyses for experimental studies 
All data are presented as means ± standard deviation or S.E.M, as indicated.  All 
experimental assays were performed in duplicate or triplicate.  Statistical analyses shown 
















Figure 4.1: PCAT-1 expression leads to defective homologous recombination in 
prostate cells. (a) A schematic illustrating PCAT-1 repression of BRCA2 leading to 
impaired homologous recombination (HR) and PARP inhibitor sensitivity.  (b)  
Expression level of PCAT-1 by qPCR in four isogenic cell lines with overexpression 
(Du145, RWPE, MCF7) or knockdown (LNCaP) of PCAT-1.  Error bars indicate S.E.M.  
(c)  Western blot analysis of BRCA2 in four isogenic cell lines with overexpression 
(Du145, RWPE, MCF7) or knockdown (LNCaP) of PCAT-1.  (d) Induction of RAD51 
foci in Du145-PCAT-1 cells following 2 Gy of ionizing radiation or treatment with 25uM 
Olaparib. (e) Quantification of RAD51 foci in isogenic Du145 and LNCaP cell lines 
following 2 Gy of radiation or treatment with 25uM Olaparib.  For LNCaP cell line 
models, cells with > 5 foci per cell were quantified.  For Du145 cell line models, cells 
with > 10 foci per cell were quantified.  Error bars represent standard deviation.  An 







Figure 4.2: Effect of PCAT-1 on RAD51 foci formation post-ABT-888 treatment.  
Isogenic Du145-PCAT1 cells or LNCAP shPCAT1 knockdown cells were treated with 
DMSO control or 100uM ABT-888.  After 6 hours, cells were fixed and stained for 
RAD51 and counterstained with DAPI.  The number of RAD51 foci were counted.  (a) 
Immunofluorescence images for RAD51 foci post-ABT-888 treatment.  (b) 
Quantification of RAD51 foci post-treatment in the respective cell populations.  Error 









Figure 4.3: PCAT-1 modulates g-H2AX foci formation following genotoxic stress.  
(a) LNCaP or Du145 cells with knockdown or overexpression for PCAT-1 were 
subjected to 4 Gy of ionizing radiation, 25uM Olaparib, 100uM of ABT-888, or control 
DMSO.  24 hours post-treatment, cells were fixed and stained for phospho-gamma-
H2AX and counterstained for DAPI.  (b) Quantification of phospho-gamma-H2AX foci 
in LNCaP and Du145 isogenic PCAT-1 cells treated with radiation or PARP inhibitors.  
For LNCaP cell line models, cells with > 5 foci per cell were quantified.  For Du145 cell 
line models, cells with > 10 foci per cell were quantified.  Error bars represent the 








































Figure 4.4: PCAT-1 expression alters clonogenic survival following PARP 
inhibition.  Isogenic cell line models were treated with increasing doses of Olaparib or 
ABT-888 and assayed by clonogenic colony formation.  (a,b) LNCaP PCAT1 
knockdown cells show increased resistance to PARP inhibitors in the clonogenic assay.  
(c,d) Du145 PCAT1 overexpressing cells show increased susceptibility to PARP 
inhibitors in the clonogenic assay.  (e,f) RWPE cells overexpressing PCAT1 show 
increased susceptibility to PARP inhibitors in the clonogenic assay.  (g,h) MCF7 cells 









Figure 4.5: PCAT-1 expression alters clonogenic survival following radiation.  
Isogenic cell line models were treated with increasing doses of ionizing radiation and 
assayed by clonogenic colony formation.  (a) LNCaP PCAT1 knockdown cells show 
increased resistance to radiation in the clonogenic assay.  (b) Du145 PCAT1 
overexpressing cells show increased susceptibility to radiation in the clonogenic assay.  
(c) RWPE cells overexpressing PCAT1 show increased susceptibility to radiation in the 
clonogenic assay.  (d) MCF7 cells overexpressing PCAT1 show no change in the 







Figure 4.6: PCAT-1 expression results in prostate cell sensitivity to PARP inhibition.  
(a,b) LNCaP cells with PCAT-1 knockdown exhibit enhanced cell survival 72 hrs post-
treatment with Olaparib (a) or ABT-888 (b).  Cell survival is determined via WST 
assays.  (c,d) Du145 cells with PCAT-1 overexpression exhibit reduced cell survival 72 
hrs post-treatment with Olaparib (c) or ABT-888 (d).  MCF7 cells with PCAT-1 
overexpression exhibit no change in cell survival 72 hrs post-treatment with Olaparib (e) 
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or ABT-888 (f).  (g) BRCA2 knockdown in LNCaP shPCAT-1 cells rescues cell 
sensitivity to Olaparib.  A Western blot showing efficiency of BRCA2 knockdown is 
included.  72 hours post-treatment with 25uM Olaparib, cells were fixed and stained for 
RAD51 foci.  Quantification of RAD51 foci shows a dose-dependent decrease in RAD51 
foci following BRCA2 knockdown.   Error bars represent standard deviation.  An asterisk 




Figure 4.7: PCAT-1 overexpression in RWPE engenders sensitivity to genotoxic 
stress.  (a) RWPE cells overexpressing PCAT1 were treated with increasing doses of 
ionizing radiation and subjected to a clonogenic assay.  RWPE-PCAT1 cells show 
increased cell death following radiation compared to RWPE-LacZ controls.  (b,c) 
RWPE-LacZ and RWPE-PCAT1 cells were treated with increasing doses of Olaparib (b) 
or ABT-888 (c).  72 hours later, cell survival was determined using WST.  (d,e)  Isogenic 
RWPE-PCAT-1 cells were treated with 4 Gy of ionizing radiation (d) or 25uM of 
Olaparib (e).  After 6 hours, cells were fixed and stained for RAD51 and counterstained 








Figure 4.8: RWPE-PCAT1 cells do not show altered sensitivity to rapamycin.  
RWPE-LacZ, RWPE-PCAT1 pool, and RWPE-PCAT1 clone 2 cells were treated to 








Figure 4.9: Modulation of PCAT1 expression does not impact cell cycle distribution.  
(a) RWPE isogenic cell lines were treated with DMSO and cell cycle was monitored over 
24 hrs.  (b) Du145 isogenic cell lines were treated with DMSO and cell cycle was 
monitored over 24 hrs.  (c) LNCaP isogenic cell lines were treated with DMSO and cell 








Figure 4.10: Treatment of PCAT-1-expressing tumors with PARP inhibitors leads to 
in vivo tumor regression.  (a) Tumor growth curves for Du145-control and Du145-
PCAT-1 xenografts following initiation of treatment with DMSO control or Olaparib.  
Tumor volumes are normalized to 100, and time = 0 represents the start of treatment 
administration.  Treatment was initiated three weeks after xenograft engraftment.  Error 
bars represent S.E.M.  (b) Treatment of Du145-control or Du145-PCAT-1 mice had no 
effect on mouse body weight over time.  (c) Expression levels of PCAT-1 and PCAT-1 
target genes (KIF15, TOP2A, E2F8, and BIRC5) are elevated in Du145-PCAT-1 
xenografts compared to Du145-control xenografts in both DMSO-treated and Olaparib-
treated mice.  A Western blot illustrating BRCA2 levels in Du145-control and Du145-








Figure 4.11: Expression of PCAT-1 regulated genes in RWPE isogenic cell lines.  
Four PCAT-1-induced genes (BIRC5, E2F8, KIF15, TOP2A) were measured by qPCR as 
well as the HMBS control housekeeping gene in the RWPE-LacZ, RWPE-PCAT1 pool, 









Figure 4.12: BRCA2 mRNA is repressed by PCAT-1 but not by an epigenetic or 
STAU-1 mediated mechanism.  (a) Expression of BRCA2 mRNA in LNCaP shPCAT1 
cells and RWPE PCAT-1 cells.  BRCA2 is upregulated upon PCAT-1 knockdown in 
LNCaP and downregulated upon PCAT-1 overexpression.  (b) RWPE-LacZ and RWPE 
PCAT-1 pool cells were treated with the demethylating agent, 5-azacytidine, the HDAC 
inhibitor, TSA, both or control DMSO.  RNA was isolated and expression levels of 
BRCA2 were measured.  BRCA2 mRNA levels were unchanged by 5-aza treatment, 
modestly upregulated by TSA in RWPE-LacZ cells, and modestly upregulated by TSA + 
5-aza in both cell lines.  BRCA2 regulation by PCAT-1 does not yield sensitivity to 
epigenetic inhibition pharmacologically.  HMBS serves as a control gene unchanged by 
the treatments.  Error bars represent S.E.M.  (c) LNCaP and VCaP cells, which 
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endogenously expression PCAT-1, were transfected with independent siRNAs for 
STAU1 or non-targeting control.  RNA was harvested and qPCR was used to analyze 
gene expression of STAU1, BRCA2, PCAT-1, and control HMBS.  qPCR data were 





Figure 4.13: The 5’ terminus of PCAT-1 represses BRCA2 via the 3’UTR of BRCA2. 
(a) Transfection of a BRCA2 full length 3’UTR luciferase construct in RWPE-PCAT-1 
cells results in repression of luciferase activity.  A schematic of the BRCA2 3’UTR 
luciferase construct is included.  (b) A schematic of PCAT-1 deletion constructs 
overexpressed in RWPE cells and validation of overexpression by qPCR.  (c)  PCAT-1 
del (1-750 bps) was able to recapitulate repression of the BRCA2 3’UTR luciferase 
construct.  (d) Endogenous BRCA2 transcript levels in RWPE cells overexpressing 
PCAT-1 deletion constructs.  (e) Treatment of RWPE cells overexpressing PCAT-1 
deletion constructs with 25uM Olaparib.  Cell survival was measured 72 hrs post-
treatment with WST. Error bars represent standard error of the mean (S.E.M.).  An 















Figure 4.14: PCAT-1 expression does not correlate with ETS status.  63 prostate 
cancer samples were assayed for PCAT-1 expression and determined for ETS fusion 
status (ERG and ETV1) by qPCR.  Stratification of samples by ETS status reveals no 
significant association between ETS expression and PCAT1 expression, although the 
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A novel, lineage-specific long non-coding RNA coordinates 





Prostate cancer is a clinically heterogenous disease, in which only a minority of 
patients have aggressive cancer.  However, the molecular basis for this dichotomy 
remains incompletely understood.  Here, we identified a novel polyadenylated, seven-
exon, nuclear long noncoding RNA (lncRNA), termed SChLAP-1 (Second Chromosome 
Locus Associated with Prostate-1) that is overexpressed in a subset of localized and 
metastatic cancers.  In vitro and in vivo gain-of-function and loss-of-function experiments 
demonstrated that SChLAP-1 is involved in prostate cancer cell invasiveness, a hallmark 
for aggressive cancers.  Mechanistically, we found that SChLAP-1 directly binds and 
antagonizes the SWI/SNF chromatin modifying complex, which functions as a tumor 
suppressor in many cancer types.  Finally, we determined that outlier expression of 
SChLAP-1 in prostate cancer was associated with clinically significant and metastatic 
prostate cancer gene signatures.  These results indicate that a SChLAP-1-SWI/SNF 
interaction coordinates cell invasiveness through competitive gene expression control.  
Our findings establish SChLAP-1 as a novel lncRNA implicated in the development of 




Long non-coding RNAs (lncRNAs) are polyadenylated RNA species >200bp in 
length commonly characterized by splicing of multiple exons, H3K4me3 promoter 
methylation, and transcription by RNA polymerase II (1).  lncRNA-mediated biology has 
been implicated in a wide variety of cellular processes, including pluripotency in stem 
cells (2) and X chromosome inactivation in women (3).  In cancer, lncRNAs are 
emerging as a prominent layer of previously unknown transcriptional regulation, 
contributing to tumor biology by modulating gene expression of key target genes, often 
by collaborating with key epigenetic complexes such as Polycomb Repressive Complex I 
(4, 5) (PRC1) and Polycomb Repressive Complex 2 (PRC2) (4, 6-9), among others.  
Clinically, overexpression of the HOTAIR lncRNA has been shown to correlate with 
aggressive breast (6), colon (10), hepatocellular (11), and gastrointestinal stromal tumors 
(12), suggesting that lncRNA-mediated biology plays a prominent role in cancer 
progression. 
However, lncRNAs frequently display lineage-specific expression patterns (13, 
14), making generalizations about their functional contributions to a variety of cancers 
difficult.  For example, expression of HOTAIR, while an important component of breast 
cancer (6), is virtually absent in prostate cancer (13).  Similarly, we have previously 
described PCAT-1 as a prostate-cancer-specific regulator of tumor proliferations (13).  
We hypothesized that prostate-specific lncRNAs mediated prostate cancer 
aggressiveness.  To explore this, we sought to discover novel prostate cancer outlier 





We have previously used RNA-seq to profile lncRNA expression in >100 prostate 
cell lines and tissues, including both localized and metastatic prostate cancers (13).  In 
this analysis, we defined a set of unannotated lncRNAs, including PCAT-1, whose 
aberrant expression associated with prostate cancer.  To uncover novel lncRNAs 
implicated in disease biology, we performed a modified cancer outlier profile analysis 
(15) (COPA) to nominate intergenic lncRNAs selectively upregulated in a subset of 
cancers.  Of >1800 integenic lncRNAs, we observed that only two, PCAT-109 and 
PCAT-114, showed striking outlier profiles and ranked among the top five outliers in 
prostate cancer when compared to protein-coding genes (Figure 5.1A and ref. 2).  
Notably, both are located in a “gene desert” on Chromosome 2q31.3, a region not 
previously examined in prostate cancer (Figure 5.1B and Figure 5.2). 
Efforts to validate PCAT-109 by PCR and rapid amplification of cDNA ends 
(RACE) failed, partly due to the fact that this gene is not robustly expressed in any 
prostate cell lines (Figure 5.1B and data not shown).  By contrast, in the PCAT-114 
region, PCR experiments and 5’ and 3’ RACE defined a 1.4 kb, polyadenylated lncRNA 
encoded by up to seven exons spanning nearly 200kb on Ch2q31.3 (Figure 5.1C and 
Figure 5.3).  We named this gene Second Chromosome Locus Associated with Prostate-1 
(SChLAP-1) after its genomic location.  To further characterize this gene, we employed a 
published ChIP-Seq dataset of prostate cancer (16) and found that the transcriptional start 
site (TSS) of SChLAP-1 was marked by trimethylation of H3K4 (H3K4me3) and its gene 
body harbored trimethylation of H3K36 (H3K36me3) (Figure 5.1C), an epigenetic 
signature consistent with canonical protein-coding genes and lncRNAs (17).  
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Interestingly, the SChLAP-1 promoter does not contain a CpG island but rather remnants 
of an ancestral retroviral long terminal repeat (Figure 5.2).  PCR assays defined 
numerous splicing isoforms of this gene, of which two constituted the vast majority 
(>90%) of SChLAP-1 expression and were termed isoform #1 and #2 (Figure 5.1D).  
Other isoforms were minority species, the most common of which was termed isoform #3 
(Figure 5.1D). 
Using quantitative PCR (qPCR), we validated that SChLAP-1 was upregulated in 
~20% of prostate cancers (Figure 5.1E), including metastatic prostate cancer.  Moreover, 
examination of SChLAP-1 expression in our RNA-seq compendium of >500 samples, 
representing >13 cancer types, demonstrated that expression of SChLAP-1 was absent 
from other tumor types (Figure 5.4), suggesting that expression of this gene is specific to 
prostate cancer biology.  To establish SChLAP-1 as a non-coding gene, we cloned three 
isoforms (isoforms 1, 2 and 3) and performed in vitro translation assays, which were 
negative (Figure 5.5).  Consistent with this, we found that SChLAP-1 RNA in prostate 
cell lines was predominantly located in the nucleus (Figure 5.1F), while most protein-
coding mRNAs are located in the cytoplasm, where they engage the ribosomal translation 
machinery. 
To elucidate the functional role for SChLAP-1 in prostate cancer, we performed 
siRNA knockdowns of this gene using two independent siRNAs as well as siRNA to 
EZH2, which is essential for cancer cell invasion (18, 19), as a positive control.  
Remarkably, in three prostate cancer cell lines but not breast and lung cancer cells 
lacking SChLAP-1 expression, knockdown of SChLAP-1 dramatically impaired cell 
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invasion in vitro at a level comparable to EZH2 (Figure 5.6A).  SChLAP-1 knockdown 
also impaired cell proliferation in prostate cells but not non-prostate cells (Figure 5.7).   
To confirm this phenotype, we overexpressed the three most abundant SChLAP-1 
isoforms in RWPE benign immortalized prostate cells at physiologic levels similar to the 
LNCaP cell line (Figure 5.8).  While SChLAP-1 overexpression did not impact cell 
proliferation (Figure 5.8), we found that RWPE cells expressing all three SChLAP-1 
isoforms, but not control cells, exhibited a dramatic ability to invade through Matrigel 
model basement membrane matrix in vitro (Figure 5.6B).  Although RWPE cells 
expressing SChLAP-1 isoform 2 had a trend towards modestly increased invasiveness 
compared to cells expressing SChLAP-1 isoforms 1 and 3, this difference was not 
statistically significant (p > 0.05).  Overexpression of SChLAP-1 in HME benign breast 
or MCF7 breast cancer cells did not induce cell invasion (Figure 5.9), suggesting that 
SChLAP-1 functions in a lineage-specific manner.  These data support a lineage-specific 
role for SChLAP-1, which is consistent with its tissue-specific expression pattern in 
prostate cancer (Figure 5.4). 
To characterize specific regions of SChLAP-1 essential for its function, we 
generated deletion constructs tiling every 250bp and overexpressed these in RWPE cells.  
This analysis identified a single 250bp region (bp 1001 – 1250 for SChLAP-1 isoform #1) 
necessary for SChLAP-1 mediated invasion in RWPE (Figure 5.6C).  This region is 
shared by all three major isoforms, and in silico modeling of the SChLAP-1 RNA 
structure using RNAfold suggested the presence of a RNA hairpin in this region that is 
lost specifically in deletion construct #5 (Figure 5.6D and Figure 5.10), potentially 
implicating this structure in the function of the molecule. 
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Xenograft analysis of 22Rv1 cells stably knocking down SChLAP-1 further 
confirmed that this gene is necessary for appropriate cancer cell metastatic seeding in 
vivo.  To test this, we performed intracardiac injection of tumor cells and monitored 
luciferase signal from mouse lungs and distant metastases.  These experiments showed 
that 22Rv1 shSChLAP-1 cells displayed impaired metastatic seeding at both proximal 
(lungs) and distal sites (Figure 5.6E and Figure 5.11).  Indeed, 22Rv1 shSChLAP-1 cells 
displayed both fewer gross metastatic sites overall (an average 3.66 metastatic sites in 
shNT mice vs. 2.07 metastatic sites in shSChLAP-1 #1 and 1.07 sites in shSChLAP-1 #2 
mice, p < 0.05, Student’s t-test) as well as smaller metastatic tumors when they did form 
(Figure 5.6F and Figure 5.11).  Interestingly, shSChLAP-1 subcutaneous xenografts 
displayed slower tumor progression due to delayed tumor engraftment in vivo, even 
though the tumor growth kinetics once tumor engraftment occurred were not affected 
(Figure 5.12).  Together, these in vitro and in vivo data support a prostate-specific role 
for SChLAP-1 in cancer cell invasion, metastasis, and aggressiveness. 
To interrogate potential mechanisms of SChLAP-1 function, we performed 
microarray profiling of 22Rv1 and LNCaP prostate cancer cells treated with SChLAP-1 
or control siRNAs.  To facilitate interpretation of these findings, we employed GSEA 
(20), which assesses the statistical overlap between a given microarray dataset and those 
from other publicly-available studies, to analyze genes with statistically significance 
changes in gene expression following SChLAP-1 knockdown.  Among the best-scoring 
concepts, we noticed prostate-cancer-specific gene signatures for genes positively or 
negatively correlated with BRM (21), an enzymatic subunit of the SWI/SNF chromatin 
modifying complex (22) (Shen_BRM) whose expression decreases in prostate cancer 
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(Figure 5.13A, left).  This signature was generated through an analysis of the SWI/SNF 
complex in human prostate cancer samples (21), making it an attractive biological insight 
due to the tissue-specific functions of this complex.  We further confirmed this 
observation in our RNA-seq dataset by generating gene signatures positive and 
negatively correlated to BRM (Figure 5.13A, right), which similarly demonstrated that 
SChLAP-1-regulated genes were also highly enriched with this set.  Importantly, 
SChLAP-1-regulated genes were inversely correlated with both BRM datasets (Figure 
5.13A), where BRM-correlated genes (which decrease in prostate cancer as BRM 
decreases) were upregulated when we decreased SChLAP-1 by siRNA.  These results 
suggested that SChLAP-1 and SWI/SNF regulate gene transcription in opposing manners, 
leading to an antagonism of SWI/SNF activity by SChLAP-1. 
The SWI/SNF complex operates as a large, multi-protein complex that utilizes 
ATPase enzymatic activity to physically move nucleosomes and, in doing so, to regulate 
gene transcription (22).  Several SWI/SNF complex members are the target of recurrent, 
inactivating mutations in cancer, including ARID1A (23, 24), PBRM1 (25), and SNF5 
(26), and numerous studies suggest that loss of the SWI/SNF complex promotes cancer 
progression (22, 27).  While SWI/SNF mutations are not commonly observed in prostate 
cancer, several reports suggest that downregulation of SWI/SNF complex members, 
particularly BRM, characterize prostate cancer (21, 28), and mice with a prostate-specific 
BRM deletion exhibit prostatic hyperplasia and castration-resistant cellular proliferation 
(21).  Thus, antagonism of SWI/SNF activity by SChLAP-1 would be consistent with the 




To test whether SChLAP-1 antagonizes SWI/SNF-mediated gene expression 
regulation, we performed siRNA knockdown of three key components of the SWI-SNF 
complex: BRM (also known as SMARCA2), BRG1 (also known as SMARCA4), and SNF5 
(also known as SMARCB1).  Like BRM, BRG1 serves as an enzymatic subunit of 
SWI/SNF complex activity, and SNF5 is an essential subunit thought to bind histone 
proteins (29).  Knockdown of BRM, BRG1, and SNF5 in two prostate cell lines, 22Rv1 
and LNCaP, followed by expression microarray profiling generated highly overlapping 
sets of up- and down-regulated genes (Figure 5.13B and Figure 5.14), demonstrating 
that these factors have broad commonalities in their function in prostate cells.  
Knockdown of BRM, BRG1 and SNF5 also increased the invasiveness and proliferation 
rate of 22Rv1 cells, consistent with the role of SWI/SNF in tumor suppression (Figure 
5.15). 
A heatmap analysis of genes commonly regulated by knockdown of all SWI/SNF 
proteins (BRM, BRG1, and SNF5) demonstrated a clear antagonism between SWI/SNF 
regulation of gene expression and SChLAP-1’s effects, whose knockdown regulated the 
same genes of SWI/SNF in the opposing direction (Figure 5.13B).  To quantify this 
globally, we used these microarray data to generate custom GSEA signatures for genes 
up- and down-regulated upon knockdown of each SWI/SNF protein (BRM, BRG1, and 
SNF5) and SChLAP-1, and we queried the overlap of these GSEA signatures against each 
other.  Performing this analysis across two cell lines (22Rv1 and LNCaP) showed that 
SWI/SNF and SChLAP-1 antagonize each other’s gene expression program in a highly 
significant manner in 23 of 24 total GSEA comparisons (FDR < 0.05) (Figure 5.13C and 
Figure 5.16).  Here, a positive GSEA enrichment score (ES) indicates genes upregulated 
166 
 
upon SChLAP-1 knockown, and a negative GSEA NES indicates genes downregulated 
upon SChLAP-1 knockdown.  Together, these data strongly argue that SChLAP-1 
functions to suppress SWI/SNF complex activity in prostate cancer. 
To examine the mechanism of SChLAP-1 regulation of the SWI/SNF complex, 
we examined whether SChLAP-1 regulated SWI/SNF complex genes themselves.  Using 
Western blots, we failed to detect any change in BRM, BRG1, or SNF5 protein 
abundance following SChLAP-1 knockdown or overexpression (Figure 5.17), suggesting 
that SChLAP-1 exerts its function post-translationally.  Motivated by reports of lncRNAs 
coordinating the function of epigenetic complexes through direct RNA-protein binding, 
we performed RNA immunoprecipitation assays (RIP) for SNF5, a core subunit essential 
for both BRG1 and BRM function, in 22Rv1 and LNCaP cells.  We found that 
endogenous SChLAP-1, but not other prostate-specific lncRNAs such as PCA3 and 
PCAT-1, bound robustly SNF5 protein (Figure 5.13D).  RIP for androgen receptor (AR) 
and SNRNP70, which specifically binds to the U1 snRNP, served as additional negative 
controls for these experiments (Figure 5.18). 
We further hypothesized that SChLAP-1-SWI/SNF interactions may underlay the 
functional role of SChLAP-1 in inducing cell invasion.  To test this, we evaluated 
SChLAP-1-SNF5 binding in our RWPE-SChLAP-1 overexpression model, including 
overexpression of SChLAP-1 deletion construct #5, which fails to induce cell invasion 
(Figure 5.6D).  Strikingly, we observed that overexpression of both SChLAP-1 isoform 
#1 and isoform #2 robustly bound to SNF5, whereas the deletion construct 5 (which lacks 
bps 1001-1250 in SChLAP-1 isoform #1) failed to bind SNF5 (Figure 5.13E).  As 
controls, we also measured AK093002 and LOC145837, two lncRNAs upregulated in 
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prostate cancer that are endogenously expressed in RWPE (data not shown).  Control 
RNA-IP experiments for SNRNP70 demonstrated uniformly strong binding of this 
protein to U1 in all RWPE cell lines evaluated (Figure 5.18).  Thus, SChLAP-1 regulates 
SWI/SNF complex activity through directly binding to SWI/SNF proteins through an 
interaction via bps 1001-1250. 
To establish a link between SChLAP-1 and aggressive prostate cancer, we 
performed bioinformatics analysis of gene expression signatures in this disease (Figure 
5.19A).  We developed a bioinformatics method to assess whether an individual gene 
associates with the compendium of clinical phenotypes defined by expression profiling.  
To do this for SChLAP-1, we used SChLAP-1 expression to classify our RNA-seq data 
for localized prostate cancers into SChLAP-1-negative and SChLAP-1-positive samples.  
This analysis generated a set of genes positive and negatively correlated with SChLAP-1 
expression only in localized tumors, to avoid bias when comparing this signature with the 
metastatic gene signatures.  Random permutations of the data enabled us to generate p-
values, FDR values, and Pearson correlations for all genes in the signature, and for our 
gene signature we used associated genes with a FDR < 0.05.  Network analysis of our 
SChLAP-1 signature using datasets from Oncomine (30) reveals a striking degree of 
overlap with concepts related to prostate cancer progression (Figure 5.19A).  Here, genes 
lowly expressed in SChLAP-1-positive tumors were similarly lowly expressed in 
metastatic and high-grade localized tumors.  Conversely, genes expressed highly in 
SChLAP-1-positive tumors were also high in metastatic cancer. 
To provide context to these findings, we expanded our analysis to include four 
additional cancer genes: EZH2, a known aggressive cancer gene (18, 19), PCA3, a 
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lncRNA biomarker upregulated in prostate cancer and used in prostate cancer diagnosis 
(31, 32), AMACR, a known prostate cancer outlier (33), and BRM, a SWI/SNF enzymatic 
subunit downregulated in prostate cancer (21).  We also analyzed nucleoporin genes, 
NUP133 and NUP155, as well as B-actin (ACTB) in this way as controls.  To facilitate 
interpretation of these data, we established a compendium of prostate cancer gene 
signatures for different stages in prostate cancer progression (cancer vs. normal, 
advanced vs. indolent cancer, metastatic vs. localized cancer) using the Oncomine 
database to extract data from published microarray studies.  We also used our RNA-seq 
data to generate gene signatures for high grade localized prostate cancer (Gleason ≥8 vs. 
Gleason 6) and metastatic vs. localized prostate cancer in our individual dataset. 
 We next evaluated the statistical overlap between each dataset in our clinical 
phenotype compendium with the gene signature derived from SChLAP-1 or other genes 
of interest (Figure 5.19B).  We computed p-values, FDR values, and odds ratios for 
every analysis between two gene sets.  Using this database of associations, we generated 
a heat-map to visualize the relationship between our genes of interest and prostate cancer 
phenotypes.  This analysis confirmed a strong association of SChLAP-1-associated genes 
and high-grade and metastatic cancers as well as poor clinical outcomes.  In this respect, 
SChLAP-1 was highly similar to EZH2, our positive control, which is widely associated 
with aggressive, lethal prostate cancer.  By contrast, PCA3 and AMACR, two biomarkers 
not associated with disease progression, strongly associate with Cancer vs. Normal 
concepts but not concepts for aggressive disease.  B-actin, NUP133, and NUP155 show 
no systematic association with prostate cancer signatures (Figure 5.19B). 
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 To establish the predictive value of our SChLAP-1 gene signature, we investigated 
whether this signature was able to stratify patient outcomes over time.  We used two 
publicly-available datasets to test whether our SChLAP-1 signature associated with 
biochemical recurrence (34) and overall survival (35).  Here, we observed a statistically-
significant (p<0.01) association between the SChLAP-1 signature and more rapid disease 
recurrence (Figure 5.19C) and lower overall survival (Figure 5.19D).  Interestingly, we 
noted that theses analyses also included several patients that received a low-grade 
Gleason score (Gleason=6) but displayed worse outcomes, consistent with the clinical 
observation that 10 – 20% of men with low-grade cancers experience disease recurrence 
following radical prostatectomy (36) and 6% of men with low-grade cancers experience 
prostate-cancer-specific mortality from metastatic disease within 15 years (37).  Finally, 
we assessed SChLAP-1 expression in urine sediment RNA from 111 biopsy-confirmed 
prostate cancer patients with Gleason score.  We found that SChLAP-1 was significantly 
higher in Gleason 7 patients vs. Gleason 6 patients (p = 0.01) (Figure 5.20), although we 
were unable to evaluate Gleason 8-10 due to low numbers of patients presenting with 
high Gleason scores at the time of PSA screening. 
 
DISCUSSION 
Here, we have discovered a novel, oncogenic lncRNA involved in prostate cancer 
cell aggressiveness and the suppression of the SWI/SNF complex.  We find that SChLAP-
1 directly binds proteins in the SWI/SNF complex through a hairpin-like structure, 
leading to reversion of SWI/SNF-mediated gene expression (Figure 5.21).  We further 
find that SChLAP-1 coordinates prostate cancer cell invasion in vitro and metastatic 
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spread in vivo, and SChLAP-1 expression characterizes a metastatic-like gene expression 
profile associated with high-grade localized prostate cancers and poor clinical outcomes.  
SChLAP-1 may therefore represent a promising prognostic biomarker for localized 
prostate cancers.  Taken together, our discovery of SChLAP-1 has broad implications for 
prostate cancer biology and provides supporting evidence for the role of lncRNAs in the 
progression of aggressive cancers. 
In several respects, SChLAP-1 resembles the lncRNA HOTAIR, which exerts 
oncogenic functions through the coordination of several epigenetic complexes such as 
PRC2 and the co-repressor NuRD (6, 7, 9).  Like HOTAIR, which is not expressed in 
prostate cancer (13), SChLAP-1 coordinates regulation of gene expression and 
characterizes aggressive disease.  However, unlike HOTAIR, which assists PRC2 
function, SChLAP-1 impairs SWI/SNF function.  It is intriguing to note that SWI/SNF 
and PRC2 have been show to play opposing roles in regulating gene expression (38, 39), 
suggesting that upregulation of SChLAP-1 may phenocopy PRC2 behavior in the 
suppression of SWI/SNF-mediated gene regulation.   
Moreover, SChLAP-1 appears to operate in a tissue-specific manner, showing 
outlier expression exclusively in prostate cancer.  This is in contrast to HOTAIR, which 
has been investigated in multiple cancer types (6, 10, 11), as well as benign cell types 
such as fibroblasts (7, 9), which show high levels of endogenous HOTAIR expression.  In 
this respect, SChLAP-1 provides a compelling argument for the importance of tissue-
specific lncRNAs and suggests that other malignancies likewise employ tissue-specific 




MATERIALS AND METHODS 
Cell lines 
All cell lines were obtained from the American Type Culture Collection (Manassas, VA).  
Cell lines were maintained using standard media and conditions.  SChLAP-1 or control-
expressing cell lines were generated by cloning SChLAP-1 or control into the pLenti6 
vector (Invitrogen).  Stably-transfected RWPE, HME and MCF7 cells were selected 
using blasticidin (Invitrogen).  For LNCAP and 22Rv1 cells with stable knockdown of 
SChLAP-1, cells were transfected with SChLAP-1 or non-targeting shRNA lentiviral 
constructs for 48 hours.  GFP+ cells were drug-selected using puromycin. 
 
RNA isolation; cDNA synthesis; and PCR experiments 
RNA isolation and cDNA synthesis was performed according standard protocols.  
Quantitative PCR was performed using Power SYBR Green Mastermix (Applied 
Biosystems, Foster City, CA), using GAPDH and HMBS as housekeeping control genes.  
The relative quantity of the target gene was completed for each sample using the ΔΔCt 
method.  The primer sequences for the transcript analyzed are provided in Appendix 2. 
 
Murine intracardiac and subcutaneous in vivo models 
All experimental procedures were approved by the University of Michigan Committee 
for the Use and Care of Animals (UCUCA). Intracardiac injection model: 5 x 105 cells 
were introduced to CB-17 severe combine immunodefiecient mice (CB-17 SCID) at 6 
weeks of age. Beginning one week post injection, bioluminescent imaging of mice was 
performed weekly using a CCD IVIS system with a 50-mm lens (Xenogen Corp.) and the 
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results were analyzed using LivingImage software (Xenogen).  See SOM for additional 
details.  Subcutaneous injection model: 1 x 106 cells were introduced to mice (CB-17 
SCID), ages 5-7 weeks, with a matrigel scaffold (BD Matrigel Matrix, BD Biosciences) 
in the posterior dorsal flank region (n = 10 per cell line). Tumors were measured weekly 
using a digital caliper, and endpoint was determined as a tumor volume of 1000 mm3. 
 
Immunoblot Analysis 
Cells were lysed in RIPA lysis buffer (Sigma, St. Louis, MO) supplemented with HALT 
protease inhibitor (Fisher).  Western blotting analysis was performed with standard 
protocols using Polyvinylidene Difluoride membrane (GE Healthcare, Piscataway, NJ) 
and the signals visualized by enhanced chemiluminescence system as described by the 
manufacturer (GE Healthcare). 
 
siRNA knockdown, proliferation and invasion studies 
Cells were plated in 100mM plates at a desired concentration and transfected with 20uM 
experimental siRNA oligos or non-targeting controls according to standard protocols.  72 
hours post-transfection with siRNA, cells were trypsinized, counted with a Coulter 
counter, and diluted to 1 million cells/mL.  Proliferation assays were performed with a 
Coulter counter, and invasion of cells through matrigel (BD Biosciences) was performed 
according to standard protocols. 
 
Chromatin immunoprecipitation 




RIP assays were performed using a Millipore EZ-Magna RIP RNA-Binding Protein 
Immunoprecipitation kit (Millipore, #17-701) according to the manufacturer’s 
instructions. 
 
Statistical analyses for experimental studies 
All data are presented as means ± S.E.M.  All experimental assays were performed in 
duplicate or triplicate.  Statistical analyses shown in figures represent Fisher’s exact tests 









Figure 5. 1: Discovery of SChLAP-1 as a prostate cancer lncRNA.  (a) Cancer outlier 
profile analysis (COPA) for intergenic lncRNAs in prostate cancer nominates two 
transcripts, PCAT-109 and PCAT-114, as prominent outliers.  (b) A comparison of 
lncRNA outliers nominated by COPA, including their location, frequency in clinical 
samples, their expression in tissues and cell lines, and whether they occur in metastatic 
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prostate samples.  (c) A representation of the SChLAP-1 gene and its annotations in 
current databases.  SChLAP-1 may consist of up to seven exons on Chr2q31.3.  An 
aggregated representation of current gene annotations for Ensembl, ENCODE, UCSC, 
Ref-Seq, and Vega shows no annotation for SChLAP-1.  No spliced ESTs represent 
SChLAP-1.  ChIP-Seq data for H3K4me3, RNA-Pol II, and H3K36me3 show enrichment 
at the SChLAP-1 gene.  Also, RNA-Seq data showing an outlier sample for SChLAP-1 
illustrates its expression.  (d) A schematic summarizing the observed SChLAP-1 
isoforms.  A total of 8 isoforms were observed, with isoform #1 and isoform #2 
accounting for >90% of transcripts.  (e) qPCR for SChLAP-1 on a panel of benign 
prostate (n=33), localized prostate cancer (n=82), and metastatic prostate cancer (n=33) 
samples.  qPCR data is normalized to the average of (GAPDH + HMBS) and represented 
as standardized expression values.  (f) SChLAP-1 expression is predominantly nuclear.  
Prostate cell lysates were fractionated and nuclear and cytoplasmic fractions were tested 










Figure 5.2: A chromosome 2 region contains prostate cancer-associated transcripts.  
A gene desert on chr2q31 between CWC22 and UBE2E3 contains multiple transcripts 
that are upregulated in prostate cancer, including the predicted outliers PCAT-109 and 










Figure 5.3: The structure and sequence of SChLAP1.  The sequences of the seven 
exons found in the SChLAP1 gene are detailed here, indicating the presence of splice 
donor and splice acceptor sites.  Nucleotides comprising the SChLAP1 gene are 












Figure 5.4: Expression of SChLAP-1 across cancers.  Over 500 cancer samples 
analyzed by RNA-seq were interrogated for SChLAP-1 expression.  High expression was 
























Figure 5.5: In vitro translation assays for SChLAP-1.  Three isoforms of SChLAP-1 
were cloned and tested for protein-coding capacity using an in vitro translation assay (see 
SOM methods).  GUS is used as a positive control.  PCAT-1 and water serve as negative 
controls.  Non-specific bands are indicated with an asterisk.  SChLAP-1 isoforms do not 








Figure 5.6: SChLAP-1 coordinates prostate cancer cell invasion.  (a) siRNA 
knockdown of SChLAP-1 in vitro.  Three prostate cell lines (LNCaP, 22Rv1, Du145) and 
three non-prostate cell lines (BT-549, MDA-MB-231, H460) were treated with two 
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independent siRNAs for SChLAP-1 and invasion through Matrigel in a Boyden chamber 
assay was monitored.  EZH2 siRNA serves as a positive control.  (b) Overexpression of 
SChLAP-1 in RWPE cells.  Benign RWPE prostate cells overexpressing three isoforms of 
SChLAP-1, but not controls, demonstrate increased cellular invasion.  (c) Deletion 
analysis of SChLAP-1.  Deletion constructs of SChLAP-1 were overexpressed in RWPE 
cells and the resulting cells were assayed for invasion in a Boyden chamber assay.  
Deletion of bps 1001-1250 impairs SChLAP-1-induced invasion.  (d) RNA structural 
analysis of SChLAP-1.  The RNA structure of wild-type SChLAP-1 isoform #1 and 
deletion construct #5 were analyzed by RNAfold.  (e) Tumor seeding with SChLAP-1 
knockdown in vivo.  Intracardiac injection of 22Rv1 cells with stable SChLAP-1 
knockdown was performed in severe combined immunodeficient (SCID) mice, and 
metastatic seeding and growth of tumor cells was monitored.  The relative intensity of 
whole-mouse luciferase signal is plotted.  (f) The number of gross metastatic sites 
observed by luciferase signal in 22Rv1 shSChLAP-1 cells or shNT controls.  Independent 
foci of luciferase signal were averaged for shNT (n=9), shSChLAP-1 #1 (n=14) and 


















Figure 5.7: Knockdown of SChLAP-1 impairs prostate cancer cell growth.  (a) 
22Rv1, LNCaP, and Du145 cells were treated with siRNAs against SChLAP-1.  qPCR 
indicates relative knockdown efficiency in these cell lines.  (b) Cell proliferation assays 
for prostate cancer cell lines (LNCaP, 22Rv1, Du145) treated with SChLAP-1 siRNAs or 
non-targeting negative controls.  EZH2 siRNA serves as a positive control.  (c) Cell 
proliferation assays for non-prostate cancer cell lines (BT-549, MDA-MB-231, H460) 
treated with SChLAP-1 siRNAs or non-targeting negative controls.  EZH2 siRNA serves 







Figure 5.8: Overexpression of SChLAP-1 does not increase cell proliferation.  (a) 
Overexpression of SChLAP-1 isoforms 1-3 in RWPE cells was confirmed using qPCR, 
which demonstrated that the overexpression resulted in comparable levels of SChLAP-1 
transcript to LNCaP cells that express this gene endogenously.  HMBS serves as a 
negative control.  (b) Cell proliferation assays for RWPE cells overexpressing SChLAP-1 











Figure 5.9: SChLAP-1 overexpression in breast cells does not increase invasion.  (a) 
HME immortalized benign breast cells or MCF7 breast cancer cells were infected with 
SChLAP-1 lentivirus and stably-overexpressing cells were generated.  SChLAP-1 
expression was measured by qPCR. (b) Invasion assays were performed for HME and 
MCF7 cells overexpressing SChLAP-1.  Invaded cells were stained with crystal violet 
and the absorbance at 560nM was measured.  Overexpression of SChLAP-1 did not result 






























Figure 5.10: Structural predictions of SChLAP-1 isoforms and deletion constructs.  
The sequences for SChLAP-1 isoforms #2 and #3 and deletion constructs 1-4 and 6 were 
analyzed by RNAfold to predict secondary structures.  Arrows identify the structural 










Figure 5.11: Intracardiac injection of SChLAP-1 knockdown cells impairs cancer 
cell metastasis.  22Rv1-shNT, sh-SChLAP-1 #1, and sh-SChLAP-1 #2, cells were 
introduced into mice via intracardiac injection and luciferase signal was monitored for 
distant metastases.  Whole-body images of mice (n=5 for each treatment in this figure) 
indicate that SChLAP-1 knockdown impairs metastatic seeding.  Above each image, the 






































Figure 5.12: Knockdown of SChLAP-1 delays tumor take but not tumor growth 
kinetics.  22Rv1 cells infected with lentivirus for shNT, sh-SChLAP1 #1, and sh-
SChLAP1 #2 were injected subcutaneously in mouse flanks and tumor growth was 
monitored by caliper measurements.  N = 10 mice for shNT cells, n = 12 mice for sh-
SChLAP1 #1 cells, n = 9 mice for sh-SChLAP1 #2 cells.  (a) Absolute tumor volume for 
22Rv1 shNT, sh-SChLAP1 #1 and sh-SChLAP1 #2 cells.  (b) Percent of mice with tumor 
engraftment over time.  Knockdown of SChLAP-1 delays the onset of tumor engraftment.  
(c)  The fraction of mice surviving following subcutaneous injection of the 22Rv1 cell 
lines.  This plot represents tumor-specific death of mice sacrificed when the tumor 
volume reached the maximum allowable volume.  (d)  The percent change in tumor 
volume per cell line normalized to the time of tumor engraftment.  (e) Tumor volume 




Figure 5.13: SChLAP-1 antagonizes SWI/SNF complex function.  (a) Gene set 
enrichment analysis (GSEA) of LNCaP and 22Rv1 cells treated with SChLAP-1 siRNAs.  
GSEA results indicate that SChLAP-1 knockdown results are inversely correlated with 
BRM-associated genes.  Left, GSEA associations using BRM signatures from Shen et al.  
Right, GSEA associations using RNA-seq data.  (b) Heatmap results for SChLAP-1 or 
SWI/SNF knockdown in LNCaP and 22Rv1 cells.  SChLAP-1 and SWI/SNF proteins 
(BRM, BRG1, SNF5) regulate expression of the same genes in opposing manners.  (c) 
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GSEA analysis of SChLAP-1 and SWI/SNF knockdowns.  Samples from (b) were 
analyzed by GSEA for overlap in gene expression regulation.  Across two cell lines 
(LNCaP and 22Rv1), SChLAP-1 knockdown had the opposite effect on gene expression 
as knockdown of BRM, BRG1 or SNF5.  (d) RNA immunoprecipitation (RIP) of SNF5 
demonstrates SChLAP-1 binding to SNF5 in 22Rv1 and LNCaP cells. PCA3 and PCAT-1 
serve as negative controls.  (e) RIP analysis of SNF5 in RWPE cells overexpressing 
LacZ, SChLAP-1 isoform #1, SChLAP-1 isoform #2, or SChLAP-1 deletion construct 5.  



















































Figure 5.14: Knockdown of SWI/SNF components produces overlapping sets of 
regulated genes.  (a) A table tabulating the number of genes upregulated or 
downregulated by knockdown of SWI/SNF components (>2-fold change), and the 
overlap between gene sets is indicated.  (b)  Statistical significance of the overlapping 
























Figure 5.15: Knockdown of SWI/SNF components increases cell proliferation and 
invasion in 22Rv1 cells.  (a) Cell proliferation assays for 22Rv1 cells treated with BRG1, 
BRM, SNF5 or control non-targeting siRNA were examined.  Knockdown of SWI/SNF 
members increases cell proliferation.  (b) Boyden chamber cell invasion assays for 
22Rv1 cells treated with BRG1, BRM, SNF5 or control non-targeting siRNA were 
examined for invasiveness through matrigel.  Invaded cells were stained with crystal 
violet and absorbance at 560nM was measured.  Knockdown of SWI/SNF components 
modestly increases cell invasiveness.  (c) Relative expression level of SNF5, BRG1, and 
BRM in 22Rv1 cells treated with siRNAs targeting those genes.  Error bars represent 















Figure 5.16: Summarized GSEA results for SChLAP-1 and SWI/SNF knockdowns.  
SChLAP-1, BRM, BRG1, and SNF5 were knocked-down using siRNAs in 22Rv1 LNCaP 
cells.  Gene expression changes were compared using GSEA to expression changes.  
GSEA enrichment scores, as well as p-values and FDR q-values, are reported for all pair-
wise comparisons performed.  23 of 24 comparisons show a significant GSEA gene 






































Figure 5.17: SChLAP-1 does not impact SWI/SNF protein expression.  Western blot 
analysis of 22Rv1 and LNCaP cells with stable knockdown of SChLAP-1 or non-
targeting control demonstrates no change in the protein levels of SNF5, BRG1, or BRM 
upon SChLAP-1 knockdown.  Similarly, overexpression of SChLAP1 in RWPE cells 





















































Figure 5.18: Immunoprecipitation of AR and SNRNP70 controls for RNA-IP 
experiments.  Left, Androgen receptor (AR) was immunoprecipitated from LNCaP cells, 
and presence of SChLAP-1, PCAT1, or PCA3 RNA transcripts was measured by qPCR.  
No significant enrichment was detected.  A Western blot for AR confirms efficient IP of 
AR protein in this experiment.  Right, RNA-IP experiments for SWI/SNF complex 
members as well as SNRNP70 shows specific binding of SNRNP70 to the U1 ncRNA, 








Figure 5.19: SChLAP-1 expression characterizes aggressive prostate cancers.  (a) 
Network analysis of a SChLAP-1 gene signature using publicly-available data from 
Oncomine.  The SChLAP-1 gene signature was generated using genes positively or 
negatively correlated with SChLAP-1 in our RNA-seq dataset (FDR<0.05).  Left, a 
network analysis of genes positively correlated with SChLAP-1.  Right, a network 
analysis of genes negatively correlated with SChLAP-1.  (b) Meta-analysis of associated 
gene signatures for other genes using Oncomine gene datasets.  (c) Stratification of 
overall survival in prostate cancer using the SChLAP-1 gene signature.  (d) Stratification 











Figure 5.20: SChLAP-1 expression urine prostate cancer urine sediments.  (a) 
SChLAP-1 expression stratified by Gleason score in a cohort of urine sediments from 
prostate cancer patients.  Serum PSA is shown for comparison.  An asterisk (*) indicates 
p < 0.05.  Two asterisks (**) indicates p < 0.01.  (b) A table detailing the clinical 
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SUMMARY OF THESIS WORK 
 This thesis sought to understand the role of lncRNAs in cancer, using prostate 
cancer as a primary model disease.  While the findings presented herein reflect aspects of 
prostate cancer biology, I speculate that these principles may be generalized to other 
disease types, including non-cancerous disease states.  In this regard, this work reflects 
merely the potential of lncRNA research, as the discovery and characterization of 
lncRNAs in other biological systems remains an active area of research.  Indeed, this 
thesis work underscores two fundamental dictums: 1) the elucidation of all lncRNA 
species in all normal and diseased tissue/cell types is of critical importance; and 2) the 
scope of lncRNA biology in other tissues and diseases, including cancers, will likely 
uncover mechanisms of tissue-specific processes. 
 For this work, we have focused on prostate cancer as a primary model system.  
We began with the supposition that the annotated protein-coding genome represents only 
a partial list of the total number of transcribed regions, and we were motivated by reports 
of functionally-relevant lncRNAs (1-3), which resemble mRNAs structurally but do not 
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encode for a protein (4).  As such, we hypothesized that lncRNAs were an 
uncharacterized (and largely undiscovered) set of genes.  To pursue this hypothesis in the 
context of cancer, we employed transcriptome sequencing of prostate cancer tissues.  We 
used cell lines as supportive research tools, recognizing that cell lines represent imperfect 
model systems that may differ substantially from human cancer (5). 
 We used ab initio transcriptome assembly as a computational method to predict 
novel transcripts bioinformatically.  We found >6,000 total unannotated transcripts 
expressed in prostate cancer, of which approximately 1,800 were intergenic.  These 
transcripts resembled protein-coding mRNAs structurally by exhibiting polyadenylation 
and promoter enrichment for H3K4me3 and RNA polymerase II; however, they lacked 
robust open reading frames in >98% of cases defining a large set on novel lncRNAs in 
prostate cancer.  Among these, we refined a list of 121 lncRNAs that exhibited 
dysregulated expression levels in cancer, often in a tissue-specific manner exclusively 
expressed in prostate cancer.  These 121 genes were termed PCATs. 
  
PCAT-1 and SChLAP-1 as novel prostate cancer genes 
From this list of candidate PCATs, we have validated many novel prostate-cancer 
associated genes and investigated two in depth: PCAT-1 and SChLAP-1, which both 
exhibit high upregulation in subsets of prostate cancer (Figure 6.1).  We defined PCAT-1 
as a two-exon gene, and in vitro and in vivo experiments demonstrated that this lncRNA 
promotes cell proliferation.  PCAT-1 regulates expression of a core set of ~250 genes that 
associate with DNA repair, DNA maintenance, and mitotic spindle formation.  Of note, 
PCAT-1 represses BRCA2, a tumor suppressor gene essential for homologous 
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recombination (HR) (6).  We demonstrated in vitro and in vivo that PCAT-1 expression 
leads to impaired repair of DNA double strand breaks by repressing HR following 
genotoxic stress.  Importantly, these studies revealed that PCAT-1 expression sensitizes 
cells to treatment with small molecule inhibitors of the PARP-1 DNA repair enzyme, 
whose inhibition in cells with BRCA1 or BRCA2 inactivation leads to gross collapse of 
genome integrity (7-10).  This repression of BRCA2 was due to microRNA-like effects 
of PCAT-1 in a post-transcriptional manner and required bps 1 – 750 of the PCAT-1 gene. 
By contrast, SChLAP-1 exhibits multiple isoforms containing up to seven exons in 
total.  SChLAP-1 is expressed in ~20% of prostate cancers as a nuclear lncRNA and 
coordinates prostate cancer cell invasion and metastasis via a 250 bp fragment between 
bp 1001-1250.  We found that SChLAP-1 associates with an aggressive cancer phenotype 
and coordinates a gene expression program associated with metastatic disease.  This gene 
expression program was antagonistic to the regulatory functions of the SWI/SNF 
nucleosome remodeling complex.  SWI/SNF serves as a tumor suppressor complex in 
multiple cancer types (11-17), and we observe that SChLAP-1 directly binds to SWI/SNF 
proteins but does not directly regulate their expression nor the expression of other major 
epigenetic complexes, suggesting that SChLAP-1 modulates the activity of epigenetic 
complexes rather than controlling their expression. 
 
EMERGING DIRECTIONS IN LONG NON-CODING RNA RESEARCH 
 This thesis work has defined novel aspects of prostate cancer biology and 
discovered genes not previously known.  As such, the implications of this work are broad 
and suggest that numerous aspects of cancer biology remain unrevealed.  While it is now 
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well-accepted that lncRNAs characterize all major cell lineages (18) and many disease 
states (1, 19, 20), the wide-ranging reports of lncRNAs in multiple cell types raise new 
questions and challenges for the field of lncRNA research and cancer biology.  Just as the 
cancer research community has spent decades understanding the functional importance of 
a variety of proteins in cancer biology, now this same community must undertake a 
comprehensive investigation of lncRNAs.  Here, I will discuss major areas of research 
that will be necessary to understand the role of lncRNAs in cancer. 
 
Defining the lncRNA component of the human genome 
Going forward, it is clear that the systematic identification and annotation of 
lncRNAs, and their expression patterns in human tissues and disease, is important to 
clarifying the molecular biology underlying cancer.  These efforts will be facilitated by 
large-scale RNA-Seq studies followed by ab initio or de novo sequence data assembly to 
discover lncRNAs in an unbiased manner (21, 22). 
However, it is increasingly appreciated that a number of annotated but 
uncharacterized transcripts are important lncRNAs—HOTTIP is one such example (23).  
Similarly, the STAU1-interacting lncRNAs described by Gong and colleagues were also 
found by screening for annotated transcripts that contained prominent Alu repeats (24).  
While these examples were annotated as non-coding genes, it is also possible that other 
annotated genes, enumerated in early studies as protein-coding but not studied 
experimentally, are mislabeled ncRNA genes.  These may include the generic “open-




Supporting this, Dinger et al. recently argued that bioinformatically distinguishing 
between protein-coding and non-coding genes can be difficult and that traditional 
computational methods for doing this may have been inadequate in many cases (25).  For 
example, XIST was initially identified as a protein-coding gene because it has a potential, 
unused open reading frame (ORF) of nearly 300 amino acids (26).  Additional 
complications further include an increasing appreciation of mRNA transcripts that 
function both by encoding a protein and at the RNA level, which would support miRNA 
sequestration hypotheses posited by Pandolfi and colleagues (27). 
 
Elucidating the role of lncRNA sequence conservation 
In general, most protein-coding exons are highly conserved and most lncRNAs 
are poorly conserved (28-30).  This is not always true, as T-UCRs are prime examples of 
conserved ncRNAs (31-34).  However, the large majority of lncRNAs exhibit substantial 
sequence divergence among species, and lncRNAs that do show strong conservation 
frequently only exhibit this conservation in a limited region of the transcript, and not the 
remainder of the gene. 
This conundrum has sparked many hypotheses, many of which have merit.  Small 
regions of conservation could indicate function domains of a given ncRNA, such as a 
binding site for proteins, microRNAs, mRNAs, or genomic DNA.  Development of 
abundant ncRNA species could also suggest evolutionary advancement as species 
develop.  In support of this latter proposition, many have commented that complex 
mammalian genomes (such as the human genome) have a vastly increased non-coding 
DNA component of their genome compared to single-celled organisms and nematodes, 
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whereas the complement of protein-coding genes varies less throughout evolutionary 
time (35). 
For lncRNAs, the issue of sequence conservation is paramount.  However, it is 
now well established that poorly-conserved lncRNAs, including PCAT-1 and SChLAP1, 
can be biologically important, but it is unclear whether these represent species-specific 
evolutionary traits or whether functional homologs have simply not been found.  For 
example, AIR was initially described in mice in the 1980s, but a human homolog was not 
identified until 2008 (36). 
Moreover, even lncRNAs with relatively high conservation, such as HOTAIR, 
may have species-specific function.  Indeed, a study of murine HOTAIR (mHOTAIR) 
showed that mHOTAIR did not regulate the HoxD locus and did not recapitulate the 
functions observed in human cells (37).  Other ncRNAs observed in mice, such as linc-
p21, also show only limited sequence homology to their human forms and may have 
divergent functions as well (2).  This may support hypotheses of rapid evolution of 
lncRNAs during the course of mammalian development.  Moreover, this may suggest 
either that lncRNAs may have functions independent of conserved protein complexes 
(which have comparatively static functions throughout evolution) or that lncRNAs may 
adapt to cooperate with different protein complexes in different species. 
 
Determining somatic alterations of lncRNAs in cancer 
To date, somatic mutation of lncRNAs in cancer is not well explored.  While 
numerous lncRNAs display altered expression levels in cancer, it is unclear to what 
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extent cancers specifically target lncRNAs for genomic amplification/deletion, somatic 
point mutations, or other targeted aberrations. 
In several examples, data suggest that lncRNAs may be a target for somatic 
aberrations in cancer.  For example, approximately half of prostate cancers harbor gene 
fusions of the ETS family transcription factors (ERG, ETV1, ETV4, ETV5), which 
generally result in the translocation of an androgen-regulated promoter to drive 
upregulation of the ETS gene (38).  One patient was initially found to have an ETV1 
translocation to an intergenic androgen-regulated region (39) which was subsequently 
found to encode a prostate-specific lncRNA (PCAT-14) (22), thereby creating a gene 
fusion between the lncRNA and ETV1.  Similarly, a GAS5-BCL6 gene fusion, resulting 
from a chromosomal translocation and retaining the full coding sequence of BCL6, has 
been reported in a patient with B-cell lymphoma (40).  Finally, Poliseno and colleagues 
demonstrated that the PTEN pseudogene, PTENP1, is genomically deleted in prostate and 
colon cancers, leading to aberrant expression levels of these genes (27). 
These initial data suggest that somatic aberrations of lncRNAs do contribute to 
their dysregulated function in cancer, although most studies to date identify gene 
expression changes as the primary alteration in lncRNA function.  Yet, the study of 
mutated lncRNAs in cancer will be an area of high importance in future investigations, as 
several prominent oncogenes, such as KRAS, show no substantial change in protein 
expression level in mutated compared to non-mutated cases.  It is likely that some 
lncRNAs exhibit altered function in cancer due to structural aberrations (mutation, small 




Characterizing RNA structural motifs 
Just as protein-coding genes harbor specific domains of amino acids that mediate 
distinct functions (e.g. a kinase domain), RNA molecules also have intricate and specific 
structures.  Among the most well-known RNA structures is the stem-loop-stem design of 
a hairpin, which is integral for miRNA generation (41).  RNA structures are also known 
to be essential for binding to proteins, particularly PRC2 proteins (42).  However, global 
profiles of lncRNA structures are poorly understood.  While it is clear that lncRNA 
structure is important to lncRNA function, few RNA domains are well-characterized.  
Moreover, it is likely that RNA domains occur at the level of secondary structure, as 
lncRNA sequences are highly diverse yet may form similar secondary structures 
following RNA folding (43). 
To this end, both computational and experimental advancements are beginning to 
address these topics.  While numerous computational algorithms have been proposed to 
predict RNA structures (43), perhaps the most dramatic advance in this area has been the 
development of RNA-Seq methods to interrogate aspects of RNA structure globally.  
Recently, Frag-Seq and PARS-Seq have demonstrated the unbiased evaluation of RNA 
structures by treating RNA samples with specific RNAses that cleave RNA at highly 
selective structural positions (44, 45).  These RNA fragments are then processed and 
sequenced to determine the nucleotide sites where RNA transcripts were cleaved, 
indirectly implying a secondary structure.  This area of research promises to yield 





IMPLICATIONS OF LONG NON-CODING RNAs IN CANCER MANAGEMENT 
lncRNA diagnostic biomarkers 
For clinical medicine, lncRNAs offer several possible benefits.  lncRNAs, such as 
PCAT-1 and SChLAP1, commonly demonstrate restricted tissue-specific and cancer-
specific expression patterns (22).  This tissue-specific expression distinguishes lncRNAs 
from miRNAs and protein-coding mRNAs, which are frequently expressed from multiple 
tissue types.  While the underlying mechanism for this is unclear, recent studies of 
chromatin confirmation show tissue-specific patterns, which may impact ncRNA 
transcription (23, 46).  Given this specificity, ncRNAs may be superior biomarkers than 
many current protein-coding biomarkers, both for tissue-of-origin tests as well as cancer 
diagnostics. 
A prominent example is PCA3, a lncRNA that is a prostate-specific gene and 
markedly overexpressed in prostate cancer.  Although the biological function of PCA3 is 
unclear, its utility as a biomarker has led to the development of a clinical PCA3 
diagnostic assay for prostate cancer, and this test is already being employed for clinical 
uses (47, 48).  In this test, PCA3 transcript is detected in prostate cancer patient urine 
samples, which contain prostate cancer cells shed into the urethra.  Thus, monitoring 
PCA3 does not require invasive procedures (Figure 6.2A) (47).  The PCA3 test 
represents the most effective clinical translational of a cancer-associated ncRNA gene to 
date, and the rapid timeline these developments—only 10 years from between its initial 
description and a clinical test—suggests that the use of ncRNAs in clinical medicine is 
only beginning.  Non-invasive detection of other aberrantly expressed lncRNAs, such as 
upregulation of HULC, which occurs in hepatocellular carcinomas, has also been 
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observed in patient blood sera (49); however other lncRNA-based diagnostics have not 
been developed for widespread use. 
 
lncRNA-based therapies 
The transition from ncRNA-based diagnostics to ncRNA-based therapies is also 
showing initial signs of development.  Although the implementation of therapies 
targeting ncRNAs is still remote for clinical oncology, experimental therapeutics 
employing RNA interference (RNAi) to target mRNAs have been tested in mice, 
cynomolgus monkeys, and humans (50), as part of a phase I clinical trial for patients with 
advanced cancer (Figure 6.2B).  Davis and colleagues found that systemic administration 
of RNAi-based therapy was able to effectively localize to human tumors and reduce 
expression of its target gene mRNA and protein (50).  Currently, ongoing clinical trials 
are further evaluating the safety and efficacy of RNAi-based therapeutics in patients with 
a variety of diseases, including cancer (51), and these approaches could be adapted to 
target lncRNA transcripts. 
Other studies investigate an intriguing approach that employs modular assembly 
of small molecules to adapt to aberrant RNA secondary structure motifs in disease (52).  
This approach could potentially target aberrant ncRNAs, mutant mRNAs, as well as 
nucleotide triplet-repeat expansions seen in several neurological diseases (such as 
Huntington’s disease). However, most RNA-based research remains in the early stages of 
development, and the potential for RNAi therapies targeting lncRNAs in cancer is still far 




lncRNAs in genomic epidemiology 
In the past decade, genome-wide association studies (GWAS) have become a 
mainstream way to identify germline SNPs that may predispose to myriad human 
diseases.  In prostate cancer, over 20 GWAS have reported 31 SNPs with reproducible 
allele-frequency changes in prostate cancer patients compared to men without prostate 
cancer (53), and these 31 SNPs cluster into 14 genomic loci (53).  In principle, profiling 
of these SNPs could represent an epidemiological tool to assess patient populations with 
a high risk of prostate cancer. 
Of the 14 genomic loci, the most prominent by far is the “gene desert” region 
upstream of the cMYC oncogene on chromosome 8q24, which harbors 10 of the 31 
reproducible SNPs associated with prostate cancer (Figure 6.2C).  Several SNPs in the 
8q24 region have been studied for their effect on enhancers (54), particularly for 
enhancers of cMYC (55), and chromosome looping studies have shown that many regions 
within 8q24 may physically interact with the genomic position of the cMYC gene (56). 
Recently, our identification of PCAT-1 as a novel chr8q24 gene implicated in 
prostate cancer pathogenesis further highlights the importance and complexity of this 
region (Figure 6.2C) (22).  Although the relationship between PCAT-1 and the 8q24 
SNPs is not clear at this time, this discovery suggests that previously-termed “gene 
deserts” may, in fact, harbor critical lncRNA genes, and that SNPs found in these regions 
may impact uncovered aspects of biology.  Relatedly, GWAS analyses of atherosclerosis, 
coronary artery disease, and type 2 diabetes have all highlighted ANRIL on Chr9p21 as a 
ncRNA gene harboring of disease-associated SNPs (57). 
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Clinically, the use of GWAS data may identify patient populations at risk for 
cancer and may stratify patient disease phenotypes, such as aggressive versus indolent 
cancer, and patient outcomes (58).  SNP profiles may also be use to predict a patient’s 
response to a given therapy (59).  As such, the clinical translation of GWAS data remains 
an area of interest for cancer epidemiology. 
 
ARE LNCRNAs REALLY NON-CODING? 
 A major assumption of this work is that computational biology can predict both 
the sequence identity of all transcripts in a cell and their protein coding potential.  While 
number studies have now addressed the first question (29, 30, 60, 61), few studies have 
rigorous tested the second: are predicted lncRNAs really non-coding transcripts?  On an 
individual level, single genes can be tested by in vitro translation assays, and these assays 
indicate that PCAT-1 and SChLAP-1, for example, are non-coding.  However, these 
assays are not suitable for large-scale analysis of thousands of genes, and thus the 
evidence that all predicted lncRNAs are truly non-coding remains anecdotal. 
 Recently, a novel method has been developed which may help to address this 
problem.  Ingolia et al. precipitated ribosomal fractions of cell lysates and, following 
partial digestion with RNAse, isolated RNA protected by the bulky ribosome machinery, 
which prevents access of the RNAse to the RNA engaged in the ribosomes (62). Using a 
modified form of RNA-seq, the authors then comprehensively determined which RNA 
species were directly engaged in the translational machinery, presumably to make 
proteins.  While this method assumes that all RNAs bound within the ribosome are 
211 
 
generating proteins, it provides the first global manner to identify putatively protein-
coding RNAs. 
 This method has been applied to multiple model systems, including yeast (62), E. 
coli (63) and mouse cells (64), and the findings from these studies are striking.  These 
studies suggest that the proteome is vastly more complex than previously appreciated.  
For example, numerous protein-coding genes are observed to give rise to many 
alternative proteins in addition to known isoforms, including novel peptides arising from 
the canonical 5’ and 3’ untranslated regions (64).  While it is unclear whether this new 
abundance of peptides represents functionally-relevant proteins or the imprecision of an 
imperfect translational machinery, their presence is intriguing and suggests that this layer 
of biology deserves exploration. 
 With respect to lncRNAs, Ingolia et al. found that nearly half of reported 
lncRNAs in mouse embryonic stem cells demonstrated translational efficiency consistent 
with protein-coding genes (4, 64), suggesting that these genes may not be non-coding at 
all.  Although these lncRNA-derived proteins have not been functionally characterized, it 
is likely that some of the presumed lncRNAs discovered as part of this thesis work are 
also translated and impart biological functions as a protein. 
 Why, then, did we not predict these proteins previously?  The answer is that these 
novel proteins are almost uniformly <100 amino acids in length, which is considered as a 
“noise” range below the level of accurate prediction computationally (65-68).  The DNA 
sequence of nearly any lncRNA can produce a predicted ORF of 10-100 amino acids, and 
conventionally these predicted ORFs have been ignored, since an analysis of random 
non-transcribed regions of DNA of similar lengths will also yield such predicted ORFs 
212 
 
(67, 68).  However, the field of small proteins has recently been explored in model 
systems such as Drosophila and bacteria (H. pylori) (69, 70); these studies show 
functional roles for small peptides produced by presumed ncRNAs and suggest that 
numerous cell processes, such as cell differentiation (71) may be regulated by this novel 
mechanism.  Thus, future efforts are needed to determine whether the newly-described 
lncRNA species in human biology and cancer also encode functional small proteins. 
 
CONCLUSION 
In the past decade, the rapid discovery of ncRNA species by high-throughput 
technologies has accelerated current conceptions of transcriptome complexity.  While a 
biological understanding of these ncRNAs has proceeded more slowly, increasing 
recognition of lncRNAs has defined them as critical actors of numerous cellular 
processes.  In cancer, dysregulated lncRNA expression characterizes the entire spectrum 
of disease and aberrant lncRNA function drives cancer through disruption of normal cell 
processes, typically by facilitating epigenetic repression of downstream target genes.  
lncRNAs thus represent a novel, poorly-characterized layer of cancer biology.  This 
thesis work, in particular, has examined the presence and role of lncRNAs in prostate 
cancer, defining 121 prostate-cancer-associated lncRNAs (PCATs) by global 
transcriptome profiling, and characterizing two novel lncRNAs, PCAT-1 and SChLAP-1, 
with oncogenic properties.  In the near term, clinical translation of lncRNAs such as 
PCAT-1 and SChLAP-1 may assist biomarker development in cancer types without robust 
and specific biomarkers, and in the future RNA-based therapies may be a viable option 
for clinical oncology.  Additional studies in the future will likely focus on the mechanism 
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of lncRNA biology, either via molecular mechanisms (epigenetics, etc), RNA structural 
motifs, sequence conservation, or the potential for encoding small proteins, as well as the 




























Figure 6.1: The role of lncRNAs in prostate cancer.  Four lncRNAs (PCA3, PCGEM1, 
PCAT-1, and SChLAP-1) have been investigated in prostate cancer.  Of these, PCA3 is a 
clinically-useful biomarker of unknown function.  PCGEM1 decreases apoptosis but its 
mechanism is unclear.  This thesis describes the discovery and characterization of PCAT-
1 and SChLAP-1, which contribute to aggressive disease through different mechanisms.  
PCAT-1 may also serve as a predictive biomarker through its regulation of homologous 








Figure 6.2: Clinical implications of lncRNAs.  (A) The PCA3 urine biomarker test for 
prostate cancer employs a non-invasive approach to disease diagnosis by collecting 
patient urine samples, isolating nucleic acids from cells in the urine sediment, and 
quantifying PCA3 expression.  (B) lncRNA-based therapies may target the lncRNA by 
utilizing either RNA interference (RNAi), which uses sequence homology between the 
lncRNA and the RNAi therapeutic molecule, or a small molecule therapy that interacts 
with the lncRNA.  These therapeutic avenues may be appropriate for systemic therapy by 
either intravenous or oral administration.  (C) Genome-wide association studies (GWAS) 
may provide germline polymorphisms that predict an individual patient’s clinical risk for 
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disease development, response to therapy, or disease aggressiveness, while also providing 
molecular information through the impact of polymorphisms on gene expression of key 
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Chapter 2, 3  3'RACE  PCAT‐1  ACCAGTGGAGAAGAGGCAGA  N/A 
Chapter 2, 3  3'RACE  PCAT‐14  TTCCACCTGAGGAGAAATGC  N/A 
Chapter 2, 3  3'RACE  PCAT‐14  GTACCACCCTGCAGGAAAA  N/A 







Chapter 2, 3  5'RACE  PCAT‐1  N/A  GCTTCAAATGCGAAAAGACC 
Chapter 2, 3  5'RACE  PCAT‐14  N/A  CGTCACTATGGCCCATTCTT 
Chapter 2, 3  5'RACE  PCAT‐14  N/A  GGTATGGTGCCGTGCTATTT 
Chapter 2, 3  5'RACE  PCAT‐26  N/A  ACAGGGGCCCAGCTCCAAAGAGT 
Chapter 2, 3  5'RACE  PCAT‐6  N/A  TGGCCTGAAGAATCTAACAGCCCCCA 





































Chapter 2, 3  PCR  HMBS  TGGGGCCCTCGTGGAATGTTA  GATGGGCAACTGTACCTGACTGGA 
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Chapter 2, 3  PCR  HOTAIR  GGTAGAAAAAGCAACCACGAAGC  ACATAAACCTCTGTCTGTGAGTGCC 
Chapter 2, 3  PCR  PCAT‐1  ACCAGTGGAGAAGAGGCAGA  GCTTCAAATGCGAAAAGACC 
Chapter 2, 3  PCR  PCAT‐1  TGTGCCTCTAAGTGCCAGTG  GGCTGGTCACTATGCTCCTC 
Chapter 2, 3  PCR  PCAT‐1  TTGTGGAAGCCCCGCAAGGCCTGAA  TGTGGGGCCTGCACTGGCACTT 
Chapter 2, 3  PCR  PCAT‐1  TGGAGCCGGAGGACCACAGCATCA  TGTGGGGCCTGCACTGGCACTT 
Chapter 2, 3  PCR  PCAT‐1  AAAAGGTCAGGGTCACTGTTTG  GGATTCAAACTCAACACCAGAA 
Chapter 2, 3  PCR  PCAT‐1  ATCCACCGCTGCTCTCTGAAT  CCAGAATCTTATGCTTTCTTTGC 
Chapter 2, 3  PCR  PCAT‐14  GGCGCAGGCCACTCCATCTGGTG  CCTCAATGACCACACTGTAGAG 
Chapter 2, 3  PCR  PCAT‐14  TTCCACCTGAGGAGAAATGC  GCTGACCGTGGACGTACTTG 
Chapter 2, 3  PCR  PCAT‐14  GAGATGGAGACACCCCAATC  CGTCACTATGGCCCATTCTT 




Chapter 2, 3  PCR  PCAT‐26  TGGGGCTTACGGTGCGGGAACG  ACCCTGATGGTAACAGGGGCCCAGC 
Chapter 2, 3  PCR  PCAT‐26  TGGGGCTTACGGTGCGGGAACGTCT  ACAGGGGCCCAGCTCCAAAGAGT 
Chapter 2, 3  PCR  PCAT‐26  AAGTGCTGGGGTTACAGGTG  CCCATCAATGGGTGTAGGAG 
Chapter 2, 3  PCR  PCAT‐29  CCGAGGAATGTGAGGTTCAT  CCTCACCCTTGGAAAATTCA 
Chapter 2, 3  PCR  PCAT‐29  GGAGCCAATCAACCTGTGCCCCTAGC  TCCCTGGGATGCATATGGTGCCCCT 
Chapter 2, 3  PCR  PCAT‐29  AACCTGTGCCCCTAGCTGATGTCCCA  GTCCCTGGGATGCATATGGTGCCCCT 
Chapter 2, 3  PCR  PCAT‐32  TGTCTGACTTCCGACTGACG  TCTCAGTGGGAATACCTGTGC 
Chapter 2, 3  PCR  PCAT‐32  ACTACCACTCTGGCCACAC  AACCATTTGGGTGCTACTGC 
Chapter 2, 3  PCR  PCAT‐32  TCCCTTACCAGTGAGCCAAC  GAATACAGCCGCAGACACAA 
Chapter 2, 3  PCR  PCAT‐43  GGTGGGTGTCTCCAAAGTGCCCACCA  TCCTGGCTCTGCCCTGTCTGTTGGCT 
Chapter 2, 3  PCR  PCAT‐43  GGAGGTGGGTGTCTCCAAAGTGCCC  AGGTTCCCTCCTGGCTCTGCCCTGT 
Chapter 2, 3  PCR  PCAT‐43  ATGCCCAGCCCTGCAGCTCAACT  GCAGGCTGACCCTGTGCAGCTCAA 
Chapter 2, 3  PCR  PCAT‐43  AGATGCCCAGCCCTGCAGCTCAA  TCTGCAGGCTGACCCTGTGCAGCTC 
Chapter 2, 3  PCR  PCAT‐6  ACTGGTACAGCCCACACTCAGAGCA  TGGCCTGAAGAATCTAACAGCCCCCA 
Chapter 2, 3  PCR  PCAT‐6  TGGTACAGCCCACACTCAGAGCAGAT  TGGCCTGAAGAATCTAACAGCCCCCA 
Chapter 2, 3  PCR  PCAT‐6  AAGGTCTTTTGGCAGCTGAA  CCTTGGGCTTTGCACATAAT 































































Chapter 2, 3  PCR  Schlap1_LINE1  GCTCAGTCCCATCCTCTCAG  GACCCTGGGAGAAGTGTTCA 
Chapter 2, 3  PCR  Schlap1_LINE1  AAGTGCCAGCATAAGCCAAC  CTGGGGACCAGGATAACAGA 
Chapter 2, 3  PCR  Schlap1_LINE1  GCTCAGTCCCATCCTCTCAG  CCTTGGTGGCTTAGGGTACA 


























































Chapter 2, 3  PCR c‐MYC  GCTCGTCTCAGAGAAGCTGG  GCTCAGATCCTGCAGGTACAA 










Urine   GAPDH  TGCACCACCAACTGCTTAGC  GGCATGGACTGTGGTCATGAG 
Chapter 2, 3 
PCR, 





Urine   PCA3  CATGGTGGGAAGGACCTGATGATAC  GATGTGTGGCCTCAGATGGTAAAGTC 
Chapter 2, 3 
PCR, 
Urine   PCAT‐14  GTACCACCCTGCAGGAAAA  AGGCAGTACCTATGCCGATG 
Chapter 2, 3 
PCR, 















Chapter 4  qPCR BIRC5 CACCGCATCTCTACATTCAAGA CAAGTCTGGCTCGTTCTCAGT 
Chapter 4  qPCR TOP2A TTGTTTCGAAAGCAGTCACAAG GTTTCTTTGCCCGTACAGATTT 
Chapter 4  qPCR E2F8 AAATGGACAATCAGTTGCTGTG CTAATTGTGACCCTTTGGGTGT 
Chapter 4  qPCR GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
Chapter 4 
qPCR B-actin AAGGCCAACCGCGAGAAG ACAGCCTGGATAGCAACGTAC
A 
Chapter 4 




Chapter 4  qPCR PCAT1 TGAGAAGAGAAATCTATTGGAACC GGTTTGTCTCCGCTGCTTTA 
Chapter 4  qPCR STAU1 TAACATCTCTTCAGGCCACGTA GTTCTTGTTGTTTTTGGGGAAG 
Chapter 4  Cloning 
BRCA2_3'U












































Chapter 5  qPCR AK093002 gggaatccccatatcacagt ggaagcttacagttttcaagca 








Chapter 5  qPCR PCAT-1 TGAGAAGAGAAATCTATTGGAACC GGTTTGTCTCCGCTGCTTTA 
Chapter 5  qPCR SNF5 GAGACTCTGACAGACGCTGAGA gtgtgctgatgggctggTTAC 
Chapter 5  qPCR BRG1 AAAATCGAGAAGGAGGATGACA CCAAGCTTGATCTTCACTTTGA 
Chapter 5  qPCR BRM GAAGAGGAAGATGAAGAAGAGTC AATCGCTCACTACAGGTTTGG 
Chapter 5  qPCR PCA3  CATGGTGGGAAGGACCTGATGATAC  GATGTGTGGCCTCAGATGGTAAAGTC 
Chapter 5  qPCR GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 
Chapter 5  qPCR HMBS  ATGGGCAACTGTACCTGACTGGA  TGGGGCCCTCGTGGAATGTTA 































































nested SChLAP-1 gtgtccccacccaaatatcatct NA 
Chapter 5 
5' 






























































score(d)  PCAT1 siRNA 1  PCAT1 siRNA 2  PCAT1 siRNA 3 
23533  RSRC1  NM_016625  ‐1.006  4.940  0.521113533  0.334288917  0.633843957 
6847  LOC651702  XR_019167  ‐0.918  4.947  0.347779207  0.440463273  0.652039537 
19313  A_24_P255865  A_24_P255865  ‐0.900  4.954  0.355193733  0.495103133  0.727612313 
7250  THC2679528  THC2679528  ‐0.976  4.959  0.863457823  1.246545633  0.657927357 
5893  DBF4  NM_006716  ‐0.893  4.962  0.300336617  0.399244567  0.391550347 
38352  MT1X  NM_005952  ‐1.337  4.973  0.884343633  0.506372153  1.472981433 
30332  TCF25  NM_014972  ‐1.043  4.973  0.410323063  0.417012783  0.443828227 
773  GPAA1  NM_003801  ‐0.909  4.980  0.39349141  0.392254013  0.374721293 
33859  SUV420H2  NM_032701  ‐0.934  4.982  0.465955283  0.3954617  0.42715913 
88  DNTTIP2  NM_014597  ‐1.022  4.983  0.438897253  0.52095768  0.301800087 
9241  ZNF292  ENST00000339907  ‐0.849  4.984  0.441384457  0.625225883  0.773401753 
1344  AKT1  NM_005163  ‐1.080  4.985  0.51938914  0.41884274  0.851518003 
22008  ABCA5  NM_018672  ‐0.917  4.986  0.389778307  0.410267573  0.634416517 
5893  DBF4  NM_006716  ‐0.923  4.987  0.305547533  0.493902177  0.418649217 
38773  FAAH  NM_001441  ‐0.944  4.988  0.391919553  0.31305381  0.533911253 
2475  KIF20A  NM_005733  ‐0.921  4.998  0.32667465  0.301709357  0.419867413 
5768  C14orf106  NM_018353  ‐1.230  5.002  0.7744003  0.507741253  1.353977367 
34338  MGC23270  BC015579  ‐0.742  5.008  0.486346933  0.509025187  0.8753982 
15486  LOC339123  NM_001005920  ‐0.906  5.009  0.35048762  0.446652143  0.66335048 
22189  GAS2L3  NM_174942  ‐0.943  5.009  0.515002413  0.405029773  0.418236747 
1858  ALDH16A1  NM_153329  ‐0.847  5.017  0.334262947  0.366175573  0.40272684 
9809  MGC27348  BC026177  ‐0.879  5.018  0.31200243  0.387968817  0.449448797 
26678  SRFBP1  NM_152546  ‐0.909  5.026  0.45372356  0.487460857  0.32052505 
12393  SAPS1  NM_014931  ‐1.092  5.030  0.442298353  0.586149067  0.679268087 
1344  AKT1  NM_005163  ‐0.949  5.032  0.381963307  0.456398187  0.71013828 
26086  CNP  NM_033133  ‐0.745  5.035  0.392566453  0.39436468  0.503181743 
28385  hCG_21078  XM_371853  ‐0.821  5.036  0.302173313  0.315085833  0.27650109 
5893  DBF4  NM_006716  ‐0.834  5.038  0.339448313  0.312095023  0.36292373 
28071  UNC84B  NM_015374  ‐1.190  5.040  0.618462433  0.561693517  0.32800544 
37861  THC2677659  THC2677659  ‐1.557  5.047  1.2097785  1.7060216  0.50454075 
31827  SGOL2  NM_152524  ‐1.356  5.050  0.915289353  1.1657253  0.41766023 
6473  DNAL4  NM_005740  ‐0.887  5.050  0.54492778  0.56360382  0.4354317 
16923  TUBA1B  NM_006082  ‐0.937  5.055  0.416320243  0.302067373  0.34673305 
2465  KNTC1  NM_014708  ‐0.853  5.055  0.34466382  0.45486941  0.377695347 
39351  CKS1B  NM_001826  ‐0.820  5.077  0.285845263  0.377309393  0.375315483 
18939  SLC3A2  NM_002394  ‐0.814  5.078  0.303155287  0.31232059  0.350279817 
20619  PPM1F  NM_014634  ‐0.852  5.084  0.366864947  0.596582467  0.554739297 
11124  AA971667  AA971667  ‐0.931  5.088  0.391513137  0.3409588  0.570428247 
24622  ARRDC1  NM_152285  ‐1.001  5.089  0.395349533  0.447496583  0.369562323 
10492  THC2679528  THC2679528  ‐1.594  5.090  0.9883614  0.99597058  1.087137167 
27966  SOX7  NM_031439  ‐0.828  5.097  0.38674495  0.502509607  0.620296883 
1344  AKT1  NM_005163  ‐0.975  5.109  0.507086017  0.400045887  0.7830165 
2086  LRRC21  NM_015613  ‐1.332  5.115  0.999061997  1.066310153  1.142748637 
39688  PKN2  NM_006256  ‐0.976  5.116  0.351516377  0.468048407  0.63927758 
40762  SCLT1  NM_144643  ‐0.924  5.122  0.409959  0.477567233  0.581112767 
229 
 
2969  EIF5B  NM_015904  ‐1.117  5.124  0.626303633  0.6574326  1.3728249 
14042  ENST00000355232  ENST00000355232  ‐1.171  5.128  0.498998637  0.526135173  0.958924633 
7545  BCL7C  NM_004765  ‐0.913  5.136  0.37449657  0.387230343  0.52944822 
2475  KIF20A  NM_005733  ‐0.892  5.136  0.334010173  0.30140925  0.39019727 
37913  SLC44A2  NM_020428  ‐1.019  5.151  0.33390072  0.393228317  0.42877775 
3685  HOXC6  NM_153693  ‐0.990  5.152  0.44696339  0.90032201  0.64609937 
40356  UBE2M  NM_003969  ‐0.823  5.158  0.316531517  0.422213473  0.471410487 
16246  NKTR  NM_001012651  ‐1.007  5.162  0.41111444  0.559825303  0.337470167 
35361  KLHL17  NM_198317  ‐1.292  5.173  0.699678543  0.40598082  0.459744953 
23798  KIAA1641  AK024934  ‐0.952  5.177  0.349477073  0.49014338  0.631385727 
7417  FKSG44  AF334946  ‐1.704  5.186  1.236010467  0.54856024  1.358906733 
26129  BF869497  BF869497  ‐0.922  5.188  0.37756848  0.460593633  0.68526819 
27339  C4orf26  NM_178497  ‐1.242  5.193  0.62882262  0.801652357  1.113803167 
12111  STK33  NM_030906  ‐0.875  5.198  0.38237799  0.337290137  0.448179493 
3968  LOC647768  XR_018202  ‐0.986  5.213  0.460610143  0.320981443  0.51993272 
1344  AKT1  NM_005163  ‐0.967  5.214  0.47592395  0.44191583  0.754791053 
2969  EIF5B  NM_015904  ‐1.142  5.216  0.659037947  0.662752087  1.395220267 
3384  ANKRD26  NM_014915  ‐1.538  5.223  1.0720811  1.2597755  0.443442473 
6272  ONECUT2  NM_004852  ‐0.833  5.229  0.373997193  0.30682604  0.392072743 
20893  MT1G  NM_005950  ‐1.470  5.234  1.025926667  0.492635607  1.4525373 
10063  EPHX1  NM_000120  ‐0.998  5.239  0.456592407  0.6393029  0.975699467 
20405  ADAMTSL5  NM_213604  ‐1.247  5.243  0.770603783  0.77379168  0.966703587 
35061  FLJ20464  AK000471  ‐1.026  5.254  0.492303003  0.635008183  1.084638367 
33073  PIK4CB  NM_002651  ‐1.035  5.259  0.403256707  0.35605781  0.479554683 
11650  C13orf3  BC013418  ‐0.893  5.262  0.33405941  0.440747533  0.353472893 
16024  AAAS  NM_015665  ‐0.997  5.265  0.40433856  0.474217983  0.72495142 
11012  TROAP  NM_005480  ‐1.000  5.267  0.47867218  0.568151587  0.33242264 
39616  MAP2K7  NM_145185  ‐0.990  5.270  1.156338833  0.96951868  1.3097191 
14385  MT1X  NM_005952  ‐1.394  5.274  0.88888579  0.52054405  1.397178833 
35151  ENST00000306565  ENST00000306565  ‐1.028  5.277  0.468886717  0.621980933  0.8518822 
3156  FAM33A  NM_182620  ‐0.974  5.277  0.387177983  0.325833457  0.360859917 
28875  ANKRD12  NM_015208  ‐2.231  5.277  1.880562533  1.833921833  0.55090053 
34058  TCOF1  NM_001008656  ‐1.084  5.296  0.510207873  0.43407404  0.826990087 
36348  ATP2B3  NM_021949  ‐0.978  5.299  0.491691977  0.714427833  0.518352133 
8105  N4BP2  NM_018177  ‐0.897  5.299  0.495253717  0.55764644  0.352215003 
21960  MT1L  X97261  ‐1.431  5.312  0.992309383  0.498003433  1.412342667 
21744  RXRB  NM_021976  ‐1.035  5.313  0.459925187  0.663733083  0.378826713 
36339  MGC11257  NM_032350  ‐0.924  5.314  0.401290763  0.685803317  0.91626706 
2465  KNTC1  NM_014708  ‐0.921  5.319  0.414101543  0.310730003  0.398239777 
38815  KLHDC3  NM_057161  ‐0.901  5.325  0.5090245  0.38581885  0.62731609 
15472  FANCM  NM_020937  ‐1.393  5.328  0.82116619  0.882122967  1.835790333 
14601  SLC25A25  NM_001006641  ‐1.073  5.351  0.560863153  0.386081937  0.709116947 
938  RIOK2  NM_018343  ‐0.819  5.361  0.36534626  0.41962721  0.46843704 
39586  CR749652  CR749652  ‐0.987  5.364  0.396294413  0.570525597  0.75641686 
1360  FLJ10781  NM_018215  ‐1.079  5.370  0.411075523  0.63895559  0.80072462 
16203  HNRPC  NM_031314  ‐0.998  5.372  0.367765797  0.593727497  0.716934797 
18700  LOC731479  ENST00000360524  ‐1.093  5.374  0.6057479  0.575617207  0.351932263 
1344  AKT1  NM_005163  ‐0.964  5.380  0.598357977  0.41825169  0.743226817 
20215  LOC390996  XR_018526  ‐0.982  5.394  0.405068833  0.545122647  0.783484877 
27320  AKAP8L  AL133576  ‐0.953  5.410  0.418468943  0.63994983  0.85365902 
10985  TGM1  NM_000359  ‐0.905  5.411  0.514855813  0.408505873  0.533184083 
21840  A_23_P95125  A_23_P95125  ‐1.206  5.412  0.651094213  0.613250533  1.248388667 
7847  CEP55  NM_018131  ‐1.093  5.418  0.5886133  0.37273417  0.41119043 
30197  CB959193  CB959193  ‐1.072  5.424  0.495321633  0.79465178  1.193498033 
39251  THC2710703  THC2710703  ‐1.053  5.425  0.428183583  0.8008507  0.970914333 
34994  MLLT6  NM_005937  ‐0.907  5.425  0.39138154  0.38074806  0.31101483 
10358  EFNA5  NM_001962  ‐0.875  5.430  0.44297139  0.932751797  0.692673767 
18239  NEK3  NM_002498  ‐1.027  5.431  0.428340593  0.572266813  0.623114333 
5692  A_24_P920715  A_24_P920715  ‐1.025  5.436  0.534330913  0.423041337  0.483264213 
5358  C10orf118  NM_018017  ‐1.188  5.438  0.750156133  0.783944547  0.40043825 
12351  CR749547  CR749547  ‐0.906  5.447  0.420484167  0.59688365  0.382436553 
2930  RAB1B  NM_030981  ‐1.040  5.452  0.472321977  0.531687413  0.70507138 
19692  ZNF136  NM_003437  ‐0.969  5.454  0.570178987  0.477400177  0.700124533 
15540  MT1B  NM_005947  ‐1.427  5.462  1.054919133  0.51508056  1.4235159 
36045  L07392  L07392  ‐0.935  5.463  0.38727173  0.80135397  0.644476297 
34376  LOC554248  BC078169  ‐0.804  5.467  0.375054717  0.434335617  0.542365383 
27300  BC068045  BC068045  ‐0.992  5.470  0.440173253  0.448673133  0.66106364 
16211  PIGU  NM_080476  ‐0.876  5.490  0.339947603  0.366708197  0.4136233 
15210  MT2A  ENST00000245185  ‐1.387  5.493  0.998746267  0.46660686  1.216663967 
26159  AK095583  AK095583  ‐0.980  5.497  0.474712203  0.385730933  0.621790057 
230 
 
25433  PRKCSH  NM_002743  ‐0.913  5.503  0.454363187  0.651303267  0.879991203 
23778  A_23_P113762  A_23_P113762  ‐1.641  5.511  0.78288683  1.084225813  1.492523767 
31306  SMC3  NM_005445  ‐1.285  5.525  0.749312787  0.756094753  0.385308323 
8894  KRR1  NM_007043  ‐0.911  5.528  0.35605963  0.328529847  0.33130613 
25932  ASNA1  NM_004317  ‐0.966  5.531  0.441434303  0.36865415  0.53366033 
9519  BIRC5  NM_001012271  ‐0.964  5.533  0.360075717  0.513889463  0.61086785 
22360  TUBA1C  NM_032704  ‐1.056  5.544  0.479116287  0.43058436  0.74580582 
22990  MT2A  NM_005953  ‐1.475  5.554  1.036564667  0.468939107  1.229061433 
5893  DBF4  NM_006716  ‐0.960  5.568  0.39454788  0.438621533  0.438768717 
7308  CDIPT  NM_006319  ‐0.918  5.577  0.446623143  0.376722447  0.401562143 
1331  CCDC41  NM_016122  ‐1.118  5.578  0.614482993  0.447735973  0.872743633 
28868  PSIP1  NM_033222  ‐1.039  5.578  0.484696477  0.557505977  0.34215584 
3815  SPINT1  NM_003710  ‐0.868  5.580  0.312147323  0.4029785  0.356640867 
5583  ACTL8  NM_030812  ‐3.854  5.581  2.942171767  1.879107207  3.912231333 
33215  C8orf70  NM_016010  ‐1.110  5.583  0.561022427  0.448351317  0.814709353 
33875  A_24_P3627  A_24_P3627  ‐2.063  5.590  0.91876261  1.081132867  1.270674253 
37791  CENPC1  NM_001812  ‐1.052  5.591  0.41824091  0.45513327  0.446136253 
5651  CENPJ  NM_018451  ‐1.046  5.593  0.429845383  0.589642533  0.411300947 
9519  BIRC5  NM_001012271  ‐0.938  5.600  0.38230024  0.43965645  0.600935233 
8327  C20orf74  AB033098  ‐1.375  5.604  0.873607833  0.67425798  1.5338235 
8287  NME6  NM_005793  ‐1.020  5.610  0.501350367  0.630588457  1.005878947 
10660  PSMD13  NM_175932  ‐0.848  5.613  0.369453267  0.339212223  0.363020023 
28039  THC2611971  THC2611971  ‐0.933  5.615  0.380078297  0.56931355  0.638574523 
25419  SDC3  AB007937  ‐0.986  5.637  0.414816043  0.568493053  0.74562811 
25843  FLJ36166  NM_182634  ‐2.103  5.645  1.196355917  1.383894067  1.365227817 
27886  PADI4  NM_012387  ‐1.040  5.648  0.46397339  0.775036417  1.039291 
5893  DBF4  NM_006716  ‐0.891  5.648  0.412957697  0.483474507  0.368978977 
1344  AKT1  NM_005163  ‐0.993  5.651  0.538901933  0.460369237  0.812115733 
5274  ELK1  NM_005229  ‐0.960  5.665  0.58595122  0.83713733  0.8490902 
37972  SOCS3  NM_003955  ‐0.971  5.676  0.50843277  0.627204463  0.99061901 
5061  ZRF1  NM_014377  ‐1.064  5.677  0.522003713  0.410465747  0.63694285 
9723  TMEM37  NM_183240  ‐1.045  5.682  0.575322717  1.055485443  1.052750633 
18366  CFL1  NM_005507  ‐0.826  5.693  0.40584895  0.57306705  0.63946067 
2475  KIF20A  NM_005733  ‐0.950  5.695  0.379517643  0.34323663  0.429874857 
9175  ARHGAP28  NM_001010000  ‐1.046  5.708  0.413240087  0.564982223  0.4670017 
37270  JRK  NM_003724  ‐1.173  5.714  0.537261523  0.55554608  0.809393483 
5893  DBF4  NM_006716  ‐0.908  5.717  0.346929533  0.442903727  0.399543373 
1369  IGFBP3  NM_001013398  ‐1.096  5.717  0.615347023  0.632599097  1.00062019 
9519  BIRC5  NM_001012271  ‐0.901  5.717  0.375764173  0.423292463  0.568327037 
17504  ADCY6  NM_015270  ‐0.970  5.735  0.356816677  0.487686517  0.466494907 
1344  AKT1  NM_005163  ‐1.216  5.735  0.55082286  0.555257  0.94155688 
6088  NEK3  NM_002498  ‐0.986  5.736  0.531334133  0.469208713  0.723086047 
2465  KNTC1  NM_014708  ‐0.940  5.738  0.490430607  0.379323967  0.416330273 
25730  GSG2  AK056691  ‐0.869  5.746  0.401150573  0.40580977  0.537110163 
20936  A_32_P135469  A_32_P135469  ‐1.224  5.751  0.55802433  0.7072993  0.47336114 
35962  AF100640  AF100640  ‐3.175  5.753  2.867817033  3.007298167  0.889591033 
37306  KIF4A  NM_012310  ‐1.056  5.758  0.492465713  0.480066237  0.796774763 
9519  BIRC5  NM_001012271  ‐0.965  5.764  0.389337  0.47915467  0.629716953 
2465  KNTC1  NM_014708  ‐0.895  5.774  0.353434943  0.359009393  0.394532187 
35194  PHIP  NM_017934  ‐1.213  5.782  0.616586533  0.62626625  0.38234558 
39248  ZNF93  AK096342  ‐1.134  5.782  0.62031509  0.37851226  0.54668243 
9519  BIRC5  NM_001012271  ‐1.005  5.802  0.397001003  0.513268363  0.658882933 
36028  LOC157627  AL832535  ‐1.201  5.808  0.637521053  0.59587838  1.0501538 
29822  A_24_P84711  A_24_P84711  ‐0.923  5.819  0.425230457  0.37065526  0.360519987 
3285  RAD50  NM_005732  ‐1.086  5.847  0.615432417  0.437646533  0.435127603 
1344  AKT1  NM_005163  ‐1.017  5.852  0.492613403  0.5295083  0.839234777 
3285  RAD50  NM_005732  ‐1.087  5.853  0.5687039  0.38603426  0.44301929 
38028  PXMP4  NM_007238  ‐1.161  5.853  0.49065798  0.872732933  1.025954233 
3944  RASL10B  NM_033315  ‐1.442  5.868  0.8276303  1.083801953  1.3806018 
8106  ZNF289  NM_032389  ‐1.131  5.869  0.592109613  0.87438897  0.49290893 
2285  CDKN3  NM_005192  ‐1.011  5.871  0.423589247  0.391312367  0.57461079 
6977  AA045093  AA045093  ‐0.857  5.904  0.596226227  0.871654783  0.977422967 
5893  DBF4  NM_006716  ‐1.026  5.904  0.37443005  0.454255473  0.45633269 
17226  COQ2  NM_015697  ‐0.951  5.909  0.41728748  0.448028367  0.524524867 
21306  BF513730  BF513730  ‐0.902  5.911  0.443364183  0.376125887  0.45001525 
9519  BIRC5  NM_001012271  ‐0.917  5.924  0.3713759  0.493588077  0.588068383 
2828  ZNF146  NM_007145  ‐0.860  5.925  0.578385017  0.509999627  0.6641796 
2465  KNTC1  NM_014708  ‐0.985  5.927  0.375158947  0.392762413  0.44181522 
19235  BC032451  BC032451  ‐1.061  5.931  0.647958147  0.666673343  1.061447053 
7065  PNPLA6  NM_006702  ‐1.048  5.973  0.420737513  0.463273803  0.502059113 
231 
 
1369  IGFBP3  NM_001013398  ‐1.370  5.974  0.6840508  0.75719114  1.186419267 
1369  IGFBP3  NM_001013398  ‐1.184  5.977  0.59713945  0.63470889  1.0765522 
39787  CRYBA2  NM_005209  ‐1.001  5.979  0.502473763  0.807285887  1.047568733 
3285  RAD50  NM_005732  ‐1.100  5.990  0.62223484  0.424403617  0.448982877 
25404  TRIP11  NM_004239  ‐2.018  5.992  1.670188267  1.542010033  0.637054323 
3827  PTTG2  NM_006607  ‐0.939  6.000  0.357020577  0.4196713  0.3748663 
40463  LOC643401  BC039509  ‐1.553  6.012  1.107100733  0.65460662  1.4675565 
3285  RAD50  NM_005732  ‐1.034  6.022  0.54367696  0.45766403  0.405674807 
34358  FLNA  NM_001456  ‐1.216  6.029  0.683593313  0.714153417  0.427904197 
9519  BIRC5  NM_001012271  ‐0.934  6.039  0.395572163  0.463541343  0.596245433 
35917  MAP9  NM_001039580  ‐1.191  6.039  0.73893866  0.804490233  0.458019097 
5917  PPOX  NM_000309  ‐1.070  6.048  0.540043097  0.409437883  0.440636673 
35830  LOC375748  NM_001010895  ‐0.952  6.055  0.42159785  0.577351457  0.70910658 
1281  AK098270  AK098270  ‐1.105  6.082  0.51618436  0.7306318  1.00736931 
17235  STAG2  NM_006603  ‐0.971  6.084  0.42422093  0.702816247  0.657899913 
1369  IGFBP3  NM_001013398  ‐1.088  6.099  0.691615633  0.58158993  0.880269103 
5683  USP5  NM_003481  ‐1.023  6.112  0.507237733  0.570293813  0.831264847 
25917  A_32_P144634  A_32_P144634  ‐1.289  6.117  0.799903247  0.769416933  1.337361733 
21905  TMTC3  NM_181783  ‐0.938  6.134  0.471269013  0.699257633  0.59849241 
25443  TTK  NM_003318  ‐1.176  6.142  0.66186526  0.951772133  0.547690443 
40405  LOC727992  BX099599  ‐1.729  6.144  1.320396533  0.947707433  1.4510644 
1111  PTK2B  NM_173174  ‐1.285  6.164  0.639258467  0.5931595  0.966420313 
32127  MT2A  NM_005953  ‐1.548  6.174  1.1225589  0.563942687  1.287562467 
34298  RAI2  NM_021785  ‐1.293  6.179  0.667352407  0.6709583  0.895283753 
24194  BAP1  NM_004656  ‐0.903  6.181  0.426247967  0.48157077  0.51867946 
15639  LOC441900  XR_018860  ‐1.239  6.194  0.687487547  0.64582657  1.0892146 
19557  EIF5A  NM_001970  ‐0.889  6.196  0.357654463  0.42287157  0.444920493 
9519  BIRC5  NM_001012271  ‐0.965  6.198  0.41817245  0.515097547  0.635008633 
1111  PTK2B  NM_173174  ‐1.133  6.209  0.557920643  0.57041109  0.851068867 
3285  RAD50  NM_005732  ‐1.107  6.225  0.606048067  0.416692487  0.478704673 
2465  KNTC1  NM_014708  ‐0.993  6.228  0.390746393  0.417130013  0.463618183 
32412  FAM44A  NM_148894  ‐1.420  6.232  0.99772192  0.8994741  0.510015133 
11015  A_32_P138933  A_32_P138933  ‐1.614  6.235  0.741806227  0.933223433  1.227980167 
9519  BIRC5  NM_001012271  ‐0.898  6.249  0.4018579  0.474494667  0.547166907 
1111  PTK2B  NM_173174  ‐1.010  6.250  0.488387477  0.602771527  0.7455181 
27954  THC2760643  THC2760643  ‐1.363  6.270  0.764793787  1.857968767  1.400994633 
39718  KIAA0586  NM_014749  ‐1.051  6.287  0.48112958  0.3730477  0.425511457 
3285  RAD50  NM_005732  ‐1.136  6.296  0.629687533  0.447152487  0.49195581 
23079  SHPRH  NM_173082  ‐1.139  6.302  0.625485767  0.423523337  0.515336883 
7148  KIAA1212  NM_018084  ‐1.511  6.314  1.048656367  0.863574257  0.79854459 
15774  A_32_P62480  A_32_P62480  ‐1.725  6.324  1.010259983  0.827800917  0.90616938 
31360  NAP1L4  NM_005969  ‐1.072  6.346  0.502304767  0.566436147  0.755094753 
36256  PHF19  NM_001009936  ‐1.063  6.353  0.546339057  0.634155567  0.492962477 
5893  DBF4  NM_006716  ‐1.035  6.357  0.4029716  0.484440597  0.472126817 
20599  WDR79  NM_018081  ‐1.133  6.366  0.64939212  0.45845425  0.70377362 
1369  IGFBP3  NM_001013398  ‐1.105  6.368  0.590328083  0.68390198  1.004822813 
21508  PPP5C  NM_006247  ‐0.925  6.369  0.673417077  0.770083807  0.651410743 
26067  IGHMBP2  NM_002180  ‐1.014  6.371  0.505392033  0.51778365  0.591812193 
13005  CGB1  NM_033377  ‐1.737  6.395  0.937694687  1.3665372  1.3151681 
40788  LYPLA2P1  NR_001444  ‐1.055  6.418  0.56050866  0.493340013  0.659833 
3642  TUB  NM_003320  ‐2.645  6.449  1.533428647  1.055873433  1.6439119 
30574  MKI67  NM_002417  ‐1.171  6.474  0.641194913  0.541955853  0.801107427 
40099  USP46  NM_022832  ‐1.074  6.484  0.459346287  0.687842643  0.678352667 
29804  AK021715  AK021715  ‐1.010  6.485  0.464045273  0.43927597  0.608874213 
5479  HLTF  NM_139048  ‐1.027  6.510  0.423599303  0.490367523  0.543025987 
28374  ASH1L  NM_018489  ‐0.984  6.516  0.538743073  0.493611357  0.478698113 
19473  GBA2  NM_020944  ‐0.894  6.516  0.428892993  0.553983553  0.5866156 
4248  SLC30A1  NM_021194  ‐1.177  6.520  0.764933833  0.6571872  1.179001833 
14291  C14orf24  NM_173607  ‐1.264  6.521  0.641755997  0.68608891  0.467153407 
22649  THC2648557  THC2648557  ‐1.314  6.539  0.783100567  0.892900767  1.218031467 
1369  IGFBP3  NM_001013398  ‐1.294  6.544  0.65774132  0.784666457  1.149141933 
1629  ENST00000371189  ENST00000371189  ‐1.100  6.545  0.559547723  0.465720677  0.578886977 
13077  CFL1  NM_005507  ‐0.985  6.545  0.46893856  0.649925093  0.776248013 
27996  BIRC7  NM_022161  ‐1.065  6.559  0.581351267  0.961036833  1.04183165 
1769  A_24_P401521  A_24_P401521  ‐1.161  6.566  0.5445388  0.847052633  1.035766233 
35959  ZNF518  NM_014803  ‐1.459  6.583  1.0154131  1.387224933  0.718855833 
1369  IGFBP3  NM_001013398  ‐1.249  6.583  0.7376502  0.645824133  1.0946908 
9519  BIRC5  NM_001012271  ‐0.941  6.586  0.420310553  0.548942607  0.606487 
31416  SNRP70  NM_003089  ‐1.119  6.587  0.540011933  0.500633767  0.42571368 
37650  FGFR1OP  ENST00000366847  ‐1.574  6.595  0.868947213  1.0405509  0.77659564 
232 
 
16819  FAM33A  NM_182620  ‐0.987  6.600  0.406282547  0.385594327  0.465264927 
38263  IGKV2‐24  BC063599  ‐1.107  6.602  0.667914563  0.889044167  1.285621467 
40224  LOC341378  XR_016562  ‐1.222  6.631  0.8158969  1.061813767  0.59359718 
1369  IGFBP3  NM_001013398  ‐1.405  6.636  0.753549653  0.746442503  1.231844333 
17086  PHF17  NM_199320  ‐1.131  6.684  0.5612181  0.6884305  0.48410086 
11553  A_24_P272503  A_24_P272503  ‐1.068  6.689  0.442968493  0.541146603  0.57413828 
39032  LOC649056  XR_018580  ‐2.262  6.704  2.5882742  2.499471133  1.478521067 
14426  TSR2  NM_058163  ‐1.302  6.706  0.790769587  0.7495985  1.3135213 
40184  SFRS12  AB209694  ‐0.965  6.713  0.65471357  0.77616179  1.076692967 
21366  KIR2DS4  NM_012314  ‐1.221  6.736  0.669957163  0.994646467  1.189627567 
41000  LRRC2  NM_024512  ‐1.339  6.739  0.671780933  1.057416867  1.081926433 
39432  THC2537856  THC2537856  ‐1.948  6.745  2.1216708  1.9880997  1.0868812 
21040  PGS1  NM_024419  ‐1.128  6.746  0.582391737  0.782717317  1.022129567 
21598  ENST00000343253  ENST00000343253  ‐1.746  6.750  1.233909167  1.384278133  0.7873888 
1369  IGFBP3  NM_001013398  ‐1.162  6.786  0.666790833  0.699803847  1.0568066 
24124  A_32_P157671  A_32_P157671  ‐1.003  6.808  0.4567525  0.506245537  0.44178937 
177  BRCA2  NM_000059  ‐2.132  6.814  1.51479272  1.304196567  1.8578466 
35045  RPA4  NM_013347  ‐1.430  6.817  0.666397837  0.80661291  0.943123237 
1999  CCDC69  NM_015621  ‐1.727  6.844  1.003219847  1.149518467  1.645128733 
14858  CD86  NM_006889  ‐1.364  6.848  0.613720477  0.831415573  0.885769663 
32076  LRRCC1  NM_033402  ‐1.637  6.859  1.3383444  1.070075333  0.674055747 
3303  UACA  NM_001008224  ‐1.456  6.863  1.0628048  0.882884047  0.580912167 
3353  A_24_P936067  A_24_P936067  ‐1.428  6.881  0.9444038  0.991508473  1.121625677 
33123  CB162722  CB162722  ‐1.176  6.952  0.574179317  0.81469171  0.753053833 
3008  THC2579650  THC2579650  ‐1.127  6.953  0.538577063  0.848946497  0.81459915 
3285  RAD50  NM_005732  ‐1.230  6.957  0.670889783  0.49312263  0.526934597 
35052  CD619445  CD619445  ‐1.507  6.961  0.74908649  0.856413467  1.004577987 
11850  LOC91431  NM_138698  ‐1.128  6.981  0.578900337  0.64622077  0.7991376 
39629  MIDN  NM_177401  ‐1.116  6.996  0.533730697  0.558181503  0.464683693 
1369  IGFBP3  NM_001013398  ‐1.262  7.039  0.722907817  0.743149467  1.120351933 
3285  RAD50  NM_005732  ‐1.105  7.056  0.6017554  0.510130527  0.458504667 
2465  KNTC1  NM_014708  ‐0.983  7.091  0.414883687  0.419636013  0.427022257 
3079  LOC727768  ENST00000339700  ‐1.146  7.112  0.557336847  0.754403767  0.931354637 
3233  PHF17  NM_199320  ‐1.123  7.133  0.50628656  0.563930333  0.471989813 
35013  AK5  NM_174858  ‐0.969  7.155  1.044879323  1.377864967  1.5065347 
26036  THC2697162  THC2697162  ‐1.282  7.180  1.5593268  1.566910267  1.388146667 
4445  SCLT1  NM_144643  ‐1.129  7.180  0.643899167  0.490144053  0.65004208 
36403  OXTR  NM_000916  ‐1.203  7.182  0.65636004  0.565799283  0.72835248 
1111  PTK2B  NM_173174  ‐1.124  7.191  0.66676948  0.55215102  0.834798657 
1111  PTK2B  NM_173174  ‐1.122  7.209  0.643002677  0.574078913  0.815721943 
13534  SASS6  NM_194292  ‐1.237  7.231  0.594469133  0.64483456  0.579460933 
22374  A_24_P349590  A_24_P349590  ‐1.070  7.237  0.50525948  0.676091217  0.738450967 
1111  PTK2B  NM_173174  ‐1.188  7.238  0.659862567  0.616939933  0.93864942 
22318  MNS1  NM_018365  ‐1.154  7.241  0.748204967  0.63778115  0.967874253 
7567  HNRPCL1  NM_001013631  ‐1.044  7.245  0.49767689  0.623966953  0.668777027 
1111  PTK2B  NM_173174  ‐1.075  7.290  0.64650101  0.594472533  0.797284517 
3285  RAD50  NM_005732  ‐1.152  7.316  0.591412067  0.466962903  0.495728847 
37364  THC2609820  THC2609820  ‐1.421  7.347  0.772510577  0.840996253  0.653292077 
8909  KIAA1212  NM_018084  ‐1.261  7.353  0.933755987  1.296268  0.921332217 
29724  THC2541992  THC2541992  ‐1.404  7.384  0.720686867  0.9446593  0.832029683 
1111  PTK2B  NM_173174  ‐1.237  7.411  0.703494947  0.626053223  0.958108077 
35716  ESF1  NM_016649  ‐1.440  7.412  1.137021667  0.76417095  0.839484913 
3285  RAD50  NM_005732  ‐1.107  7.413  0.591186447  0.5369251  0.46867373 
15  EHMT2  NM_006709  ‐1.263  7.534  0.720532753  0.722599553  0.584685687 
33059  ZNF91  NM_003430  ‐1.259  7.538  0.734496273  0.825897767  0.562209833 
2329  PLK1  NM_005030  ‐1.000  7.549  0.52634977  0.585007443  0.518939517 
13995  KIF11  NM_004523  ‐1.041  7.562  0.540392967  0.61345032  0.700575577 
26524  SETD1A  NM_014712  ‐1.347  7.591  0.847271053  0.8893106  0.665379177 
7597  BX537520  BX537520  ‐1.590  7.617  0.994465267  1.166917517  1.7125249 
1111  PTK2B  NM_173174  ‐1.163  7.667  0.675232173  0.61131437  0.89205528 
22388  THC2672325  THC2672325  ‐1.144  7.712  0.598596057  0.53114055  0.663180083 
9086  FLJ32679  NM_001012452  ‐1.429  7.727  0.72971708  1.1258943  1.051355313 
8520  THC2669975  THC2669975  ‐1.914  7.730  1.213353143  1.489653933  0.941284133 
30402  NCAPG  NM_022346  ‐1.055  7.752  0.488393787  0.445999163  0.476008677 
9830  CASC5  NM_170589  ‐1.267  7.767  0.857022123  0.90044062  1.359233567 
24750  LRRCC1  NM_033402  ‐1.693  7.812  1.353386833  1.195211567  0.79812034 
21761  ZBTB20  BC010934  ‐1.581  7.891  1.078137813  0.80133861  0.929186493 
10879  PHF20L1  NM_032205  ‐1.228  7.949  0.76263021  0.772459547  0.66079625 
20162  PCM1  NM_006197  ‐1.268  7.977  0.7725081  0.775718483  0.708234167 
979  PPIG  NM_004792  ‐1.136  8.018  0.5626696  0.545135547  0.674137473 
233 
 
38228  KTN1  NM_182926  ‐1.531  8.039  0.99858982  0.942887673  0.649512647 
16734  AKAP9  NM_147171  ‐2.137  8.068  1.8441631  1.9191385  1.008073767 
177  BRCA2  NM_000059  ‐2.360  8.116  1.833684833  1.277420657  1.922160733 
1111  PTK2B  NM_173174  ‐1.160  8.119  0.610866813  0.72691395  0.8754361 
7434  FANCM  NM_020937  ‐1.253  8.147  0.73361958  0.941641633  0.796186443 
12294  LOC150759  AK057596  ‐1.194  8.183  0.6840992  0.6965006  0.544409453 
177  BRCA2  NM_000059  ‐2.060  8.238  2.008979467  1.4975493  1.7193468 
5666  MAF1  NM_032272  ‐1.137  8.266  0.614623  0.726426197  0.85673299 
20611  DYNC2H1  NM_001080463  ‐1.175  8.308  0.814906827  1.146598567  1.169911767 
40329  BRWD1  ENST00000380831  ‐1.340  8.349  0.815870987  1.229598567  1.280002433 
39405  SLITRK6  NM_032229  ‐1.324  8.446  0.74691398  0.857483533  0.66426292 
20557  FLJ39660  NM_001080539  ‐1.273  8.483  0.6875299  0.7474494  0.86463523 
37322  A_32_P11673  A_32_P11673  ‐1.469  8.514  1.065185867  1.763905833  1.295553467 
3367  ASPM  NM_018136  ‐1.645  8.573  1.2849287  1.312144533  0.813613333 
13791  A_32_P222060  A_32_P222060  ‐1.443  8.617  0.848227383  1.258495633  1.234294367 
177  BRCA2  NM_000059  ‐1.383  8.714  1.229256033  1.493195267  1.148547567 
20461  MAP9  NM_001039580  ‐1.160  8.743  0.718646133  0.738837733  0.682114653 
17879  ATRX  BC002521  ‐1.307  8.817  0.856297917  1.006538533  0.699420147 
177  BRCA2  NM_000059  ‐2.407  8.918  1.613167367  1.654055667  2.218758133 
11257  NCAPH2  NM_014551  ‐1.349  9.101  0.851816193  0.669243023  0.846574533 
18995  C1QTNF5  NM_015645  ‐1.668  9.182  1.3833096  1.4210258  1.155814013 
177  BRCA2  NM_000059  ‐2.033  9.235  1.429109433  1.699343633  1.660988667 
9559  RBBP6  NM_006910  ‐1.317  9.413  0.8733457  0.77431249  0.67727055 
3856  FAM44A  NM_148894  ‐1.346  9.561  0.94367407  0.83779945  0.71739828 
9007  C9orf39  NM_017738  ‐1.356  9.615  0.9222772  0.978756967  1.02163632 
19154  TPR  NM_003292  ‐1.306  9.677  0.8499103  0.90162223  0.683191657 
6209  CENPF  NM_016343  ‐2.283  9.798  1.861923633  1.663239267  1.1828924 
2833  FLJ20054  AL831839  ‐1.642  9.942  1.343169733  1.020266333  1.5220943 
26199  GOLGA4  NM_002078  ‐1.758  10.005  1.3932187  1.432338733  0.963317613 
35429  MALAT1  NR_002819  ‐1.148  10.136  0.64240878  0.62262942  0.708047977 
31550  A_32_P167111  A_32_P167111  ‐3.289  10.191  2.194734433  2.402190167  2.364924667 
10950  SLC30A1  ENST00000367000  ‐1.456  10.431  1.04046762  1.1783135  1.4918507 
6839  BDP1  NM_018429  ‐1.243  11.168  0.71055601  0.72444531  0.703755983 
26596  CEP290  NM_025114  ‐2.084  11.490  1.835236567  1.494201267  1.382930533 
36285  GOLGB1  NM_004487  ‐1.407  11.523  0.885280433  0.90882262  1.064330267 
12826  TPR  NM_003292  ‐1.672  11.800  1.290544267  1.281429067  0.99407887 
13760  GOLGA4  NM_002078  ‐1.709  11.822  1.2912084  1.332447533  1.00790459 
5153  NSBP1  NM_030763  ‐1.414  11.889  0.99900175  1.144781533  0.943524167 
5153  NSBP1  NM_030763  ‐1.506  12.006  0.944791343  1.137348733  1.026634233 
177  BRCA2  NM_000059  ‐1.971  12.083  1.905555633  1.4945863  1.487126333 
5153  NSBP1  NM_030763  ‐1.437  12.215  1.0286332  1.081336033  0.957489913 
177  BRCA2  NM_000059  ‐1.944  12.266  1.804701433  1.488850133  1.380489533 
32450  ASPM  NM_018136  ‐1.571  12.640  1.061606767  1.060196717  0.997615553 
37979  ESF1  NM_016649  ‐1.589  12.644  1.141323667  1.009812867  1.1480279 
5153  NSBP1  NM_030763  ‐1.370  12.775  0.9431407  1.030663177  0.890224167 
5153  NSBP1  NM_030763  ‐1.404  12.987  0.956047347  1.076132167  0.91721711 
177  BRCA2  NM_000059  ‐1.991  13.109  1.648784767  1.360648833  1.566621333 
5153  NSBP1  NM_030763  ‐1.463  13.506  1.058007  0.984533533  0.968643367 
5153  NSBP1  NM_030763  ‐1.452  13.705  1.031717833  1.120189433  0.964975123 
7171  FANCM  NM_020937  ‐1.438  13.711  0.988120267  0.985151513  1.111268667 
5153  NSBP1  NM_030763  ‐1.479  13.861  1.011338267  1.126205  0.974511767 
5153  NSBP1  NM_030763  ‐1.487  14.304  1.02291508  1.046319933  0.9767779 
39026  GOLGB1  NM_004487  ‐1.588  14.454  1.158623267  1.213636767  1.037703967 
5153  NSBP1  NM_030763  ‐1.496  15.014  1.0095847  1.0738679  0.996408 
17589  CEP290  NM_025114  ‐3.085  15.766  2.433021867  2.3530326  1.897406867 
177  BRCA2  NM_000059  ‐2.095  15.853  1.751690633  1.5872352  1.738965433 
8003  ANKRD12  NM_015208  ‐2.243  15.986  1.894270967  1.819415033  1.527371967 
16091  NSBP1  NM_030763  ‐1.607  16.576  1.219613033  1.327510767  1.390599533 
34297  ANKRD12  NM_015208  ‐2.015  17.894  1.822984667  1.764787967  1.727613833 
36127  MPHOSPH1  NM_016195  ‐2.824  18.713  2.1652628  2.436810133  2.223331867 
966  CENPE  NM_001813  ‐2.860  25.769  2.236115633  2.434618067  2.382718733 
966  CENPE  NM_001813  ‐2.566  26.158  2.3450358  2.4236443  2.1953522 
966  CENPE  NM_001813  ‐2.690  26.519  2.274578267  2.493755367  2.316120067 
966  CENPE  NM_001813  ‐2.745  26.785  2.2597778  2.383257133  2.3263037 
966  CENPE  NM_001813  ‐2.534  27.526  2.202902867  2.374423033  2.183361767 
966  CENPE  NM_001813  ‐2.603  28.753  2.373398167  2.371493567  2.219390933 
966  CENPE  NM_001813  ‐2.668  28.921  2.2899048  2.4357717  2.290984567 
966  CENPE  NM_001813  ‐2.623  29.979  2.279469567  2.4181044  2.270165267 
966  CENPE  NM_001813  ‐2.776  30.171  2.3647857  2.471678167  2.3492171 
966  CENPE  NM_001813  ‐2.952  30.271  2.342841133  2.455456233  2.435027933 
234 
 
3122  PLAT  NM_000930  3.085  ‐13.137  ‐2.340478267  ‐2.026714733  ‐2.671139967 
3122  PLAT  NM_000930  2.860  ‐12.507  ‐2.1033524  ‐2.028532167  ‐2.640381633 
3122  PLAT  NM_000930  2.718  ‐12.403  ‐1.954678333  ‐2.289306633  ‐2.457411767 
28729  PCSK9  NM_174936  2.378  ‐11.839  ‐1.844288967  ‐1.946876433  ‐2.597768133 
3122  PLAT  NM_000930  3.175  ‐11.802  ‐2.005144867  ‐2.2210379  ‐2.72335 
3122  PLAT  NM_000930  2.824  ‐11.471  ‐2.091276333  ‐1.9414295  ‐2.563950333 
16285  THRSP  NM_003251  1.503  ‐10.792  ‐1.001892567  ‐1.353822233  ‐1.390107833 
3122  PLAT  NM_000930  2.429  ‐10.077  ‐2.096323933  ‐1.939678033  ‐2.416908067 
29947  BC092452  BC092452  1.272  ‐9.652  ‐0.70470064  ‐0.632113287  ‐0.75194113 
4874  PTGS2  NM_000963  1.906  ‐9.182  ‐1.344396267  ‐1.0644167  ‐1.602369367 
29984  TNFAIP2  NM_006291  1.358  ‐9.009  ‐0.836702917  ‐0.66639271  ‐0.906576047 
16181  A_23_P158380  A_23_P158380  1.390  ‐8.989  ‐0.8601257  ‐0.89270486  ‐0.8823348 
3122  PLAT  NM_000930  1.780  ‐8.989  ‐1.950646333  ‐1.654256333  ‐2.2400057 
20806  MICALCL  NM_032867  1.266  ‐8.709  ‐0.663635113  ‐0.93141427  ‐0.9377677 
15877  TRIM7  NM_033342  1.257  ‐8.707  ‐0.741735467  ‐0.620950323  ‐0.83477832 
17204  CA314936  CA314936  1.358  ‐8.199  ‐0.767004867  ‐0.831700933  ‐0.591780793 
6201  GIPR  NM_000164  1.953  ‐8.158  ‐1.804223367  ‐1.746254433  ‐1.0566193 
38671  KCNK5  NM_003740  1.204  ‐8.118  ‐0.604492907  ‐0.618442513  ‐0.756560563 
29188  THC2644803  THC2644803  1.714  ‐7.954  ‐1.26182429  ‐1.165831  ‐1.711233533 
1679  STAT1  NM_139266  1.073  ‐7.851  ‐0.50780306  ‐0.5694386  ‐0.658531 
4968  RBP5  NM_031491  1.203  ‐7.726  ‐0.591627873  ‐0.590485747  ‐0.614274423 
22503  ARHGAP20  NM_020809  1.812  ‐7.627  ‐1.01966633  ‐1.3101279  ‐0.905578033 
4874  PTGS2  NM_000963  1.816  ‐7.564  ‐1.467643233  ‐1.147307933  ‐1.5689084 
27777  AA854957  AA854957  2.283  ‐7.480  ‐1.472720567  ‐1.4402429  ‐2.321127767 
21454  ISGF3G  NM_006084  1.277  ‐7.414  ‐0.759572553  ‐0.917330233  ‐1.326219533 
1679  STAT1  NM_139266  1.083  ‐7.323  ‐0.473540337  ‐0.6225738  ‐0.660685347 
7483  LAIR1  NM_021706  1.330  ‐7.298  ‐0.702031433  ‐0.886803153  ‐1.007378067 
4193  THC2656519  THC2656519  1.233  ‐7.245  ‐0.68373928  ‐0.849298617  ‐1.135062433 
7432  AATK  NM_001080395  1.093  ‐7.244  ‐0.570042307  ‐0.54732772  ‐0.773487233 
7410  SLC39A10  NM_020342  1.727  ‐7.190  ‐1.182429333  ‐0.696937927  ‐1.300920633 
15020  AK098478  AK098478  1.889  ‐7.147  ‐1.14753615  ‐0.785391933  ‐1.114865733 
21657  RHO  NM_000539  1.035  ‐7.094  ‐0.67730392  ‐0.603532777  ‐0.613235513 
38347  DHTKD1  NM_018706  1.136  ‐7.079  ‐0.538328167  ‐0.621389337  ‐0.764034233 
26487  RAB11FIP4  NM_032932  2.024  ‐7.070  ‐1.5672953  ‐1.2021582  ‐0.772028633 
5310  CV800748  CV800748  1.235  ‐7.060  ‐0.665014247  ‐0.65054795  ‐0.499491453 
15185  FNDC3A  NM_014923  1.198  ‐6.987  ‐0.575411163  ‐0.5936698  ‐0.848950613 
4874  PTGS2  NM_000963  1.986  ‐6.981  ‐1.7415197  ‐1.009077947  ‐1.7641105 
39636  GGTA1  NR_003191  1.506  ‐6.974  ‐0.972879833  ‐0.978762567  ‐0.563704367 
22382  ACSS2  NM_018677  1.020  ‐6.946  ‐0.467846453  ‐0.70541827  ‐0.677347163 
20311  PRKCH  NM_006255  1.284  ‐6.934  ‐0.614962163  ‐0.80861181  ‐0.5616557 
32516  SLC16A3  NM_004207  1.274  ‐6.906  ‐0.71810998  ‐1.2199086  ‐1.4702735 
1194  LOXL2  NM_002318  0.980  ‐6.893  ‐0.465528853  ‐0.61158034  ‐0.572988537 
3122  PLAT  NM_000930  1.624  ‐6.863  ‐1.598028433  ‐1.649845133  ‐1.8902052 
39779  JMJD1A  NM_018433  1.125  ‐6.858  ‐0.544273133  ‐0.515954377  ‐0.6290375 
30172  THC2727548  THC2727548  3.013  ‐6.831  ‐1.57174358  ‐1.495704033  ‐2.141288067 
30066  RGS9BP  NM_207391  1.024  ‐6.817  ‐0.438772233  ‐0.546024937  ‐0.62252312 
14619  DLGAP4  NM_014902  1.007  ‐6.753  ‐0.486158857  ‐0.589980647  ‐0.68890402 
35907  AQP5  BC032946  1.899  ‐6.701  ‐1.146254867  ‐1.0118404  ‐0.77202461 
1679  STAT1  NM_139266  0.978  ‐6.662  ‐0.440554857  ‐0.539309153  ‐0.605579023 
1679  STAT1  NM_139266  1.085  ‐6.616  ‐0.447193077  ‐0.552272707  ‐0.670089053 
20413  PIGR  NM_002644  1.068  ‐6.604  ‐0.531717127  ‐0.952244533  ‐0.929526513 
15979  THC2528836  THC2528836  1.237  ‐6.579  ‐0.620215433  ‐0.654062567  ‐1.00645251 
15191  FAM114A1  NM_138389  1.031  ‐6.552  ‐0.51933855  ‐0.48077252  ‐0.505364447 
15985  PHLDA2  NM_003311  1.047  ‐6.506  ‐0.48567673  ‐0.85902754  ‐0.81389132 
38178  CFB  NM_001710  1.205  ‐6.480  ‐0.609473247  ‐1.306936133  ‐1.1029469 
7414  IFITM1  NM_003641  1.227  ‐6.445  ‐0.65705865  ‐1.1763182  ‐0.733485597 
21113  C8orf4  NM_020130  1.392  ‐6.390  ‐0.928227193  ‐1.090246133  ‐1.105645157 
1679  STAT1  NM_139266  1.054  ‐6.363  ‐0.437865333  ‐0.506963193  ‐0.644507987 
18536  UQCRC2  NM_003366  1.031  ‐6.362  ‐0.454220093  ‐0.5004366  ‐0.469320307 
18166  ENST00000372045  ENST00000372045  2.269  ‐6.356  ‐1.24716358  ‐0.818261367  ‐1.637104067 
37683  AI263083  AI263083  1.622  ‐6.347  ‐1.211870467  ‐1.142831767  ‐0.598803333 
3191  KAZALD1  ENST00000224809  1.019  ‐6.311  ‐0.467684917  ‐0.754526733  ‐0.548066653 
36814  KIAA1446  NM_020836  1.294  ‐6.309  ‐0.707675717  ‐0.50107563  ‐0.80290935 
26130  AP2B1  NM_001282  1.045  ‐6.292  ‐0.44220838  ‐0.409955203  ‐0.473319857 
13330  ACSS2  NM_018677  1.063  ‐6.290  ‐0.47101459  ‐0.741283013  ‐0.822097243 
39521  AA573434  AA573434  1.948  ‐6.254  ‐0.80939348  ‐1.405408433  ‐1.406230733 
29855  TTTY14  NR_001543  0.979  ‐6.237  ‐0.501440753  ‐0.438080143  ‐0.604608467 
1679  STAT1  NM_139266  0.924  ‐6.230  ‐0.42827529  ‐0.484838647  ‐0.55202351 
9926  ANXA9  NM_003568  1.051  ‐6.216  ‐0.447571523  ‐0.791058947  ‐0.778667223 
28754  P2RY2  NM_176072  1.274  ‐6.200  ‐0.622990947  ‐1.1232551  ‐0.83217842 
235 
 
13081  ZNF226  NM_015919  1.010  ‐6.185  ‐0.425115263  ‐0.640717713  ‐0.51760771 
10338  PLEKHA2  AK098787  1.532  ‐6.180  ‐0.988053043  ‐0.54755066  ‐1.1418981 
40095  LPIN1  AF147446  1.123  ‐6.152  ‐1.1019879  ‐1.405928953  ‐1.9759118 
19789  MORF4L2  NM_012286  0.982  ‐6.138  ‐0.462598667  ‐0.423519463  ‐0.495940317 
5485  GUSBL2  BC065547  1.009  ‐6.130  ‐0.460201847  ‐0.817949553  ‐0.60525911 
3122  PLAT  NM_000930  2.027  ‐6.109  ‐2.016946033  ‐1.18573686  ‐2.295623 
39778  LMAN1  NM_005570  0.913  ‐6.090  ‐0.388900693  ‐0.491598853  ‐0.440477677 
1679  STAT1  NM_139266  0.987  ‐6.057  ‐0.40078041  ‐0.520509533  ‐0.62760689 
11473  CXCL10  NM_001565  1.322  ‐6.056  ‐0.74504858  ‐1.8006046  ‐1.203655633 
39018  TBC1D24  NM_020705  1.160  ‐6.039  ‐0.5083218  ‐0.499618133  ‐0.67593672 
1679  STAT1  NM_139266  1.121  ‐6.029  ‐0.42952224  ‐0.607455713  ‐0.686771333 
25288  EHD4  NM_139265  0.994  ‐6.021  ‐0.42301759  ‐0.367750437  ‐0.376609233 
22818  TBXA2R  NM_001060  1.101  ‐6.009  ‐0.590554657  ‐0.584686533  ‐0.407919817 
37812  NAP1L5  NM_153757  1.006  ‐6.004  ‐0.38303683  ‐0.563317283  ‐0.612914333 
28638  ECGF1  NM_001953  0.904  ‐5.999  ‐0.34716604  ‐0.420867013  ‐0.4133207 
29208  SPRR2G  NM_001014291  1.511  ‐5.998  ‐0.897242567  ‐0.84823631  ‐0.524488863 
15603  THC2585656  THC2585656  0.976  ‐5.996  ‐0.39185481  ‐0.56994412  ‐0.64962875 
27294  ATP8B3  NM_138813  1.704  ‐5.983  ‐0.965753843  ‐0.883361  ‐1.5825865 
1194  LOXL2  NM_002318  1.153  ‐5.949  ‐0.55721845  ‐0.461396557  ‐0.6771499 
25086  THC2524477  THC2524477  1.366  ‐5.948  ‐0.709317707  ‐0.685945063  ‐0.617770563 
428  TNFSF10  NM_003810  1.188  ‐5.946  ‐0.605115613  ‐1.561742133  ‐1.4817489 
304  CAV1  NM_001753  2.550  ‐5.928  ‐1.310676643  ‐1.320399133  ‐1.246139833 
28045  HCP5  L06175  1.063  ‐5.928  ‐0.433519643  ‐0.666887393  ‐0.814911487 
24161  JMJD1A  NM_018433  1.229  ‐5.918  ‐0.54888245  ‐0.566548287  ‐0.9242438 
14359  DIO3  NM_001362  1.192  ‐5.888  ‐0.728894363  ‐1.964018233  ‐2.156623367 
13037  S100A10  NM_002966  1.139  ‐5.881  ‐0.502858483  ‐0.788590417  ‐0.507900437 
18094  ZNF554  NM_152303  0.995  ‐5.867  ‐0.371312037  ‐0.434138917  ‐0.443653677 
19826  AF075063  AF075063  1.038  ‐5.859  ‐0.4193786  ‐0.488466087  ‐0.57874784 
1337  DQ168992  DQ168992  1.507  ‐5.849  ‐1.099717433  ‐0.841722523  ‐0.74513289 
31949  ST3GAL4  AK021929  1.470  ‐5.840  ‐0.897867257  ‐0.97820588  ‐1.922555133 
1679  STAT1  NM_139266  0.893  ‐5.837  ‐0.40610774  ‐0.471493773  ‐0.540889453 
3122  PLAT  NM_000930  3.854  ‐5.817  ‐1.723109533  ‐1.52871322  ‐2.754939 
8534  FCGBP  NM_003890  1.163  ‐5.802  ‐0.584425627  ‐0.493120387  ‐0.90010621 
1679  STAT1  NM_139266  0.935  ‐5.781  ‐0.360812767  ‐0.52107687  ‐0.57605729 
11995  STMN3  NM_015894  1.114  ‐5.739  ‐0.5513997  ‐0.75211232  ‐1.185465367 
17918  KIAA1913  BC044246  1.324  ‐5.716  ‐1.2799507  ‐0.908144267  ‐1.247602733 
7749  CCDC78  NM_173476  0.889  ‐5.702  ‐0.35366142  ‐0.588982633  ‐0.520895863 
27212  LRRC1  NM_018214  1.172  ‐5.697  ‐0.548923173  ‐0.367040983  ‐0.5135225 
25794  JMJD1A  NM_018433  1.037  ‐5.692  ‐0.462893907  ‐0.404190307  ‐0.50302585 
9255  IL6  NM_000600  1.238  ‐5.692  ‐0.63877709  ‐0.950256223  ‐0.912880973 
1194  LOXL2  NM_002318  1.189  ‐5.689  ‐0.50370099  ‐0.501074107  ‐0.719080057 
2546  ZNF143  NM_003442  0.952  ‐5.679  ‐0.452416983  ‐0.34543331  ‐0.45091503 
35567  GDF15  NM_004864  1.024  ‐5.662  ‐0.37247048  ‐0.651989723  ‐0.55763635 
16250  IL27RA  NM_004843  1.230  ‐5.657  ‐0.638516037  ‐0.592530947  ‐1.0635951 
28592  NFKBIZ  NM_031419  0.838  ‐5.656  ‐0.399276763  ‐0.680252967  ‐0.5927032 
26609  BTBD14B  NM_052876  0.867  ‐5.647  ‐0.33442763  ‐0.337814103  ‐0.399638613 
14164  TLL1  NM_012464  0.901  ‐5.647  ‐1.036844167  ‐1.574607867  ‐2.007416733 
23903  ZNF135  AL157426  1.718  ‐5.628  ‐1.082710887  ‐1.1724996  ‐0.55194276 
40233  SLC6A20  NM_020208  1.656  ‐5.619  ‐0.7845902  ‐0.817978057  ‐1.318159147 
26973  SARDH  AF095737  1.012  ‐5.616  ‐0.5262521  ‐0.46970009  ‐0.36188557 
17701  HFE  NM_139006  1.478  ‐5.604  ‐1.057104637  ‐1.2436246  ‐0.927780383 
428  TNFSF10  NM_003810  1.179  ‐5.598  ‐0.552905147  ‐1.6183674  ‐1.3932727 
428  TNFSF10  NM_003810  1.114  ‐5.589  ‐0.54777098  ‐1.528908167  ‐1.354601533 
4685  BQ933774  BQ933774  0.953  ‐5.587  ‐0.498210983  ‐0.913987767  ‐1.2186037 
24261  BRP44L  NM_016098  0.915  ‐5.583  ‐0.34748953  ‐0.51741003  ‐0.563602347 
26184  SPON2  NM_012445  1.607  ‐5.583  ‐0.74982117  ‐0.55882658  ‐0.709754973 
11848  USP18  NM_017414  0.947  ‐5.583  ‐0.350507593  ‐0.577703833  ‐0.553424653 
32079  SMURF1  NM_020429  1.302  ‐5.536  ‐0.80861452  ‐0.492267317  ‐1.085724233 
3101  DCT  NM_001922  1.015  ‐5.529  ‐0.45967827  ‐0.372466253  ‐0.431676983 
8850  AK021467  AK021467  2.645  ‐5.521  ‐1.370444067  ‐0.99604464  ‐1.832363467 
23403  LOC283152  NM_001033658  1.089  ‐5.511  ‐0.420166723  ‐0.402091063  ‐0.514176857 
40790  CCNL2  NM_001039577  0.967  ‐5.503  ‐0.45281468  ‐0.491834283  ‐0.334235203 
12222  CXCL11  NM_005409  1.280  ‐5.496  ‐0.697059053  ‐2.217573367  ‐1.5537052 
32449  ANGPT2  NM_001147  1.955  ‐5.489  ‐1.326668333  ‐0.967197253  ‐1.18942161 
4467  PDGFRB  NM_002609  1.288  ‐5.480  ‐1.2410021  ‐0.923295633  ‐1.286995283 
29897  ARP11  AB039791  1.141  ‐5.452  ‐0.575639843  ‐0.41502278  ‐0.807079533 
511  AK027383  AK027383  1.140  ‐5.442  ‐0.58401715  ‐0.4991183  ‐0.9423341 
31274  C19orf31  NM_001014373  1.561  ‐5.431  ‐1.0191593  ‐0.823552207  ‐1.545054533 
428  TNFSF10  NM_003810  1.045  ‐5.426  ‐0.537792677  ‐1.568648  ‐1.273448467 
2693  C9orf21  NM_153698  0.958  ‐5.405  ‐0.43896087  ‐0.411266743  ‐0.63277822 
236 
 
428  TNFSF10  NM_003810  1.110  ‐5.382  ‐0.51798715  ‐1.600457933  ‐1.337337867 
36450  THC2669063  THC2669063  0.640  ‐5.381  ‐0.455537077  ‐0.70895041  ‐0.637471933 
39568  SPEG  AK055387  1.371  ‐5.331  ‐0.81259646  ‐1.110026933  ‐2.1280302 
428  TNFSF10  NM_003810  0.961  ‐5.329  ‐0.486004013  ‐1.461768667  ‐1.238813267 
7848  THC2589620  THC2589620  1.560  ‐5.328  ‐0.861425253  ‐1.048731  ‐0.445495297 
428  TNFSF10  NM_003810  1.104  ‐5.324  ‐0.511457367  ‐1.577113467  ‐1.3176588 
19075  A_24_P630916  A_24_P630916  1.136  ‐5.321  ‐0.501575477  ‐0.53755618  ‐0.317769267 
4985  PDXK  NM_003681  0.844  ‐5.320  ‐0.312371203  ‐0.47346731  ‐0.49974734 
1326  KCNK6  NM_004823  0.889  ‐5.319  ‐0.350867107  ‐0.673042287  ‐0.53419706 
428  TNFSF10  NM_003810  1.046  ‐5.311  ‐0.479290667  ‐1.448819733  ‐1.302678033 
6588  CACNA1B  ENST00000371372  1.323  ‐5.302  ‐1.1743241  ‐0.8529725  ‐1.170360383 
5285  APOL6  NM_030641  2.417  ‐5.297  ‐1.754723567  ‐2.460166133  ‐0.707609757 
30362  CXCL11  NM_005409  1.212  ‐5.282  ‐0.594433043  ‐2.067847733  ‐1.5501496 
17787  TMEM173  NM_198282  0.809  ‐5.280  ‐0.3642342  ‐0.600631587  ‐0.75335053 
28635  DMKN  NM_033317  2.256  ‐5.270  ‐1.3613215  ‐1.009538667  ‐1.183411727 
15265  PLA2G3  NM_015715  1.226  ‐5.268  ‐0.698538867  ‐0.885502533  ‐1.711716633 
34693  CLN3  BC111068  0.902  ‐5.266  ‐0.312308133  ‐0.35800294  ‐0.378894863 
428  TNFSF10  NM_003810  1.001  ‐5.265  ‐0.492812863  ‐1.536260633  ‐1.2612175 
4413  THC2590490  THC2590490  1.410  ‐5.261  ‐0.693449963  ‐0.945177547  ‐0.453792683 
15932  PDLIM2  AK074031  1.162  ‐5.260  ‐0.883031367  ‐0.45855397  ‐0.739803267 
15830  RSAD2  NM_080657  1.060  ‐5.259  ‐0.522487177  ‐1.648276867  ‐1.705192467 
33137  SHC3  NM_016848  1.650  ‐5.250  ‐1.080824567  ‐1.643162367  ‐0.638431073 
5497  HRASLS5  BC034222  0.821  ‐5.246  ‐0.449225453  ‐0.39539804  ‐0.434927643 
4940  ACLY  U18197  0.945  ‐5.225  ‐0.378183017  ‐0.541948567  ‐0.779965267 
3882  COL13A1  NM_005203  1.179  ‐5.220  ‐0.8208332  ‐0.698674687  ‐1.455585967 
24047  TMEM45A  NM_018004  1.164  ‐5.216  ‐0.5148523  ‐0.9053135  ‐1.3825128 
29759  LGALS1  NM_002305  1.306  ‐5.209  ‐0.652095797  ‐0.4727589  ‐1.058351 
 
